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Abstract
Vision is the most important sensory modality for many species, including humans.
Damage to the retina results in vision loss or even blindness. One of the most serious
complications of diabetes, a disease that has seen a worldwide increase in prevalence, is
diabetic retinopathy. This condition stems from consequences of pathological metab-
olism and develops in 75% of patients with type 1 and 50% with type 2 diabetes. The
development of novel protective drugs is essential. In this review we provide a descrip-
tion of the disease and conclude that type 1 diabetes and type 2 diabetes lead to the
same retinopathy. We evaluate existing experimental models and recent developments
in finding effective compounds against this disorder. In our opinion, the best models are
the long-term streptozotocin-induced diabetes and Otsuka Long–Evans Tokushima
Fatty and spontaneously diabetic Torii rats, while the most promising substances are
topically administered somatostatin and pigment epithelium-derived factor analogs,
antivasculogenic substances, and systemic antioxidants. Future drug development
should focus on these.
st0015 ABBREVIATIONS
dt0005 ACE angiotensin-converting enzyme
dt0010 ACEI angiotensin-converting enzyme inhibitor
dt0015 AG aminoguanidine
dt0020 AGE advanced glycosylated end product
dt0025 AIF apoptosis-inducing factor
dt0030 ALE advanced lipoxidation end product
dt0035 AQP aquaporin
dt0040 BB/W Bio-Breeding/Worcester
dt0045 BDNF brain-derived neurotrophic factor
dt0050 BRB blood–retina barrier
dt0055 BSA bovine serum albumin
dt0060 CAV-1 caveolin 1
dt0065 CBD cannabidiol
dt0070 CGA chlorogenic acid
dt0075 CNTF ciliary neurotrophic factor
dt0080 CTGF connective tissue growth factor
dt0085 DAG diacylglycerol
dt0090 DR diabetic retinopathy
dt0095 E4 exendin-4
dt0100 EPO erythropoietin
dt0105 ERK extracellular signal-regulated kinases
dt0110 ERG electroretinogram
dt0115 FDP-lysine Ne-(3-formyl-3,4-dehydropiperidino)lysine
dt0120 GABA g-aminobutyric acid
dt0125 GBE Ginkgo biloba leaf extract
dt0130 GCL ganglion cell layer
dt0135 GDNF glial cell line-derived neurotrophic factor
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dt0140 GFAP glial fibrillary acidic protein
dt0145 GK Goto–Kakizaki
dt0150 GLAST glutamate aspartate transporter
dt0155 GLP-1R cognate receptor
dt0160 GLUT1 glucose transporter 1
dt0165 Grx1 glutaredoxin 1
dt0170 GS glutamine synthase
dt0175 GSPE grape seed proanthocyanidin extracts
dt0180 GT green tea
dt0185 HIF1a hypoxia-inducible factor-1a
dt0190 H2S hydrogen sulfide
dt0195 IBA Au5-1 ionized calcium-binding adaptor molecule 1
dt0200 ICAM-1 interstitial cell adhesion molecule Au61
dt0205 IGF-1 insulin-like growth factor 1
dt0210 IL-1 interleukin-1
dt0215 ILM inner limiting membrane
dt0220 INL inner nuclear layer
dt0225 IOP intraocular pressure
dt0230 IPL inner plexiform layer
dt0235 JNK c-Jun N-terminal kinase
dt0240 LDL low-density lipoprotein
dt0245 LETO Long–Evans Tokushima Otsuka
dt0250 LPA lysophosphatidic acid
dt0255 MAPK mitogen-activated protein kinase
dt0260 mtDNA mitochondrial DNA
dt0265 NF-kB nuclear factor kB
dt0270 NFL nerve fiber layer
dt0275 NGF nerve growth factor
dt0280 NMDA N-methyl-D-aspartate
dt0285 nNOS neuronal Au7nitric oxide synthase
dt0290 OLETF Otsuka Long–Evans Tokushima Fatty
dt0295 OLM outer limiting membrane
dt0300 ONL outer nuclear layer
dt0305 OP oscillatory potential
dt0310 OPL outer plexiform layer
dt0315 OS outer segment
dt0320 PACAP pituitary adenylate cyclase-activating polypeptide
dt0325 PARP poly-(ADP)-ribose polymerase
dt0330 PEDF pigment epithelium-derived factor
dt0335 PI3K phosphatidylinositide 3-kinase
dt0340 PKC protein kinase C
dt0345 PKCa protein Au8kinase Ca
dt0350 PKCz protein kinase Cz
dt0355 PPAR peroxisome proliferator-activated receptor
dt0360 PRL photoreceptor layer
dt0365 RA retinoic acid
dt0370 RAGE receptor of AGEs
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dt0375 RAS renin–angiotensin system
dt0380 RGC retinal ganglion cell
dt0385 ROS reactive oxygen species
dt0390 RPE retinal pigment epithelium
dt0395 SDT spontaneously diabetic Torii
dt0400 SST somatostatin
dt0405 STZ streptozotocin
dt0410 TC Tinospora cordifolia
dt0415 TNFa tumor necrosis factor-a
dt0420 TH tyrosine hydroxylase
dt0425 TUNEL terminal dUTP nick-end labeling
dt0430 UCP-2 uncoupling protein 2
dt0435 VEGF vascular endothelial growth factor
dt0440 VEP visually evoked potential
dt0445 VIP vasoactive intestinal peptide
dt0450 ZDF Zucker diabetic fatty
dt0455 ZF Zucker fatty
dt0460 ZFDM Zucker fatty diabetes mellitus
s0005 1. PREVALENCE AND CAUSES OF DIABETIC
RETINOPATHY
s0010 1.1. Why experimental models are needed
p0465 The visual world is the most important environmental information source
for many species, including humans. None of the other sensory signals
reaches the brain in such variety and none is processed by as many cortical
areas as the visual cues. The first steps of visual processing are performed by a
thin sheath of neural tissue at the back of the eye, called retina. After pho-
totransduction, light information is translated into neural signals and shaped
by the retinal interneurons. Bipolar cells transmit the processed signal to gan-
glion cells that project to the brain and this is the sole source of visual signals
arriving there. Therefore, any damage to the retinal tissue immediately
results in vision loss and, in the worst case, causes total blindness.
p0470 Many retinodegenerative disorders such as glaucoma, ischemia, and dia-
betic retinopathy (DR) are thought to be consequences of pathological met-
abolic processes (Osborne et al., 2004). Metabolic insults vary and include
exposure to extremely strong light and changes in hormone/metabolite
levels or in blood/aqueous humor pressure. These processes lead to elevated
extracellular glutamate levels and can provoke excitotoxic insults (Atlasz
et al., 2008). The balance between the neurotoxic and neuroprotective
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factors is crucial in determining the survival of retinal neurons (Hernandez
and Simo, 2012). DR, a common complication of diabetes, develops in 75%
of patients with type 1 and 50% with type 2 diabetes, progressing to legal
blindness in about 5% (Engerman and Kern, 1995). Type 1 diabetes occurs
most commonly in children and young adults and constitutes 5–10% of the
diagnosed diabetics (Maahs et al., 2010). Type 2 diabetes accounts for
90–95% of diagnosed diabetes cases globally and typically develops in
middle-aged adults. Both type 1 and type 2 diabetic patients may develop
retinopathy; in particular, almost everyone with type 1 diabetes will develop
it over a 15–20-year period and greater than 60% of type 2 diabetes patients
will have retinopathy after 20 years (Hazin et al., 2011).
p0475 The aforementioned data call for increased efforts to learn more from the
pathogenesis of this disease and search for possible treatments/cures. Apart
from the increased diagnostic opportunities (e.g., the use of optical coher-
ence tomography) and the carefully analyzed results of clinical trials regard-
ing invasive and noninvasive treatment options (Gabriel, 2013; Hammes,
2013), experimental models are also necessary to utilize. However, one
has to be careful when translating results obtained in commonly used animal
models, because, besides similarities in the pathogenesis, profound differ-
ences can also be found (vascular symptoms and proliferativity) between ani-
mal models and human disease. Despite these differences, several animal
models have been developed and used successfully in revealing basic mech-
anisms both in the pathogenesis of DR and in studying possible protective
treatments. This is because the underlying physiological and biochemical
processes in humans are identical or very similar to those of experimental
animals.
p0480 The same statement applies also for the causes, as hyperglycemia is amajor
risk factor for the development and progression of DR. It plays an important
role in the pathogenesis of diabetic complications by increasing the levels of
advanced glycosylated end products (AGEs), which are late products of
nonenzymatic glycation. The accumulation of AGEs appears to be a key
factor in the development of DR. AGEs are thought to promote many
diabetic complications, including retinopathy, nephropathy, neuropathy,
and cardiovascular disease (Brownlee, 2005; Huebschmann et al., 2006).
p0485 Capillary occlusions are also characteristic features of early DR and are
presumed to initiate neovascularization. Diabetic rats (2–9 months into the
disease) showed capillary occlusions by leukocytes (especially monocytes),
endothelial cell damage, extravascular macrophage accumulation, and tissue
disintegration. In both induced diabetes and genetically diabetic mice, the
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development of diabetes is macrophage-dependent. The presence of
numerous interstitial macrophages is characteristic to DR. Leukocytes in
general and monocytes/macrophages in particular may not only be involved
in the pathogenesis of early DR but may also, at least in part, initiate the
microvascular pathology observed at later stages. Occluding monocytes or
granulocytes were found only in diabetic retinas. In rat models, areas of cap-
illary loss and neovascularization were associated with the presence of
monocytes or macrophages. Phagocytes are known to be necessary for
the removal of products of pathological processes. Capillary disintegration
is also a major factor in disease development. Accordingly, pericytes are
absent from the postmortem diabetic retinas. Some blood vessels that still
contained intact endothelial cells and vessels with microaneurysms tended
not to contain pericytes, suggesting that their loss permits uncontrolled pro-
liferation of endothelial cells. Pericyte dropout has been used as an index of
DR (Kern and Engerman, 1994). Permeability increase occurs in many ves-
sels simultaneously, first occurring in the larger superficial vessels and then
progressing to the capillaries of the outer retina within 2 months from the
onset of diabetes. The vascular permeability increase is a consequence of reg-
ulatory changes in tight junction proteins within a broad population of
endothelial cells rather than the apoptosis of a small number of endothelial
cells. Increased permeability causes edema in the nearby tissue. Edema is the
main reason of impaired vision in nonproliferative DR. Water transport
through aquaporins (AQPs) facilitates the development of ischemic edema
in the retina. Experimental diabetes is associated with the altered regulation
of AQPs in the pigment epithelium and the outer retinal layers. These alter-
ations might be involved in the adaptation of retinal cells to hyperglycemic
conditions and the development and/or resolution of retinal edema
(Hollborn et al., 2011).
s0015 1.2. Aims
p0490 As it can clearly be seen from the aforementioned facts, there are several areas
of research that have led and may further lead to breakthroughs in either the
diagnosis or treatment of DR. This review focuses on the recent advances
and current hopes in the area of experimental DR from the following
aspects: (i) What are the primary mechanisms driving the pathogenesis?
How do different neuronal cell types change during DR and what may help
to possibly rescue them? (ii) Which molecular pathways lead to cell death?
What is the contribution of nonneuronal cell types of the retina to these
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signaling pathways? (iii) Are there any differences between type 1 diabetes
and type 2 diabetes in the course of pathogenesis in developing DR? Can
animal models be established to study those? (iv) Which animal models
are the best for translational research? Finally, we will also give an overview
of a number of endogenous compounds and list several other (synthetic or
natural) substances that showed discernible protection against DR. In some
cases, their mode of action will also be discussed.
s0020 2. DIABETIC RETINOPATHY: EARLY SIGNS
AND LATE-DEVELOPING SYMPTOMS
p0495 As the worldwide prevalence of diabetes continues to increase, DR is a
leading cause of vision loss in developed countries (Fong et al., 2004). The
inability of the retina to adapt to metabolic stress leads to a glucose-mediated
microvascular disease along with chronic inflammation, which finally causes
neurodegeneration and dysfunction in the retina. The retina is one of the
most metabolically demanding tissues in the body, and therefore, it is highly
vulnerable. The interplay between the neuroretina and the vasculature is
critical in developing neurological symptoms of disease. In DR, the rate
of neuronal loss in the retina is slow, leading to a gradual, cumulative reduc-
tion mostly in amacrine and ganglion cells (Liu et al., 2008). Two forms of
DR can be clearly distinguished: an early, nonproliferative DR, when
neovascularization of the macula is not evident, and proliferative DRwhere
the symptoms includemacular neovascularization. Other vascular symptoms
involve microangiopathy, formation of microaneurysms, flame hemor-
rhages, leukocyte adherence to the vascular wall, and formation of exudates
in the extravascular space. These observations have led to the theory that
DR is primarily a vascular disorder whose degrading effects are due to
the consequences of vascular failure: ischemia followed by increased reactive
oxygen species (ROS) production, as in the case of the retinal ischemic dis-
eases (Fulton et al., 2009).
p0500 However, it has also been described that neuronal damage may precede
any detectable microvascular change (Barber et al., 1998). The deterioration
of the intrinsic time and also of oscillatory potentials (OPs) in the electro-
retinogram (ERG) starts early, in some cases as early as 2 days after induction
of diabetes in experimental animals (Li et al., 2002). These observations led
to the formulation of the “neurodegeneration-first” hypothesis (Villaroel
et al., 2010). Patients suffering from DR experience gradual vision loss; after
ERG deterioration, the visually evoked potentials (VEPs) also start to
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decrease (Wolff et al., 2010), which indicates cortical dysfunction. How-
ever, recent observations led to the conclusion that inflammation may pre-
cede or at least runs parallel with the vascular and neural events ( Joussen
et al., 2004; Liu et al., 2008; Tang and Kern, 2011).
p0505 Inflammatory molecules in the retina can be produced not only by leu-
kocytes but also by glial cells; many of them are produced by the Mu¨ller glia
(Bringmann and Wiedemann, 2012). Mu¨ller cells are primarily responsible
for ion and volume regulation of the retina and also control extracellular glu-
tamate levels through their excitatory amino acid transporters. They also
participate in protection against free radicals and hypoxic damage through
glutathione synthesis. Usually the first sign of the Mu¨ller cell stress is
upregulation of glial fibrillary acidic protein (GFAP) content, which may
be accompanied by hypertrophy and proliferation under certain damaging
conditions. Diabetes itself is able to upregulate GFAP inMu¨ller cells without
the presence of other symptoms of DR in humans (Villaroel et al., 2010),
and this goes along well with what we see in experimental models where
after 2 days of diabetes induction, GFAP upregulation is already apparent
(K. Szabadfi, unpublished observation). All the aforementioned observations
may lead to the formation of a fourth hypothesis of the initiation of DR, the
“glial cells-first” scenario. In this case, Mu¨ller cells, by sensing the elevated
glucose level, activate their volume and ion-regulating machinery and
release vasoproliferative vascular endothelial growth factor (VEGF;
Amandio et al., 2010; Eichler et al., 2000) and inflammatory substances
(prostaglandins, tumor necrosis factor (TNF), and interleukins; Behl
et al., 2008; Joussen et al., 2009; Tang and Kern, 2011). These would in turn
initiate neurodegeneration, inflammation, and vascular growth. Although
the exact order of events is unknown, all the aforementioned evidences sug-
gest that low oxygen supply and high blood glucose level are important pro-
DR parameters and all signaling pathways converge to activate VEGF
production.
p0510 The intraocular concentration of VEGF is closely correlated with active
neovascularization in diabetes. Hypoxia increases VEGF expression in ret-
inal cells, which promotes retinal endothelial cell proliferation, suggesting
that VEGF plays a major role in mediating intraocular neovascularization
resulting from ischemic retinal diseases. An increased expression of VEGF
in the retina is involved in generating vascular leakage and angiogenesis
in DR. In addition to VEGF, pigment epithelium-derived factor (PEDF),
a potent inhibitor of angiogenesis, is also involved in the pathogenesis of
DR (Patel et al., 2006). The time course of the VEGF-to-PEDF ratio
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change is correlated with the development and progression of retinal
neovascularization. The VEGF-to-PEDF ratio represents a dynamic balance
between the angiogenic stimulators and inhibitors; a disturbance in the bal-
ance plays a key role in the pathogenesis of DR (Chen et al., 2008; Gao et al.,
2001, 2002). Vascular changes especially regarding permeability have been
reported to occur as early as 8 days after onset of diabetes in rats (Do Carmo
et al., 1998). Capillary dilation and increased blood flow are some of the ear-
liest signs of diabetes both in rats (Cringle et al., 1993) and in humans
(Grunwald et al., 1994), supporting a “capillaries first” hypothesis.
s0025 2.1. Histological alterations
p0515 The neural retina is composed of diverse neurons characterized by morpho-
logical and biochemical criteria and numerous neural networks formed
through chemical and electrical synapses among the processes of these neu-
rons. These neuronal components are arranged into layers. Retinal ganglion
and displaced amacrine cells form the ganglion cell layer (GCL); bipolar,
horizontal, and amacrine cells occupy the inner nuclear layer (INL), while
the processes (and synapses) of the bipolar and amacrine cells and the gan-
glion cells contribute to assemble the inner plexiform layer (IPL). The
somata of photoreceptors (rods and cones) gather in the outer nuclear layer
(ONL), and their light-sensitive processes form the layer of the outer seg-
ments (PRL). The photoreceptors synapse with the horizontal and bipolar
cells in the outer plexiform layer (OPL).
p0520 The limits of the retina from the intravitreal side are the inner limiting
membrane (ILM), which is a close association of Mu¨ller glial cells end feet
and the pigment epithelial cells on the opposite side. Mu¨ller cells are the
major glial elements of the retina; their somata are positioned in the INL
and extend their processes toward the photoreceptors and retinal Au9ganglion
cells (RGCs).
p0525 The retinal pigment epithelium (RPE) is composed of a single layer of
hexagonal cells that are densely packed with pigment granules. The RPE
shields the retina from excess incoming light. It supplies omega-3 fatty acids
and glucose, the former for building photoreceptive membranes and the lat-
ter for energy. It also serves as a layer limiting transport, thus maintaining and
protecting the retinal environment.
p0530 The diabetic damage inflicted on all retinal (neuronal and nonneuronal)
cells by high glucose initiates a number of metabolic processes that altogether
closely approximate the molecular basis for the loss of vision associated with
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this disease. Here, we give a point-to-point overview about the retinal com-
partments that are altered by (experimental) diabetic retinal degeneration.
s0030 2.1.1 RGCs and the optic nerve
p0535 RGCs are the output elements of the retina. Their death immediately and
directly leads to loss of visual information. They have high sensitivity to cel-
lular damage and neurotoxicity; thus, RGCs are prone to degeneration in
diabetic retinas. All studied rat strains have shown RGC loss or damage
in diabetes starting from 4 weeks after the onset of diabetes up until
12 months (Kern and Barber, 2008). Reduced number of RGCs was dem-
onstrated in the retina of 15-week diabetic rats (Hammes et al., 1995b) and
also in short-term (4 weeks) diabetes (Zeng et al., 2000).
p0540 In ocular conditions, RGC loss is often associated with elevated intraoc-
ular pressure (IOP). The levels of IOP in 6- and 12-week diabetic mice
(C57BL/6) were significantly higher than their controls. In parallel with
these phenomena, the number of RGCs was significantly decreased after
only 6 weeks of diabetes. During a 12-week examination period, IOP
remained constantly high. However, it has to be noted that elevated
IOP-induced cell loss is not specific to induced diabetes, but rather is an
accompanied symptom of several ocular diseases (Yang et al., 2012).
p0545 In diabetic retina, structural alterations in RGCs can be easily recog-
nized. Their features include swellings on axons, often associated with con-
striction close to the cell body. There is structural remodeling of dendrites,
including an increase in the total length, density, and number of branches.
These changes surprisingly were found limited to the large ON-RGCs in
short-term diabetes and did not occur in any class of OFF-RGCs (Kern
and Barber, 2008). Similar changes in RGC morphology have been
observed in human retinas (Meyer-Rusenberg et al., 2007). This alteration
in a subset of RGCs could alter the functional output of the certain subtypes
of RGCs (Kern and Barber, 2008), leading to changes in VEPs (see later
text). While neurons in the INL were resistant to stable and long-lasting
moderate hyperglycemia during a 2-months’ period, the GCL underwent
both reactive and destructive changes. Chromatolytic changes to the RGCs
were in the foreground, and there was a somewhat less marked increase in
the number of pyknomorphic RGCs (Logvinov et al., 2010). Several
molecular and cellular mechanisms may be involved in RGC loss, which
will be discussed in the later text.
p0550 The number or density of axons in the rat optic nerve was found reduced
in induced diabetes in some, but not in all, rodent studies (Kamijo et al.,
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1993). The cross-sectional area of the optic nerves was not changed at 8 or
12 weeks of diabetes, but the percentage of area occupied by glial cells
increased and the axonal component decreased significantly. These alter-
ations showed highly significant correlations with the associated prolonga-
tion of the latencies of the VEPs, suggesting that axoglial disjunction and
axonal atrophy are major determinants for impaired optic nerve function
(Kamijo et al., 1993).
s0035 2.1.2 Amacrine, horizontal, and bipolar cells
p0555 These classes of cells represent the interneurons of the retina. Bipolar cells
transmit the signals from the photoreceptors to the RGCs, while horizontal
and amacrine cells are the constituents of the lateral signaling pathways in the
OPL and IPL, respectively. Despite the fact that bipolar cells are thought to
dominantly contribute to the b wave of the ERG, which is a major func-
tional marker of retinal health, there are currently no data available elucidat-
ing the bipolar cell reaction to diabetic conditions. The same also applies to
horizontal cells.
p0560 The most prominent change in the ERG seen in the early stages of dia-
betes involves the loss of OPs that are thought to derive from dopaminergic
amacrine cells (Shirao and Kawasaki, 1998). Therefore, the alterations in the
dopaminergic system seem to be among the first significant events in the
development of DR. Seki et al. (2004) named several possible mechanisms
underlying the degeneration of dopaminergic amacrine cells in diabetic ani-
mals: (i) severe insulin deprivation, (ii) hyperglycemia, and (iii) dysfunction
of Mu¨ller glial cells. The retina of the insulin-deficient Ins2Akita mice con-
tained 16% less dopaminergic amacrine cells than nondiabetic age-matched
control littermates (Gastinger et al., 2006). An extensive loss of cells, den-
dritic varicosities, and tyrosine hydroxylase (TH) content was seen in acute
(3 weeks) diabetes in rats (Szabadfi et al., 2012; see also Fig. 1.1).
p0565 The total number of cholinergic amacrine cells in the diabetic mice was
20% less than that in nondiabetic animals, but they were lost in a random
pattern. Diabetes leads to a greater reduction of cholinergic amacrine cell
density in the peripheral retina than in the central regions (Gastinger
et al., 2006). In the rat retina, most of the neurons containing neuronal nitric
oxide synthase (nNOS) appear to be amacrine cells, residing in the INL or
displaced to the GCL and closely related to vessels. The number of these
nNOS-containing cells was found to decrease by 32% as early as 1 week after
the streptozotocin (STZ)-induced diabetes and remained reduced for up to
8 months (Goto et al., 2005). These results suggest that some amacrine cell
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Figure 1.1f0005 Tyrosine hydroxylase (TH) immunoreactivity in healthy and diabetic rat ret-
inas. The dopaminergic amacrine cells are situated in the inner retinal layers, at the bor-
der of INL and IPL of the retina as were shown in the control vertical retinal section (B).
Representative fields of whole-mount retinal preparations of control (A), 3-week dia-
betic (C), and insulin-treated chronic diabetic animals (4 months of diabetes; E) and ret-
inal cross sections from the same three groups (B, D, F). TH immunoreactivity was in
higher density in the control retinas (A) compared with the two diabetic groups (C,
D and E, F, respectively), where the arborization of the TH-positive cells was also
reduced. Scale bars are 200 mm in pictures A, C, and E and 20 mm in pictures B, D,
and F. Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer.
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types may play pivotal roles in maintaining retinal integrity and if these cells
are damaged, retinal circuitry Au10suffers nonreparable consequences. Also, these
cells may not be the most numerous—dopaminergic and nitrergic cells both
represent less than 1% of amacrine cells but may confer widespread regula-
tory functions.
s0040 2.1.3 Photoreceptors
p0570 Various aspects of visual information are transmitted in parallel from photo-
receptors to the output neurons of the retina, which code for many different
signals, for example, brightness, darkness, contrast, color, and motion. Pho-
toreceptors are one of the most metabolically active cell types of the retina
(Wassle, 2004). There are several factors such as metabolic changes associ-
ated with diabetes that may lead to outer retinal dysfunction. Aizu and
coworkers (2002) provided the first evidence showing changes of photore-
ceptor layer (PRL) during DR; the shortening of the photoreceptor outer
segment (OSs) and the increase in the number of fragmented cone photo-
receptors and a disrupted photoreceptor–RPE cell complex were shown by
electron microscopy in rats with very early stage of diabetes (1 month after
the onset of diabetes). Since RPE cells produce a variety of trophic factors
and have an important role in renewing the photoreceptor OSs, their dam-
age will also influence the phototransduction process. A 2-month diabetic
period induced destructive changes in the neurosensory cells. Fragmentation
and vacuolar degeneration of the OSs are characteristic, as well as nuclear
pyknosis, edema of the perikaryon, and enlargement of the scleral processes
of Mu¨ller cells, which actively phagocytose degraded OSs. Quantitative
analysis demonstrated a threefold increase in the proportion of photorecep-
tors with pyknotic nuclei (Logvinov et al., 2010).
p0575 As a consequence of the aforementioned structural damage after
diabetes-induced dysfunction, the retinal phototransduction is apparently
hindered even in early-stage diabetes, including deterioration of the flash
response and light adaptation (Kim et al., 2005).
s0045 2.1.4 Synaptic layers
p0580 The signal transmission of various classes of retinal neurons is the physiolog-
ical bases for visual processing and requires a range of synapses with different
kinetics, such as electrical synapses, conventional chemical synapses, and rib-
bon synapses. Diabetes impacts a broad population of retinal synapses, which
may explain significant thinning of the IPL, after a longer duration of dia-
betes (Barber et al., 1998, 2005). Ribbon synapses in both plexiform layers
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are especially strongly affected (Fig. 1.2). The thickness of the IPL in the
6-month diabetic rats was markedly reduced (Aizu et al., 2002). There
was a 22% decrease in the thickness of the IPL in rats after 7.5 months of
STZ-induced diabetes, suggesting a cumulative loss of neural dendrites
and synapses in the inner retina (Barber et al., 1998).
p0585 After 1 month of STZ-induced diabetes, synaptophysin content was
found reduced in the whole retina and also in isolated retinal synaptosomes.
The size and density of synaptophysin-immunoreactive punctawere reduced
in the plexiform layers. The loss of synaptic proteins in retinal synaptosomes
was accompanied by decreased mRNA content after 1 month of diabetes;
therefore, diabetesmay increase local degradation rate of presynaptic proteins
at retinal synapses and also that of their mRNA (VanGuilder et al., 2008).
Indeed, synaptophysin mRNA translation continues at a higher rate after
the induction of diabetes as a compensatory mechanism of the reduction
of themature protein.Nevertheless, there is also an increase in its degradation
during an early stage of its maturation, possibly during its posttranslational
processing (D’Cruz et al., 2012). These findings suggest multiple potential
regulatory mechanisms for synapse disintegration.
s0050 2.1.5 Müller glial and retinal pigment epithelial cells
p0590 Although often considered as nonprincipal components, these cell types are
integral constituents of the retinal metabolism.
s0055 2.1.5.1 Müller glial cells
p0595 Mu¨ller glial cell is the principal glia of the retina, which expresses a diversity
of ion channels and transporters, releases a variety of cytokines and survival
factors, and has receptors for numerous neurotransmitters and growth fac-
tors. Mu¨ller cells play an active, dynamic role in the retina. They are radially
oriented and span the depth of the retina from the vitreal border to the inter-
photoreceptor matrix of the subretinal space. Their processes are in close
apposition to neuronal cell bodies, neurites, and synapses, and blood vessels
and their processes make contact with most neural cells (Sarthy and Harris,
2001). They also form end feet on both large vessels and capillaries in the
inner and outer retinal vessel beds. Mu¨ller glial cells are vital for maintaining
normal neuronal and vascular function in the retina. Their mechanical role is
stabilizing the retinal architecture, and they are involved in regulating retinal
glucose metabolism, modulating the ionic and molecular composition of the
retinal microenvironment, altering blood flow to match the local metabolic
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Figure 1.2f0010 Ultrastructure of the outer and inner plexiform layers (OPL and IPL) of con-
trol, early diabetic (3 weeks) and chronic diabetic (4 months) rat retinas. Although rib-
bons of the photoreceptors are still present in the OPL of both diabetic retinas (arrows:
C, E), they are less densely packed and shorter than those of the controls (A). Some
degenerative profiles appear (asterisks: C, E). The processes are often devoid of synaptic
vesicles. In the IPL, the ribbon and conventional synapses are (arrowheads) healthy in
the control retinas (B) if compared with the same structures of the diabetic retinas (D, F).
The shape of the ribbons was distorted in diabetic animals; they did not have sharp con-
tours as found in control retinas. Almost no synapses were present in the IPL compared
with the control (B); some unusual ribbons and degenerating synaptic profiles were
seen in the IPL (arrowheads: D, F). Scale bars: indicated in the images.
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needs, and contributing to the maintenance of the inner blood–retina barrier
(BRB; Bringmann et al., 2006).
p0600 In normal conditions, the end feet of the glia express GFAP. Increased
GFAP expression has been widely used as a cellular marker for several retinal
pathologies. It has been suggested that elevated expression of GFAP in the
cell body and processes is an aspecific metabolic stress signal (Lundkvist et al.,
2004). Mu¨ller glial cells regulate the extracellular environment of neurons in
the retina by clearing glutamate from synaptic clefts and by providing glu-
tamine to neurons for the resynthesis of glutamate to be used in neurotrans-
mission. This ability of glia in diabetic rat retina is reduced to only 65%,
which results in an overall increase of total extracellular glutamate levels that
is toxic to retinal neurons. Mu¨ller glial cells in diabetes showed reduced glu-
tamate aspartate transporter (GLAST) function (Li and Puro, 2002) and
impaired glutamine synthesis. The adverse effects of diabetes on the function
of Mu¨ller cells in transporting glutamate by GLAST or in metabolizing glu-
tamate by glutamine synthase (GS) have been widely studied (Kowluru
et al., 2001; Li and Puro, 2002; Lieth et al., 2000). Although alterations
in GLAST activity during diabetes remain controversial, impairment of
GS activity is convincingly evident (Mysona et al., 2009; Ward et al.,
2005; Zeng et al., 2009). A positive-feedback loop involving oxidative stress
and dysfunction of GLAST may be important in the progression of DR
(Puro, 2002). These dysfunctions also participate in creating elevated gluta-
mate levels in the microenvironment of diabetic retinas, whichmight induce
excitotoxicity in amacrine cells and RGCs (Lieth et al., 1998).
p0605 Glial cells not only send signals to other components of the retina but also
change their own makeup. Changes in glia are accompanied by several dys-
functional responses, including altered potassium and glutamate regulation
(Li and Puro, 2002; Lieth et al., 1998) and g-aminobutyric acid (GABA) accu-
mulation (Ishikawa et al., 1996). One of the early histological alterations in the
retina of the diabetic ratswas the increase inGFAPexpressionof theMu¨ller cell
processes as early as few days after the onset of diabetes, which is a nonspecific
response to pathophysiological conditions (Fig. 1.3). Mu¨ller glia is adversely
affected early in the course of diabetes, the reactive “phenotype” characterized
by hyperplasia and upregulation of GFAP (Lieth et al., 1998). Apart from the
aspecific glial reactions, hyperglycemia leads to overexpression of several bio-
logically active factors, like proinflammatory cytokines (Gerhardinger et al.,
2005) and insulin-like growth factor 1 (IGF-1; Inokuchi et al., 2001).
p0610 Besides excitotoxicity-induced changes, products of carbohydrate
metabolism may also cause alterations in Mu¨ller glia functions. During early
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experimental diabetes, there is a selective accumulation of the acrolein-
derived advanced lipoxidation end products (ALEs), one of which is Ne-
(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine), originally restricted
to the end feet at the ILM, but as the disease progresses, this adduct appears
in the radial fibers. This agent is pathogenic for theMu¨ller glia itself; changes Au11
in polyamine catabolism could underlie the diabetes-induced accumulation
of FDP-lysine. The observed accumulation of these adducts could poten-
tially contribute to Mu¨ller cell dysfunction and death during long-term dia-
betes (Yong et al., 2010). Despite all these unfavorable processes, Mu¨ller
cells are not among the retinal cell populations undergoing apoptosis early
in diabetes (Ali et al., 2008).
p0615 During diabetes, hyperglycemia and oxidative stress upregulate VEGF
that induces retinal neovascularization, vascular leakage, andmacular edema.
VEGF may also be expressed in, to a lesser extent, endothelial cells, astro-
cytes, RPE, and RGCs. However, Mu¨ller cells are the major source of
VEGF in DR (Arjamaa and Nikinmaa, 2006; Kim et al., 2009b). VEGF
plays a leading role in inducing retinal inflammation and vascular leakage
that occurs as a consequence of diabetes. The loss of Mu¨ller cell-derived
VEGF significantly inhibits diabetes-induced vascular leakage and attenuates
capillary acellularity. It is possible that VEGF derived from other endothelial
and retinal cells contributes to diabetes-induced retinal inflammation and
vascular leakage in the presence of Mu¨ller cell-derived VEGF, which
together may serve as a key to the “pathological threshold” (Wang et al.,
2010a). While the endothelial cell-derived VEGF plays a role in the
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Figure 1.3f0015 Immunofluorescent labeling of glial fibrillary acidic protein (GFAP) in the rat
retinas. In normal conditions, only the end feet of the Müller glia (ILM) express GFAP (A).
Damaging conditions such as diabetes are able to initiate the upregulation of GFAP in
the whole extent of the cells. In STZ-induced hyperglycemia, GFAP upregulation is read-
ily observed (B), as well as after 3 weeks of diabetes (C). Upregulation may be present
even if insulin treatment is applied in chronic diabetes (4 months; E). Reduced GFAP
expression is detected in PACAP-treated 3-week acute diabetic retinas (D). Scale bar:
20 mm. Abbreviations: OLM, outer limiting membrane; ILM, inner limiting membrane.
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pathogenesis of DR (Huang and Sheibani, 2008), the RPE-derived VEGF
rather contributes to the RPE–choriocapillaris interaction and regulates
outer BRB (Hartnett et al., 2003), which may influence the osmotic balance
and the nutrient supply of the outer retina.
p0620 Diabetes also alters osmotic swelling characteristics of glial cells. Glial
cells in diabetic retinas are more sensitive to osmotic stress. The functional
K+ channels in retinal glial cells undergo alterations in the course of exper-
imental diabetic conditions, and these are associated with the changed swell-
ing characteristics of retinal glial cells, which contribute to the development
of edema. Retinal edema also develops under ischemic–hypoxic and/or
inflammatory conditions. Osmotic glial cell swelling has been linked to
the decrease of the main K+ conductance of the cells and to endogenous
formation of arachidonic acid in response to osmotic stress (Pannicke
et al., 2006), which may in turn regulate the inflammatory responses. This
aspect is critical to retinal integrity, since inflammatory cells to the retina
mostly arrive through the ILM, which is formed by the end feet of Mu¨ller
cells. Indeed Au12, Mu¨ller cells form two discreet barriers at two strategic loca-
tions. Apart from the aforementioned ILM, the second barrier is formed
at the top of the ONL, which is a discontinuous, lace-like structure sur-
rounding the photoreceptor cell bodies. It can be disrupted during diseases
such as DR (Omri et al., 2010). The apical processes of Mu¨ller cells are
attached to each other and to inner segments of the photoreceptor cells that
collectively form the outer limiting membrane (OLM). The junction pro-
teins are located in the OLM. Adherens junctions, occludins, and desmo-
somes have been identified there. OLM could serve as a gate for
macromolecule transport into the retina and act as a semipermeable barrier.
During DR, the Mu¨ller cells are not only swollen, but they lose their
occluding power at the OLM level, which leads to cyst formation (Omri
et al., 2010).
p0625 Since astrocytes are also present in the nerve fiber layer (NFL) and
around the capillaries, here, early changes in astrocytes are coincident with
inner retinal hypoxia and RGC functional deficits. Therefore, astrocytes
may contribute to changes in retinal vasculature and inner retinal dysfunc-
tion in diabetes (Ly et al., 2011).
s0060 2.1.5.2 Pigment epithelial cells
p0630 The inner BRB is formed by tight junctions between vascular endothelial
cells, whereas the outer retinal barrier is specific to the eye and consists of
the tight junction present in a monolayer epithelium, the RPE cells. The
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apical side of RPE faces the photoreceptor OSs of the neuroretina, and the
basolateral side lies on Bruch’s membrane, which separates the RPE from
the fenestrated endothelium of the choriocapillaris (Simo et al., 2010).
The RPE is a selective exchange platform between the systemic circulation
and the retina, and the subretinal space between RPE and the neuroretina is
considered as an immune-privileged site (Xu et al., 2009). Glucose entry
into the retina occurs at two major anatomical interfaces: the retinal capil-
laries and the RPE. These cells form part of the BRB. Glucose entry into the
retina through the BRB is mediated by a saturable, facilitated transport pro-
cess involving glucose transporter 1 (GLUT1), a member of a family of
sodium-independent glucose transporter proteins (Kumagai, 1999). It has
already been demonstrated that GLUT1 has asymmetrical distribution
between the luminal and abluminal membranes (with a 4-to-1 ratio) of
the inner BRB in normal rats (Fernandes et al., 2003). Glucose transport
in the retinal endothelial cells is mediated by a number of different factors,
including hypoxia, hyperglycemia, and cytokines, through a variety of dif-
ferent signaling pathways (DeBosch et al., 2002). Several factors associated
with the development and progression of DR, such as hypoxia, VEGF, and
IGF-1, have been demonstrated to increase GLUT1 expression and/or glu-
cose transport (DeBosch et al., 2002; Sone et al., 1997).
p0635 High blood glucose results in high glucose levels in the retina by
transporting more glucose with the GLUT1 between the blood and retina.
Changes in retinal endothelial cell GLUT1 expression and glucose transport
may have a major impact in providing substrate to the various pathogenic
processes. It has also been thought to underlie the development of DR
and be the ultimate cause of it (Kumagai, 1999). To protect the intracellular
environment from excessive glucose flux and/or diabetes, most tissues
downregulate glucose transport in response to elevated extracellular glucose
concentration. In STZ-induced diabetic rats, Badr et al. (2000) reported a
50% decrease in total retinal GLUT1 and retinal microvascular GLUT1 after
8 weeks of diabetes. Persistently high glucose levels may induce the prolif-
eration of RPE cells. RPE cells also secrete VEGF, which is believed to play
an important role in the neovascularization of the retina. RPE showed deep-
ened hollows in the basal infoldings 1 month after the onset of diabetes. After
6 months, the RPE contained large concavities, which were created by
depressions of basal infoldings. Both the microvilli and the basal infoldings
were degenerated, which suggests the destruction of the transport pathway
between the choroid and the outer retina suggesting a possible breakdown of
the BRB (Aizu et al., 2002; Fig. 1.4).
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Figure 1.4f0020 Electron micrographs of pigment epithelial cells (RPE) and photoreceptor
outer segments (OS) in control, early diabetic (3 weeks) and chronic diabetic (4 months)
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s0065 2.1.6 Cells migrating to the retina in response to diabetes
p0640 DR is a chronic inflammatory disorder; low-grade inflammation has been
observed in the retinas of both diabetic animals and human patients
(Kern, 2007; Krady et al., 2005; Zeng et al., 2008).
p0645 Microglial cells, the main resident sentinel immune cells in the healthy
retina, are located in the inner retina, around blood vessels. These cells
become activated andmigrate in the subretinal space in several retinopathies,
including DR (Zeng et al., 2000, 2008). The activation of microglia induced
by hyperglycemia has been associated with the early development of DR and
occurs as early as electroretinographic modifications (Gaucher et al., 2007;
Kern, 2007). Cytokines, among other cells released by activated microglia,
were shown to contribute to neuronal cell death (Krady et al., 2005). Acti-
vated displaced microglial cells have a pathogenic role in the time course of
DR. Indeed, activated microglia produce cytotoxic substances, such as
TNFa, ROS, proteases, and excitatory amino acids, whichmay induce neu-
ronal degeneration. In vivo, the time course of diabetes in noninsulin-
dependent Goto–Kakizaki (GK) rats is modified by microglia/macrophage
trafficking, leading to subretinal accumulation and potential toxicity medi-
ated by these cells. “Pores” in RPE cells are formed at the early stages of
DR, when tight junctions between RPE cells are still intact and serve as a
migratory pathway for inflammatory cells (microglia/macrophages). This
“transcellular” route is also used by leukocytes or lymphocytes for migration
through the endothelial cell bodies. The transcellular pathway is established
inRPE cells in the following steps: (i) the identification of “tunnel structures”
crossing thewhole thickness of the cell with preserved tight junctions, (ii) the
recruitment of interstitial cell adhesion molecule 1 (ICAM-1) and caveolin 1
(CAV-1) around the pores and getting protein kinase Cz (PKCz) involved in
the pore formation, and (iii) the identification of ionized calcium-binding
adaptor molecule 1-positive cells (resident microglial cells) crossing the
RPE through the pore. The presence ofmicroglia/macrophages in the retina
of diabetic GK rat could be related to the expression of ICAM-1, which is
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rat retinas. In normal retinas, intact structures of the RPE and the OSs were seen (A). Early
diabetic retinas contained abnormal blood vessels with red blood cells inside the retina,
nearby the RPE. The somata of RPE were pycnotic; themembranes between the RPE and
choroid have swollen (B). RPE had intact appearance in chronic diabetic retinas, and it
seemed like the control retinas; however, their microvilli were missing and several
degenerative structures were seen at the junction of the RPE and OS (C). Scale bars: indi-
cated in the images. Abbreviations: OS, outer segment; RPE, pigment epithelium; RBCs,
red blood cells.
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essential for inflammatory cell migration. At the early stages of diabetes
(5 months of hyperglycemia), the RPE transcellular pathway is functional.
Later in the course of diabetes (12 months), ICAM-1 and CAV-1 protein
expressions in RPE cells decrease and the accumulation of subretinal
microglia/macrophages is observed, together with significant decrease in
the number of RPE pores. Morphological abnormalities are observed in
the outer retina, withRPE vacuolization and loss of junction integrity as well
as disorganization of photoreceptor OSs. A migration of cells from the retina
toward the choroid could occur through RPE; PKCz is a new actor partic-
ipating in this process (Omri et al., 2011). Via the inhibition of PKCz signal-
ing pathway,macrophage survival and deactivation are promoted possibly by
changing the intraocular immune environment (Mantovani et al., 2004).
PKCz is induced by TNFa, suggesting its possible implication in diabetes-
induced BRB breakdown (Aveleira et al., 2010).
p0650 Leukocyte-mediated retinal cell apoptosis is among the earliest patholog-
ical manifestations of DR and results in the formation of acellular-occluded
capillaries, microaneurysms, and vascular basement membrane thickening
(Engerman and Kern, 1995). The role of VEGF in the development of these
diabetic complications in the eye is well established. In human DR, all types
of macrophages could be detected regardless of clinical history and duration
of the disease. In the eye of a 47-year-old man with simple DR, numerous
spherical cells with pseudopodal protrusions were observed throughout the
retina. They were identified as macrophages in light, scanning electron and
transmission electron microscopic studies. The macrophages were particu-
larly dense and were arranged in a circinate pattern corresponding to circi-
nate lesions within the retina. The macrophages also densely populated
retinal areas with hard exudates. In areas adjacent to the macrophages, the
inner retinal surface lost its smooth and continuous structure. The matrix
in the ILM disappeared in such areas so that a coarse network of filaments
lay bare on the retinal surface (Kishi et al., 1982). In the sclera of alloxan-
induced diabetic mice, the number of mast cells was significantly increased.
No increase in the mast cell number could be observed in the sclera of the
obese hyperglycemic mice. The lack of insulin may be of importance for the
accumulation of mast cells in the sclera of mice with hyperglycemia ( Jansson
and Naeser, 1987).
s0070 2.2. Molecular alterations
p0655 As we have shown in the preceding text, DR is a multifactorial progressive
disease where its pathogenesis is extremely complex involving many
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different cells, molecules, and factors. Diabetes-induced metabolic changes
in the retina induce a range of molecules and pathways involved early in the
pathophysiology of DR.
s0075 2.2.1 Apoptotic markers
p0660 Many kinds of retinal cells undergo accelerated apoptosis before other his-
topathologic changes are detectable in diabetes. One of the most perplexing
biochemical changes in DR is the persistent, slow apoptosis of vascular and
neural cells, which has been observed in retinal tissues from humans with
diabetes and diabetic animal models. The relationship Au13between apoptoses
of vascular and neural cells is unclear, with the possibility that loss of these
different classes of the cells occurs over different time frames and by
unrelated mechanisms (Barber et al., 2011). Significant neural apoptosis is
an earlier event than vascular apoptosis, and the rate of neural apoptosis
remains constant throughout the duration of diabetes. Since neurons are
unable to proliferate, apoptosis of these cells will result in cumulative loss
leading to chronic retinal degeneration (Barber et al., 2011).
p0665 In rats, a 10-fold increase in the frequency of the apoptosis was observed
comparedwith control animals after only 1month of STZ-induced diabetes,
continuing with the same frequency for at least 12months. The vast majority
of apoptotic cells appeared to be RGCs (Barber et al., 1998; Lorenzi and
Gerhardinger, 2001). Apoptotic events can be revealed by in situ DNA
terminal dUTP nick-end labeling (TUNEL) or measuring active caspase
3. After only 2 weeks, STZ-induced diabetic rat retinas, besides 2.5-fold
more TUNEL-positive nuclei, had the highest density of caspase
3-immunopositive cells compared to the control (Gastinger et al., 2006).
Labeling could be found in photoreceptors and dopaminergic amacrine cells
as well. Both methods showed significantly more apoptotic cells in the ret-
inal layer in 6-week diabetic mouse retinas, and in addition, electron micro-
scopic analysis revealed cells in the GCL that had the classical morphological
characteristics of apoptosis (i.e., disintegrating nuclei) (Martin et al., 2004).
p0670 Several studies demonstrated that oxidative stress induced by hypergly-
cemia is closely linked to apoptosis in a variety of retinal cell types (Abu
El-Asrar et al., 2007). This may partly be linked with the changes of capillary
structure and distribution. Engerman and Kern (1995) had found a small but
significant increase in the number of TUNEL-positive apoptotic cells in the
capillaries of postmortem human diabetic retinas (who had diabetes for an
average of 10 years) compared with normal retinas. A similarly modest
increase in vascular cell death was found in rats after 31 weeks of STZ-
induced diabetes. The increase in vascular cell apoptosis suggests a potential
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mechanism for the appearance of acellular capillaries given that the endothe-
lial cell bodies and nuclei were thought to disappear while leaving their
intact basement membranes behind (Mizutani et al., 1996). Vascular cell
dropout can be a response to reduced metabolic demands from the sur-
rounding neurosensory retina, as in photoreceptor degeneration; hence, it
is conceivable that vascular apoptosis represents a final response to localized
cell death in the surrounding neural tissue (Barber et al., 2011).
s0080 2.2.2 Glutamate excitotoxicity-induced apoptosis in diabetic retina
p0675 Diabetes may impair glutamate uptake and metabolism resulting in accumu-
lation of extracellular glutamate, leading to excitotoxicity in which excess
glutamate stimulation causes an uncontrolled intracellular calcium response
in postsynaptic neurons (Laabich and Cooper, 2000). This is primarily true
for ganglion cells, which are known to possess NMDA receptors (Thoreson
and Witkovsky, 1999). The elevated aspartate immunoreactivity of Mu¨ller
cells in diabetic rats suggests slower clearance of glutamate, whereas excised
Mu¨ller cells from STZ-treated rats after 1 month of diabetes demonstrated
reduced glutamate transporter activity (Li and Puro, 2002; Puro, 2002;
Ward et al., 2005). Diabetes may also alter the regulation of glutamate recep-
tor expression. The combined changes in the glutamate signaling system
may ultimately increase apoptosis despite compensatory mechanisms
designed to protect neurons, and the resultant imbalance in neurotransmis-
sion could also lead to dysfunction in visual signal processing in the retina.
Thus, glutamate excitotoxicity suggests a mechanism for not only the
increases in cell death but also the altered ERG response and the loss of visual
function in diabetes (Barber et al., 2011).
s0085 2.2.3 Pathways
p0680 Hyperglycemia has been considered the key initiator of retinal damage asso-
ciated with DR by activation or dysregulation of several (glycolytic, protein
kinase C (PKC), polyol, poly-(ADP)-ribose polymerase (PARP), and
hexosamine) pathways. All these converge to increase the production of
ROS, which induces apoptosis and inflammatory responses and promotes
angiogenesis (Ola et al., 2012). It also induces the diacylglycerol (DAG)
pathway de novo, initiating its synthesis through actions of phospholipase
C. The elevated level of DAG has been linked to vascular dysfunctions
and pathogenesis of DR (Geraldes and King, 2010). The activity of PKCs
is greatly enhanced by DAG, which has been implicated in several cellular
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and structural abnormalities occurring in DR (Curtis and Scholfield, 2004;
Das Evcimen and King, 2007).
p0685 The overexpression of the pro nerve growth factor (NGF) mimics dia-
betes action resulting in retinal neurodegeneration in vivo and in vitro. RGCs
are more sensitive to death signals in response to proNGF. The direct apo-
ptotic effect of proNGF on RGCs delineates the apoptotic role of RhoA
activation in retinal neurodegeneration. The significant activation of
RhoA/p38 mitogen-activated protein kinase (MAPK) pathway causes neu-
ronal death with increasing phosphorylation of c-Jun N-terminal kinase
(JNK) and p38 MAPK in response to overexpression of proNGF in the dia-
betic rat retina (Al-Gayyar et al., 2013).
p0690 The polyol pathway of glucose metabolism becomes active when intra-
cellular glucose levels are elevated. The polyol pathway is the only mecha-
nism of glucose toxicity currently proved to be responsible for the spectrum
of neural, glial, and vascular abnormalities detectable during the develop-
ment of DR (Dagher et al., 2004). Aldose reductase is the key and rate-
limiting enzyme in polyol pathway, and galactose and glucose are substrates
to this enzyme. Under diabetic conditions, the increased level of glucose
activates this pathway, which causes reduced NADPH level in the cyto-
plasm. The resulted decrease in glutathione and increased oxidative stress
are the major factors of the retinal damage (Barba et al., 2010). The polyol
pathway is therefore a rational candidate mechanism for the ganglion cell
apoptosis and Mu¨ller glial cell activation that occur early in both human
and rat diabetes (Lorenzi and Gerhardinger, 2001). Further, the polyol path-
way initiates and multiplies several mechanisms of cellular damage by acti-
vation of aldose reductase and other pathogenetic factors such as advanced
glycosylated end product (AGE), activation of oxidative–nitrosative stress,
and PKC pathway that may lead to initiation of inflammation and growth
factor imbalances (Obrosova and Kador, 2011). PARP activation in diabetic
retinas causes DNA breaks, thus exacerbating oxidative and nitrosative stress
(Drel et al., 2009). The progression of axonal atrophy and axoglial disjunc-
tion in the optic nerve in 12-month diabetic Bio-Breeding/Worcester (BB/
W) rats is a polyol pathway-related mechanism activated by hyperglycemia
and galactosemia. Hexosamine has been shown to impair insulin signaling in
retina (Nakamura et al., 2001), therefore being also considered as a potential
pathway implicated in DR (Ola et al., 2012).
p0695 The high glucose and the diabetic state stimulate different pathways to
produce excess levels of ROS. It is still unclear whether oxidative stress
has a primary role in the pathogenesis of diabetic complication occurring
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at an early stage in diabetes or whether it is a consequence of the tissue dam-
age (Fernandes et al., 2011; Izuta et al., 2010). Mitochondria play a key role
in the control of apoptotic cell death. Bad is a proapoptotic member of Bcl-2
family that promotes apoptosis by binding to and inhibiting functions of
antiapoptotic proteins Bcl-2 and Bcl-xL. Early during the apoptotic process,
mitochondria can release several apoptogenic proteins, such as cytochrome c
and apoptosis-inducing factor (AIF), into the cytosol (van Gurp et al., 2003).
Increased ratio of Bax to Bcl-2 occurs early in the DR and plays a role in the
apoptosis of retinal cells (Gao et al., 2009b). Retinal mitochondria become
leaky during diabetes (8 months). When capillary cell apoptosis is observed,
cytochrome c starts to accumulate in the cytosol and Bax is secreted into the
mitochondria. The inhibition of superoxides Au14in turn inhibits the glucose-
induced release of cytochrome c and Bax and inhibits apoptosis in both
endothelial cells and pericytes (Kowluru and Abbas, 2003).
p0700 Mitochondria are also the major endogenous source of superoxides and
hydroxyl radicals. Reactive oxidant intermediates can trigger mitochondria
to release cytochrome c, resulting in activation of caspase 3 (Sandbach et al.,
2001). Overproduction of superoxides by mitochondria is considered a
causal link between elevated glucose and the major biochemical pathways
postulated to be involved in the development of diabetic complications
(Brownlee, 2001). According to a recent report, mitochondrial structure,
mitochondrial function, and mitochondrial DNA (mtDNA) are damaged
in the diabetic retina and its vasculature, and the mtDNA repair machinery
is also compromised. Diabetes also facilitates epigenetic modifications,
which contribute to the mitochondria damage. Diabetes-induced abnor-
malities in mitochondria continue even when the hyperglycemic insult is
terminated and are implicated in the metabolic memory phenomenon asso-
ciated with the continued progression of DR (Kowluru, 2013).
p0705 An increase in peroxynitrite as indicated by tyrosine nitration correlates
with accelerated retinal endothelial cell death, breakdown of the BRB, and
accelerated neuronal cell death in experimental models of diabetes, inflam-
mation, and neurotoxicity (Ali et al., 2008; Du et al., 2002; El-Remessy
et al., 2003a,b, 2005). Peroxynitrite plays a key role in mediating different
aspects of DR. In response to hyperglycemia-induced oxidative stress, both
microglial and macroglial cells are activated, and the function of macroglia in
transporting glutamate by glutamate transporters and in metabolizing gluta-
mate by GS may be impaired (Li and Puro, 2002; Lieth et al., 1998, 2000).
This may lead to glutamate accumulation, such as that reported in the vit-
reous humor of diabetic patients (Ambati et al., 1997) and in the retina of
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:49:51 Page Number: 26
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
26 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
diabetic animals (Kowluru et al., 2001; Lieth et al., 1998). GS is susceptible
to tyrosine nitration, which subsequently can impair the enzyme activity
(Gorg et al., 2005, 2007). This vicious cycle of glial dysfunction will result
in cell death and the injury of adjacent retinal neurons.
s0090 2.2.4 Metabolic end products
p0710 Glycation is an important event that occurs in physiological and pathophys-
iological circumstances. Acute hyperglycemia and chronic hyperglycemia
are known to enhance early, intermediate, and advanced glycation. The
deposition of hyperglycemia-induced AGEs in retinal blood vessels plays
an important role in the onset and development of DR in vivo. AGEs are
late products of nonenzymatic glycation. The pathogenic significance of
ALEs in DR is less well known (Shanmugam et al., 2008; Stitt et al.,
2004) than those of AGEs (Denis et al., 2002). AGEs/ALEs can form on
the amino groups of proteins, lipids, and DNA through a number of com-
plex pathways including nonenzymatic glycation by glucose and reaction
with metabolic intermediates and reactive dicarbonyl intermediates.
AGEs/ALEs are known to accumulate in the diabetic retina where they
are thought to influence retinal vascular cell function (Stitt et al., 2004).
A possible pathway of oxidative stress in the development of DR that
may contribute to retinal cell dysfunction and degenerative changes is the
formation of ALEs. ALEs may induce a variety of cytopathologic effects,
including cross-linking of cell surface proteins, inactivation of enzymes,
and stimulation of proinflammatory and proapoptotic signaling pathways.
p0715 During the pathological action, AGEs promote the upregulation of
SLIT-ROBO signaling, which acts as a cue in neuronal guidance during
development and plays a role in vasculogenesis and angiogenesis throughout
life. Hereby, it may actively participate in the progression of DR (Zhou
et al., 2011). The SLIT-ROBO signaling cascade includes Slit family of
secreted proteins (Slit1, 2, and 3) and their corresponding receptors
(Robo1, 2, 3, and 4). Robo1 and 4 are involved in retinal vasculogenesis
and angiogenesis (Huang et al., 2009a,b, 2010) and are expressed in the cho-
roid and the retinal endothelial and RPE cells. RPE cells autosecrete Slit2,
which then binds the single-pass transmembrane receptor, Robo1, under
conditions of DR. AGEs promote the upregulation in Robo1 and Slit2
expressions, which may be involved in the pathological action of AGE.
N-Slit2 (the recombinant protein) results in increased proliferation, attach-
ment, and migration of RPE cells, which increases VEGF mRNA expres-
sion and VEGF secretion (Zhou et al., 2011).
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p0720 AGEs initiate the onset of DR through both receptor- and nonreceptor-
mediated pathways. AGE cross-linking causes proteins that are normally
flexible to become rigid, resulting in their dysfunction. The binding of
AGEs with receptors in macrophages and endothelial cells initiates a release
of a large number of cytokines, inducing endothelial cell proliferation and
damaging retinal blood vessels (Qazi et al., 2009). Glucose irreversibly mod-
ifies long-lived macromolecules by forming AGEs during periods of normal
glucose homeostasis, which may explain the phenomenon of hyperglycemic
memory. AGEs cause qualitative and quantitative changes in extracellular
matrix components such as collagen and laminin and can affect cell adhesion
and growth and matrix accumulation, thus altering cell function. AGEs can
attack the nucleus directly and block DNA synthesis, thus interfering with
the proliferation of pericytes. AGEs disturb microvascular homeostasis
through interaction with the receptor of AGEs (RAGE). This AGE–RAGE
axis plays a central role in the inflammation, neurodegeneration, and micro-
vascular dysfunction in DR (Zong et al., 2011).
p0725 Increased AGEs formation and accumulation have been found in retinal
blood vessels and vitreous of diabetic patients and animals, which correlate
with a degree of DR (Goh and Cooper, 2008). Retinal pericytes accumulate
AGEs during diabetes,which are implicated in endothelial cell injury andBRB
dysfunction (Stitt et al., 2000). AGEs increase VEGF, monocyte chemo-
attractant protein 1, and ICAM-1 expressions in microvascular endothelial
cells through increased intracellularROS generation causing apoptosis of peri-
cytes and other retinal cells (Ibrahim et al., 2011; Yamagishi et al., 2008a,b).
Luo et al. (2012) found no significant differences in the amount of AGEs
between 3- and 6-month STZ-induced diabetic rats, suggesting that AGE
deposition in the retinal blood vessels occurs prior to obvious morphological
changes inDR; thus, the damage to blood vessels byAGEs is a chronic process.
The degree of AGE deposition was negatively correlated with pericyte num-
ber, but positively correlated with endothelial cell number, suggesting that
AGEs damage pericytes in a cumulative manner. Without pericyte support,
retinal capillaries could expand to form microaneurysms and acellular capil-
laries, which are closely linked with nonperfusion areas and could potentially
lead to the onset and development of proliferative DR (Luo et al., 2012).
s0095 2.3. Electrophysiological changes
p0730 Tissue injuries and neurochemical changes of the retina are reflected in elec-
trophysiological changes at all levels of visual information processing. Two
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such electrophysiological recordings are practiced routinely: ERG that
reflects retinal functions and VEP that shows cortical processes.
p0735 The ERG recordings had long been believed to be useless for the detec-
tion of early DR, because the classical ERG components at that time, such as
the a and b waves, had been proven to be normal at early stages of DR. Only
after introducing better recording techniques (Galloway et al., 1971) did it
become possible to detect fine differences between signals derived from
healthy and diseased tissues. The a wave arises principally from photorecep-
tors, whereas the b wave originates mainly from ON bipolar cells. OPs rep-
resent the contribution of certain amacrine cells. Abnormal ERG in diabetic
rats suggests the dysfunction of the retinal neuronal processing and reflects
deterioration of function (Li et al., 2002). ERG deficit was found as early as
2 weeks after induction of diabetes indicating that the functional integrity of
the diabetic retina had been compromised (Li et al., 2002).
p0740 After the first clinically validated change of the OPs, they were widely
accepted as one of the earliest manifestations of DR (Galloway et al.,
1971). The OP generator is presumed to lie in the intraretinal feedback neu-
ronal circuity, which consist of the interneurons. The disturbance of dopa-
mine metabolism in the retina may play a role in the OP abnormality in
diabetes. Morphological changes of the neural cells are seen 10 weeks after
the induction of diabetes in mice and rats. This suggested that the alterations
of the OPs probably represent metabolic disturbances affecting inner retinal
function at the early stages of DR: the depletion of dopamine and abnormal
dopamine metabolism (Gibson, 1988). In STZ-induced diabetic rats, the
OPs have significantly prolonged implicit times and reduced amplitudes as
early as 2 weeks following the induction of hyperglycemia (Hancock and
Kraft, 2004). These abnormalities are restored by the administration of insu-
lin, suggesting that the abnormal OPs seen in early DR represent only met-
abolic and/or functional changes of the neurons. During 6 weeks of diabetes,
the peak latency of the OPs was prolonged (Shirao and Kawasaki, 1998).
p0745 The amplitudes of a and b waves and OP1, OP2 and OP3 of ERG were
reduced in rats 1 month after the onset of diabetes. The peak latencies of a
and b waves were not delayed, but the OP2 and OP3 were (Aizu et al.,
2002). The RGC-dominated positive scotopic threshold response was
reduced following a single episode of acute IOP elevation in STZ-induced
diabetic rats, but not in control rats after 11 weeks of diabetes. These data
indicate that hyperglycemia renders the inner retina more susceptible
(Kohzaki et al., 2012). The peak latency of the OPs is one of the most sen-
sitive markers for the early phase of DR, while in later phases, the intensity
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response curves of the ERG b wave of diabetic rats during the 25 weeks’
diabetic period were shifted to higher intensities. This, along with significant
reductions in the maximal amplitude of the b wave, means reduced sensi-
tivity. The maximal amplitude of the b wave was more reduced than the
corresponding parameter of the a wave. These observations suggest that
the photoreceptors are relatively resistant to the pathological processes in
early diabetes (Li et al., 2002; Samuels et al., 2012).
p0750 The loss of amacrine cells may play a role in the reduction of the OPs in
animals and humans with diabetes (Dong et al., 2004). The source of abnor-
mal or missing OPs may be from the altered synaptic activity between
amacrine and bipolar cells or RGCs. These deficits could be explained by
the degeneration in synaptic neurotransmission and/or combined loss of
amacrine neurons and RGCs (Kern and Barber, 2008). The function of
RGCs is compromised when there is a loss of dopaminergic or cholinergic
signaling in the retina (Amthor et al., 2002). Loss of dopaminergic and cho-
linergic neurons may cause changes to visual processing that play a role in the
vision loss associated with diabetes (Gastinger et al., 2006). The significantly
prolonged peak latency of the OPs in the ERG and the increased VEGF
level are correlated with the increased serum AGE concentration (Segawa
et al., 1998).
p0755 In diabetic patients, a functional loss of the inner retina has been detected
by ERG and VEP recordings before vasculopathy (Moreo et al., 1995).
Spontaneously, diabetic BB/W rats develop central sensory neuropathy,
characterized functionally by modification of VEP and structurally by dys-
trophy in the RGCs and optic nerve fibers without visible vascular changes.
The amplitude alterations of ERG and VEP begin 1 week after STZ injec-
tion in rats and progress week by week reaching a stable reduction by the end
of the first month of diabetes. The b wave and VEP latency changes, how-
ever, were significant only after 1 month of diabetes (Biro et al., 1998). Sim-
ilar VEP latency changes appeared to be parallel with RGC dystrophy and
optic nerve axonopathy in 6-month diabetic BB/W rats (Kamijo
et al., 1993).
s0100 3. EXPERIMENTAL MODELS OF DIABETIC RETINOPATHY
p0760 This field became a major focus area in the recent years. Journals and
academic departments devoted to target this area of research exclusively.
Experimental models of any kind of human disorder undergo vigorous eval-
uation from time to time. DR is no exception from the rule. In this section,
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besides reviewing scientific achievements in the field, this aspect is put to the
forefront. To understand the pathophysiological mechanisms of diseases and
to test the pharmacological effects of new drugs, animal models for the dis-
eases have been developed and widely utilized. These efforts called to life a
new scientific discipline, translational medicine.
s0105 3.1. Type 1 diabetes
p0765 Due to the early discovery of easy inducibility of this disorder (Szkudelski,
2001), an enormous body of data has accumulated over the years. Therefore,
most of the solid knowledge on diabetes has been gained through this
approach.
s0110 3.1.1 Chemical induction
p0770 Alloxan and STZ are widely used as diabetogenic agents in experimental
animal models that include rodents, dogs, and primates (Szkudelski, 2001).
This approach replicates some of the early symptoms of DR and has the
advantage that the onset of diabetes can be defined as the time of injection
of the toxin. However, toxin-induced diabetes in mice has been less success-
ful because of strain-dependent resistance to STZ (Rossini et al., 1977).
s0115 3.1.1.1 Alloxan
p0775 Alloxan is synthesized by uric acid oxidation and exerts its diabetogenic
action by intravenous, intraperitoneal, or subcutaneous administration.
Alloxan induces insulin release for a short duration inducing complete sup-
pression of the islet response to glucose. The mechanism of alloxan action is
through the formation of ROS, and in the pancreas, it is preceded by rapid
uptake by the b cells (Weaver et al., 1978). Alloxan elevates cytosolic free
Ca2+ concentrations in pancreatic b cells (Park et al., 1995) and also targets
DNA; its fragmentation takes place in b cells exposed to alloxan (Sakurai and
Ogiso, 1995).
s0120 3.1.1.2 Streptozotocin
p0780 STZ is synthesized by Streptomyces achromogenes and is used to induce insulin-
dependent diabetes mellitus (Szkudelski, 2001). STZ-induced diabetic rats
are useful models of human type 1 (insulin-dependent) diabetes mellitus
with hyperglycemia. STZ action in b cells is accompanied by characteristic
alterations in blood insulin and glucose concentrations. This is reflected in
the abnormalities in b cell function. STZ is taken up by pancreatic b cells via
the glucose transporter GLUT2. It impairs glucose oxidation and decreases
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insulin biosynthesis and secretion. At first, it abolishes the b cell response to
glucose. Intracellular action results in changes in DNA in pancreatic b cells
comprising its fragmentation and alkylation (Elsner et al., 2000). Some ancil-
lary factors are involved in the process of the STZ effects: nitric oxide, ROS,
and superoxide anions. Inhibition of the Krebs cycle and limited mitochon-
drial ATP production activate poly-ADP ribosylation (Sandler and Swenne,
1983) and are also characteristic of this condition.
p0785 Although STZ-injected rats provide an intensively studied model of dia-
betes, this is not identical to the clinical situation. One reason for this is that
uncontrolled hyperglycemia is not typical in patients. Also, of course, rats
may respond differentially to hyperglycemia and hypoinsulinemia than
humans. Additionally, a chemically induced loss of b cell function is very
rare in humans (Puro, 2002). Still, the most widely accepted animal model
for the evaluation of retinal complication of diabetes is the STZ-induced
diabetic rats. It has been shown that in STZ-treated rats, significantly more
cells undergo apoptosis, resulting in cell loss in the retinas of diabetic rats and
not in control animals (Asnaghi et al., 2003; Barber et al., 1998). However,
some typical clinical symptoms (neovascularization and macular edema)
could not be detected in rats.
p0790 During the preclinical phase of diabetes drug research, it is indispensable
to perform experiments on a reliable animal model to mimic diabetes-related
complications. Recently, several reviews have been published summarizing
the existing methods for the investigation of diabetic eye disorders in rodents
(Islam, 2013; Jo et al., 2013; Kong et al., 2013; Robinson et al., 2012). Now-
adays, a number of diabetes models are well known and widely used, but
only a few of them offer a thorough examination of the diabetic manifesta-
tions in their complexity. Such diabetic state should be extended for a time
interval, long enough to allow the formation of accurately detectable func-
tional and morphological diabetes-related complications in various sever-
ities. However, the main limitation of the currently available diabetes
models is that the experimental subjects cannot tolerate the severe general
conditions in the absence of any antidiabetic therapy (Fox et al., 1999).
Therefore, it is essential to apply an experimental design enabling tolerable
general states of the animals. Maintenance of a suboptimal glycemic control
mimics the diabetic conditions and permits the development of chronic
complications. Our group has recently developed a novel chronic,
insulin-controlled method for the investigation of diabetic ocular changes.
Diabetes was induced by single-dose STZ injection andmaintained for 12 or
16 weeks in male Sprague–Dawley rats. Diabetic rats were divided into four
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groups according to the different doses of insulin replacement with subcu-
taneously applied implants. In groups where blood glucose levels were
between 5–10 mmol/l and around 20 mmol/l, resulting in mild and
medium severe forms of diabetes, we found only minimal functional and
histopathologic changes in the eye. When the blood glucose concentration
was over 30 mmol/l, severe pathophysiological signs developed. Marked
corneal neovascularization, retinal degeneration, and cataract formation
were observed. This chronic, insulin-controlled animal model is available
for the preclinical studies of promising drug candidates against diabetic com-
plications (Hajna et al., 2013).
s0125 3.1.2 Genetic defects
p0795 Using the advantages of the widespread controlled breeding of laboratory ani-
mals (primarily rats and mice), a number of inbred strains were selected with
metabolic deficiencies, several of those bearing the hallmarks of diabetes.
s0130 3.1.2.1 BB/W rats
p0800 The BB/W Wistar rat develops autoimmune diabetes similar to type 1
human diabetes mellitus. The syndrome is characterized by sudden onset
of hyperglycemia, ketonemia, and pancreatic b cell destruction; therefore,
BB/W rat strain is a model of type 1 diabetes. In these animals, diabetes
develops spontaneously. It is an excellent laboratory model of type 1
juvenile-onset diabetes mellitus from both a metabolic point of view and
an immunological point of view. The diabetic syndrome of these rats spans
a spectrum of increasing severity from insulitis without glucoregulatory
changes to insulin-dependent diabetes with massive b cell destruction. Obe-
sity is absent, both sexes are affected, and peak incidence of diabetes occurs
around the age of sexual maturation (80–100 days). Sublines Au15with expected
zero incidence and high diabetes incidence (40–100% overt type 1 diabetes)
have been developed. However, these animals have never been examined
extensively for DR syndromes. It remains to be shown that these animals
develop DR at all (Yale and Marliss, 1984).
s0135 3.2. Type 2 diabetes
p0805 Type 2 diabetes is a complex, heterogeneous, polygenic disease character-
ized mainly by insulin resistance and pancreatic b cell dysfunction. Appro-
priate experimental models are essential tools for understanding the
molecular basis, pathogenesis of the vascular and neural lesions, actions of
therapeutic agents, and genetic or environmental influences that increase
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the risks of type 2 diabetes. In contrast to type 1 diabetes, where rats are used
most often, there are several mouse models of type 2 diabetes too.
s0140 3.2.1 OLETF rats
p0810 A spontaneously diabetic rat with polyuria, polydipsia, and mild obesity was
discovered in 1984 in an outbred colony of Long–Evans rats. A strain of rats
developed from this rat by selective breeding has since been maintained at
the Tokushima Research Institute and named Otsuka Long–Evans
Tokushima Fatty (OLETF) strain. They became a widely used model of
noninsulin-dependent diabetes. The characteristic features of OLETF rats
are late onset of hyperglycemia (after 18 weeks of age), a chronic course
of disease, mild obesity, inheritance by males, hyperplastic foci of pancreatic
islets, and renal complication (nodular lesions). Histologically, the changes in
pancreatic islets can be classified into three stages: (1) an early stage
(6–20 weeks of age) of cellular infiltration and degeneration, (2) a hyperplas-
tic stage (20–40 weeks of age), and (3) a final stage (at >40 weeks of age).
These clinical and pathological features of disease in OLETF rats resemble
those of human noninsulin-dependent diabetes mellitus. Architectural
defects of the islet capillaries can cause impaired b cell function in aged
OLETF rats (Mizuno et al., 1999).
p0815 OLETF rats exhibited a significantly reduced total retina thickness,
especially that of the NFL at 28, 36, and 40 weeks of age. Histological
examination revealed increased apoptosis (active caspase 3-positive and
TUNEL-positive cells in NFL) and a decrease in the number of RGCs
(Yang et al., 2013a). GFAP immunofluorescence staining was upregulated
in vertical sections and showed a more ramified pattern in whole-mount ret-
inas. VEGF expression extended into the OPL ( Jung et al., 2013). The INL
decreased from 3–4 rows to 2 rows, whereas the photoreceptor cell nuclei
decreased from 8 rows to 3–6 rows. These results suggest that retinal neu-
rodegeneration occurs in type 2 diabetic OLETF rats. RPE decreased in
height, and basal infoldings were poorly developed. Retinal capillary base-
ment membranes were significantly thicker in the OLETF rats than in the
Long–Evans Tokushima Otsuka (LETO) rats, and endothelial cell damage
was observed (Lu et al., 2003). In the 64-week-old OLETF rats without
treatment, corrosion cast revealed diabetic retinal and choroidal vascular
changes: tortuosity of the vessels, variations in caliber, narrowing of arteries,
arterio-arterial anastomoses and hairpin loop formation in precapillary arte-
rioles, sparse collecting venules in the choroid, and marked capillary changes
such as caliber irregularity, narrowing, tortuosity, loop formation and
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decreased capillaries, outpouching, and microaneurysms (Bhutto et al.,
2002). However, they are not the most suitable animal model for the study
of angiopathic DR because retinal capillaries of OLETF rats were found to
remain morphologically normal and pericyte ghosts were barely detectable.
There was no difference in the number of acellular capillaries in the retinas
between OLETF and control LETO rats. Formation of acellular capillaries
and pericyte ghosts, the characteristic morphological changes in early DR, is
not accelerated in OLETF rats (Matsuura et al., 2005).
s0145 3.2.2 Zucker diabetic fatty rats
p0820 The Zucker diabetic fatty (ZDF) rat is most widely used for studying type 2
diabetes associated with obesity. The initial characterization of a novel type 2
diabetes model derived from Zucker fatty (ZF) rats. Further inbreeding
resulted in new phenotypes.
p0825 Zucker fatty diabetes mellitus rats develop diabetes as early as 10 weeks of
age, which reaches 100% incidence at around 20 weeks of age. This rat strain
possesses high reproductive efficiency and therefore should serve as a useful
model of young- to middle-aged adult-onset type 2 diabetes in the studies of
the pathophysiology, therapeutic interventions, and complications of the
disease (Yokoi et al., 2013).
p0830 Retinal VEGF mRNA and protein expression increased in ZDF rats
after 2 months of disease, but not in ZF rats. Some oxidative stress and
inflammatory markers (TNFa, IL-6, ICAM-1, and IL-1b) were upregulated
in the retina of ZDF rats after 4 months of the disease. In contrast, activation
of nuclear factor kB (NF-kB) in the retina was observed in ZF and ZDF rats
(Mima et al., 2012). ZDF rats had thicker basement membranes and more
cells per unit capillary length (Yang et al., 2000). Diabetes
Au16
-increased acti-
vated caspase 3- and TUNEL-positive microvascular cell numbers and acel-
lular capillary formation were reduced in ZDF rats (Behl et al., 2008). Acute
hyperglycemia did not have an effect on control rats, while chronic hyper-
glycemia in ZDF rats was associated with enhanced scotopic ERG ampli-
tudes, which were up to 20% higher than those of age-matched controls
(8–22 weeks Au17of age), and a reduction in a wave amplitudes and maximum
slopes of about 30%. The electrophysiological differences between untreated
ZDF rats and controls preceded an activation of Mu¨ller cells in the ZDF rats
(upregulation of GFAP), which was attenuated by insulin treatment. There
were otherwise no signs of cell death or morphological alterations in ZDF
groups ( Johnson et al., 2013). These data show that under chronic hyper-
glycemia, the ZDF rat retina became abnormally sensitive to variations in
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substrate supply. In diabetes, a similar inability to cope with intensive glu-
cose lowering could render the retina susceptible to damage.
s0150 3.2.3 Spontaneously diabetic Torii rats
p0835 A new spontaneously diabetic strain of the Sprague–Dawley rat was
established in 1997 and named the spontaneously diabetic Torii (SDT) rats.
The SDT rat strain should be a useful model to understand the pathology of
the diabetic disease. An SDT rat spontaneously develops hyperglycemia
resulting from a defect of insulin secretion due to tissue damage and dysfunc-
tion of the pancreatic islets. Glucose tolerance in SDT rats was impaired in
correspondence with the decreased insulin secretion. Diabetes in SDT rats
directly results from absolute decrease of insulin secreted from pancreatic
b cell. The body mass of the SDT rats decreased after the onset of hypergly-
cemia, but the SDT rats did not show obesity throughout their lives. The
SDT rats exhibited reduced pancreatic insulin content at 20 weeks and a
decreased mass of b cell at 10 weeks. The b cells of the SDT rats are in
the sense of “overworking” to fulfill the insulin demand of the peripheral tis-
sueswith a limited number ofb cells and increased bodymass before the onset
of diabetes. Males spontaneously develop hyperglycemia predominantly due
to an insulin secretory defect resulting from pathological damage to the pan-
creatic islets (Masuyama et al., 2004). Glucose tolerance in SDT rats was
impaired in correspondence with the decreased insulin secretion. The age
of onset of diabetes in SDT rats depends on the magnitude of glucose intol-
erance observed prior to the onset of diabetes (Masuyama et al., 2003).
Inflammation could be observed in the SDT rats, such as lymphocyte infil-
tration consistently observed in autoimmune diabetes (Komeda et al., 1998;
Like et al., 1982). Male SDT rats spontaneously develop hyperglycemia
without obesity after 20 weeks of age with an incident rate reaching 100%
at 40 weeks of age. At 38 weeks, almost all the b cells disappear from the pan-
creatic islets of SDT rats that show overt hyperglycemia and marked hypo-
insulinemia accompanied by decreased body weight and body mass index
(Masuyama et al., 2004). SDT rats develop severe diabetic ocular complica-
tions such as cataract and proliferative retinopathy (by 40 weeks of age) and
tractional retinal detachment with fibrous proliferation (by 70 weeks of age)
and massive hemorrhaging in the anterior chamber (by 77 weeks of age),
which resemble human diabetic ocular complications (Shinohara et al.,
2000). The SDT rat is a useful animal model to elucidate the underlying
mechanism of nonobese type 2 diabetes mellitus where the pancreatic islet
tissue is thought to play the main role in the development of diabetes.
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p0840 The SDT rat is considered to be a potentially useful model for studies of
DR encountered in humans (Shinohara et al., 2000). This notion is
supported by the fact that large retinal folds mimicking diabetic tractional
retinal detachment were observed in SDT rat retinas like retinal hemor-
rhages, a neovascular fibrous membrane around the iris, a massive anterior
chamber hemorrhage, an area of nonperfusion and/or extensive
hyperfluorescence, acellular capillaries and pericyte loss, and retinal changes
(Kakehashi et al., 2006). Apoptotic cells in the GCL and the INL were
numerous in 40-week-old SDT rat retinas; GFAP immunoreactivity
spanned the whole retina in SDT rats. The perivascular AQPs shifted from
AQP4 to AQP1 in 40-week-old SDT rats that exhibited marked hypergly-
cemia. Thus, the development of diabetes increases neuroretinal apoptosis
and coincides with an altered expression pattern of GFAP and water-
selective channels AQP1 and AQP4 in SDT rats (Fukuda et al., 2010). In
44-week-old animals, a and b waves and the OPs were significantly reduced
with prolonged implicit times in the SDT rats compared with Sprague–
Dawley rats (Okuno et al., 2008). The depressed ERG may reflect vascular
and neuronal damage throughout the retina as are seen in the advanced
stages of human DR. Further, in SDT rat, hyperglycemia-induced abnormal
retinal vascular bed was formed and the optic disc protruded (Sasase et al.,
2009). Thus, the SDT rat can be used to study the physiology of DR.
s0155 3.2.4 GK rats
p0845 The GK rat is a spontaneous model of noninsulin-dependent diabetes
mellitus without obesity, which was developed by repeated selective breed-
ing of normalWistar rats using glucose intolerance as a selection index (Goto
and Kakizaki, 1981). Glucose intolerance appears after 2 weeks of age (Goto
and Kakizaki, 1981) and a significant hyperglycemia is found as early as
4 weeks of age, and the animals show hyperinsulinemia and decreased pan-
creatic insulin stores. Development of type 2 diabetes mellitus in the GK
model results from the complex interaction of multiple events such as
(i) the presence of several susceptibility loci containing genes responsible
for some diabetic traits, (ii) gestational metabolic impairment inducing an
epigenetic programming of the offspring pancreas and the major insulin tar-
get tissues, and (iii) environmentally induced loss of b cell differentiation due
to chronic exposure to hyperglycemia/hyperlipidemia, inflammation, and
oxidative stress (Portha et al., 2012). The adult GK body weight is
10–30% lower than that of age- and sex-matched control animals. Signs
of early neuropathy (2 months) have been reported in GK adult rats, while
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nephropathy and retinopathy develop late (12 months; Portha, 2005). In the
NFL, RPE, and choroid, strong VEGF immunoreactivity was noted only in
the GK rat. Increased VEGF production in certain ocular tissue, similar to
that in humans, is observed quite early, at least before the appearance of
observable retinal changes in the diabetic GK rat (Sone et al., 1997).
p0850 GK rats do not exhibit cataracts for a long time because of their moderate
diabetic state. However, they provide a useful model for the investigation of
the retinal microcirculatory changes of diabetes mellitus over an extended
time, since they show decreased retinal blood flow with reduced oxygen
consumption without serious retinopathy; at the same time, decreased ret-
inal metabolism, increased blood viscosity, and increased vascular resistance
to flow can be detected in them (Miyamoto et al., 1996).
p0855 In the GK rats, immunoreactivity to L-glutamate and GABA was
observed in the Mu¨ller and photoreceptor cells in addition to the immuno-
reactivity in normal rats. These immunoreactivity patterns in the GK rat ret-
ina might be induced by ischemia associated with diabetes mellitus (Takeo-
Goto et al., 2002). Morphological changes could be demonstrated in retinal
vessel preparations of GK rats; the endothelial/pericyte ratio was found to be
higher in GK rats aged 8 months and after 24–30 months compared with
their matched controls. Furthermore, in 24- to 30-month-old GK rats,
the endothelial/pericyte ratio was higher than in 8-month-old GK rats
(Agardh et al., 1997). In vivo studies indicated that in GK rats, the BRB per-
meability was increased; ex vivo studies showed that in retinas from GK rats,
NOS activity was also higher; there is an increased production of NO,
which may contribute to the BRB breakdown (Carmo et al., 2000).
p0860 The amplitudes of ERG a and b waves and also the OPs of the GK rats
were reduced between 4 and 48 weeks of age. The a wave latencies in GK
rats were significantly prolonged, but not the implicit times of OPs. At
14 days of age, the a wave amplitudes were significantly smaller in GK rats
than in Wistar rats. Functional abnormalities of photoreceptors might be
induced by inheritable degeneration at an early age in the GK rat. Although
hyperglycemia would cause retinal hypoxia, it would not be severe enough
to disturb the generation of OPs (Matsubara et al., 2006). Taken together,
the GK rat appears to be a suitable model for experimental studies of chronic
complications of diabetes, including DR. These results also suggest that the
GK rat can be used as a model of initial-phase or latent-phase DR.
s0160 3.2.5 ob/ob mice
p0865 ob/ob mice are hyperphagic, obese, hyperinsulinemic, and hyperglycemic,
so they are used as a model for diabetes and obesity. ob/ob mice are
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indistinguishable from their lean littermates at birth, but later, they become
heavier and develop hyperinsulinemia. These differences are much more
pronounced after weaning, and overt hyperglycemia is observed during
the fourth week. The blood glucose rises to reach the peak after 3–5 months
when themice also have very high food intake and a rapid growth. After that,
blood glucose values decrease and eventually become nearly normal at old
age. The animals remain insulin-resistant, but impaired glucose tolerance
and glycosuria after a glucose load are observed mostly in the postweaning
period of rapid growth, and this usually becomes normalized when the mice
get older (Lindstrom, 2007). In ob/obmice, insulin receptor, insulin receptor
substrate 1, and insulin receptor substrate 2 proteins and phosphorylation
were maintained or increased, while protein levels and phosphorylation of
pyruvate dehydrogenase kinase and Akt were decreased in the retina. Inter-
estingly, phosphorylations of p38 MAPK and extracellular signal-regulated
kinase 1 (ERK1) were responsive to insulin in the retina. At the same time,
hypoxia-inducible factor (HIF)-1a and VEGF were increased and endothe-
lial NOS was decreased there (Kondo and Kahn, 2004).
s0165 3.2.6 db/db mice
p0870 The db/db mice are perfect animal models of type 2 diabetes. The pheno-
types of severe obesity, hyperphagia, polydipsia, and polyuria are due to a
spontaneous mutation of leptin receptor. The db/db mice are differentiated
by the spontaneous mutations in different sites of leptin receptors. The
db/db mice have abnormal phenotypes in their metabolic, reproductive,
and immune systems (Wua et al., 2013). The genetically diabetic db/db
mouse is a model of type 2 diabetes, where nephropathy and neuropathy,
but not retinopathy, were observed in early examinations. Midena and
coworkers (1989) showed a marked increase in the ratio of endothelial cells
to intramural pericytes in diabetic mice compared with controls. This
increase resulted from a selective and highly significant loss of pericytes in
db/db mice. Some strand-like and relatively acellular capillaries were also
observed. Basement membrane thickening and an accumulation of base-
ment membrane material in the capillaries of the OPL of retinas from dia-
betic db/db mice were observed.When the thickness of the whole retina, in
particular the INL and ONL, and the integrity of the RPE and the RGC
numbers were examined, all were found decreased in db/db mice (Tang
et al., 2011). At the same time, expression levels of Nox4 and VEGF were
significantly increased in their retinas (Li et al., 2010).
p0875 In 15-month-old db/db mice, signs of DR, including BRB breakdown,
loss of pericytes, neuroretinal apoptosis, glial reactivation, and proliferation
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of blood vessels, were evident. These changes in the diabetic retina were
associated with increased expression of aldose reductase (Cheung et al.,
2005). The db/db mice at the age of 19 weeks exhibited significantly
increased retinal vascular leakage and decreased tight junction protein level
in the retina. Moreover, the expression of proinflammatory factors, for
example, ICAM-1 and TNFa, was drastically upregulated in diabetic retina
(Li et al., 2009).
p0880 The altered visual functions of RGCs were characterized by the reduced
receptive field center size, elevated luminance response, and attenuated con-
trast gain in 12- and 20-week db/db mice, respectively. These altered visual
functions could, at least partly, be due to oxidative stress (Xiao et al., 2012a).
Therefore, the db/dbmouse may represent an adequate model for studies on
the pathogenesis of DR.
s0170 3.2.7 Ins2Akita mice
p0885 An autosomal-dominant mutation that produces juvenile-onset hyperglyce-
mia and insulinopenia in the absence of obesity was discovered in C57BL/6
mice. The Ins2Akita mutation disrupts normal insulin processing and causes a
failure in secretion of mature insulins, which results in the early development
of hyperglycemia (Mathews et al., 2002). The Ins2Akita mutation results in a
single amino acid substitution in the insulin 2 gene and replaces a cysteine
with tyrosine at the seventh amino acid of the A chain of the insulin 2 gene
product, blocking the formation of an essential disulfide bond between the
A and B chains of the mature protein, that causes misfolding of the insulin
protein. The mutation arose and is maintained on the C57BL/6J back-
ground. Male mice heterozygous for this mutation have progressive loss
of b cell function and decreased density with significant hyperglycemia as
early as 4 weeks of age (Barber et al., 2005).
p0890 As we have mentioned earlier, dopaminergic and cholinergic amacrine
cells are lost during the early stages of retinal neuropathy in diabetes. Loss of
these neurons may play a critical role in the development of visual deficits
(Gastinger et al., 2006). Within the first 3 months of diabetes, RGCs are lost
from the peripheral retina of Ins2Akita mice, and the dendrites of surviving
large ON-type cells undergo morphological changes. These abnormalities
may explain some of the early anomalies in visual function induced by dia-
betes (Gastinger et al., 2008). Ins2Akita diabetic models are characterized by
upregulation of a-, b-, and g-crystallins in the retina. Despite being over-
expressed, the molecular properties of a-crystallins are disrupted by diabetes
and contribute to the loss of neuroprotective function. Identification and
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prevention of these alterations could lead to the emergence of new therapies
for DR (Losiewicz and Fort, 2011). Although both choroidal and retinal
blood flow and vision were altered after prolonged diabetes in the Ins2Akita
mouse, choroidal blood flowwas reduced early, suggesting that ocular blood
flow deficit could be an early pathological change in DR (Muir et al., 2012).
p0895 Diabetes increases retinal vascular permeability in mice. The number of
leukocytes adherent to the vascular wall was significantly elevated in the
Ins2Akita mouse, confirming that the vascular inflammatory component of
DR is present in this model. Astrocytes in some regions of the Ins2Akita
mouse retinas contained reduced GFAP immunoreactivity with shorter pro-
cesses, suggesting atrophy or loss of contact with blood vessels, but increased
GFAP expression was not observed. Regions of the Ins2Akita mouse diabetic
retinas contained microglia with swollen and contracted processes,
suggesting a reactive state. Thinning of the inner layers of the retina suggests
that chronic degeneration occurs after 22 weeks of hyperglycemia. The sig-
nificantly reduced thickness of the peripheral INL suggests loss of horizontal,
bipolar, and amacrine cell bodies. The thickness of the IPL was significantly
reduced in all regions measured, indicating atrophy of the processes between
neurons in all parts of the retina. There was no significant loss of the ONL
and the OSs of the photoreceptors, suggesting that the degeneration pre-
dominantly occurs in the inner retina. Increased apoptosis was found in
Ins2Akita mice after 4 weeks of hyperglycemia (Barber et al., 2005). No ret-
inal thinning or disruption of retinal architecture was observed by optical
coherence tomography or resin histology up to 6 months of age. In addition,
no vascular changes were detected by fluorescein angiography or by scan-
ning laser ophthalmoscopy. With the exception of microglial activation,
reduced GFAP expression in astrocytes, and an increase in GFAP expression
by Mu¨ller cells, no other changes were observed in the Ins2Akita mouse ret-
ina. These observations indicate that the classical clinical correlates of human
DR are absent in Ins2Akita mice up to 6 months of age suggesting either that
the histopathologic processes underlying the development of DR in this
model require longer than 5 months of hyperglycemia to result in disruption
of retinal architecture or that advanced DR is not a feature of the Ins2Akita
diabetic mouse (McLenachan et al., 2013).
p0900 As can be seen from the aforementioned facts, the Ins2Akita mouse has sev-
eral important advantages over other animal models. First, the autosomal-
dominantmutation provides the opportunity to study heterozygotic animals.
Second, the mice are fertile and breed well. Third Au18, they have stable diabetes
with insulin deficiency and can bemaintained in a noncatabolic state without
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exogenous insulin. Fourth, themechanism of diabetes onset does not involve
systemic immunologic alterations, and it is therefore possible to evaluate the
metabolic impact on the retina (Barber et al., 2005). Therefore, the use of the
Ins2Akita mouse is an excellent choice to explore the molecular mechanisms
involved in the initiation and progression of DR in older ages.
s0175 3.3. Ex vivo and in vitro models
p0905 There is increasing pressure from the society to find viable alternatives for
animal research. Along with this requirement, scientists tried to set up exper-
imental models for DR, which did not involve long-term keeping of sick-
ened animals. In the succeeding text, we collected the results obtained in
these models and evaluate how well they fare compared with in vivomodels.
Also, we try to pinpoint those aspects of DR, which can be studied using
these approaches.
s0180 3.3.1 Retinal ganglion cell lines
p0910 The retinal ganglion cell line RGC-5 is a transformed line obtained from
postnatal Sprague–Dawley rats. For studies of the effect of high glucose
levels, cells were grown in a medium supplemented with 11 mM glucose
(control) plus 34 mM mannitol or 28 mM glucose (medium glucose) plus
17 mM mannitol, 45 mM glucose (high glucose), and 10 mM succinate.
Mannitol was added to control for osmolar effects (Hu et al., 2013; Ola
et al., 2002). After incubation with succinate and various concentrations
of glucose, the expression of VEGF in RGC-5 cells was elevated. The phos-
phorylation levels of ERK1/2, p38 MAPK, and JNK in RGC-5 cells after
exposure to high glucose were increased (Hu et al., 2013). The type 1 sigma
receptor (sigmaR1) has numerous pharmacological and physiological func-
tions. This sigmaR1 is expressed under hyperglycemic conditions both
in vitro and in vivo (Ola et al., 2002), and its expression has been demonstrated
recently in RGCs, which undergo apoptosis early in DR via NMDA
receptor-mediated overstimulation. It can be concluded that this model is
suitable to study the molecular events of neuronal apoptosis in DR.
s0185 3.3.2 Müller glial cell lines
p0915 Isolated rat retinal Mu¨ller cells (rMC-1) (from 5-day-old Wistar rats) were
cultured, and passaged cells were seeded for 2 weeks in a culture to mimic
diabetic conditions. In other experiments, rMC-1s were plated on tissue
culture plastic. When the cells reached 70% confluence, they were treated
with different concentrations of glucose (normal group, 5 mM glucose, and
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high-glucose group, 25 mM glucose) in test medium for an indicated time
(Du et al., 2003; Zhang et al., 2011). The cells in the glucose-treated group
showed elevated VEGF immunoreactivity and significantly more VEGF
mRNA than the control cells. The expression of VEGF in Mu¨ller cells
increased after a short 3-day exposure to high glucose in culture
(Ke et al., 2012). Hyperglycemia significantly increased the amount of
GAPDH protein in the nucleus above normal within the first 48 h and
induced apoptosis. The nuclear translocation of GAPDH is closely associ-
ated with the induction of apoptosis (Kusner et al., 2004). Glutaredoxin
(Grx1) plays a key role in such regulation because it is a specific and efficient
catalyst of deglutathionylation, and an increased level of Grx1 could be
observed in retina of diabetic rats and in rMC-1 cultured in high glucose.
Diabetes or incubation in elevated glucose concentration significantly
increased superoxide production, which contributes to impaired viability
and increased cell death under those circumstances (Du et al., 2003). The
upregulation of Grx1 was concomitant with NF-kB activation and induc-
tion of ICAM-1, which play a central role in diabetic complications in vivo
and also in these cell cultures (Shelton et al., 2009).
p0920 It is also possible to prepare freshly isolated human retinal Mu¨ller cell cul-
ture. The eyes were enucleated, packed on wet ice, and received in the lab-
oratory within 12 h after death. Cells were plated on tissue culture plastic in
the medium and allowed to attach and grow at 37 C in a humidified cham-
ber. Mu¨ller cells were isolated after the second passage of cells; cultures were
95% pure for Mu¨ller cells as assessed by immunohistochemistry using anti-
bodies to GS, GFAP, and vimentin. Cells were switched to normal
(7.8 mM) or high glucose (25 mM glucose). Cells were grown for up to
5 days (Kusner et al., 2004). These cell cultures are suitable to study Mu¨ller
cell reactions to hyperglycemia and diabetes but obviously not fit for study-
ing retinal changes as a whole, not to speak about the functional integrity of
the retinal tissue.
s0190 3.3.3 Retinal pigment epithelial cell lines
p0925 Human retinal pigment epithelial (ARPE-19) cells were cultured at 37 C,
after the cells were grown to 90% confluence; they were cultured for
another 48 h in the presence of D-glucose at a concentration of 5, 7.5,
12.5, or 17.5 mM, which we refer to as very low glucose, low glucose,
medium glucose, or high-glucose culture medium, respectively. ARPE-
19 cells were cultured for 72 h (Xie et al., 2012; Yokouchi et al., 2013).
Other cultures were exposed to D-glucose at a final concentration of
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25 and 100 mM (corresponding to 2 h after meal plasma glucose level of dia-
betic patients and glucose level in uncontrolled diabetic patients, respec-
tively) and compared with cultures exposed to 5.5 mM D-glucose as
control (corresponding to fasting plasma glucose level of diabetes-free peo-
ple). After exposure for at least 3 weeks, the monolayer cultures were used
for further analysis (Chen et al., 2012b). A significant cellular damage was
seen in ARPE-19 cells after a 48 h treatment with high glucose, accompa-
nied by a decrease in SOD activity and glutathione concentration; high glu-
cose also caused ARPE-19 cell apoptosis and activation of p38 MAPK and
ERK (Xie et al., 2012). ANGPTL4, the major angiogenic factor released by
ARPE-19, was induced by high glucose in RPE cells (Yokouchi et al.,
2013). Fifty-six proteins showed significant changes in expression in cul-
tured ARPE-19 cells. Significant changes in thiol reactivity were seen in
response to high glucose concentration. Some of the identified proteins have
been validated with clinical samples and provide potential targets for the
prognosis and diagnosis of DR (Chen et al., 2012b). Thus, this methodology
may provide molecular markers for improving diagnostic possibilities
in DR.
s0195 3.3.4 Retinal endothelial cell lines
p0930 Bovine primary retinal endothelial cells were incubated in 5 or 25 mM glu-
cose (Du et al., 2003). For high-glucose treatment, endothelial cells were
cultured for 10 days in media supplemented with additional glucose to a final
concentration of 25 mM. Control cells were simultaneously treated with
either 25 mM L-glucose or 5 mM D-glucose. Primary retinal endothelial
cells were used between passages 10 and 13 (Aranda et al., 2012). In another
study, a transformed endothelial cell line was isolated from the BRB of trans-
genic mice. The cells were cultured in 5 or 25 mM glucose (Shelton et al.,
2009). Rhesus retinal vascular endothelial cell line RF/6A is also thought to
be a useful cell line for modeling DR (Hu et al., 2013). High-glucose treat-
ment of the aforementioned retinal explants mimicked the diabetic pheno-
type. Similarly, primary retinal endothelial cells, which were subjected to
high-glucose treatment, organized into tubes that were resistant to
lysophosphatidic acid (LPA). Hyperglycemia caused LPA resistance within
retinal endothelial cells by elevating ROS, which stimulated the ERK path-
way, which antagonized LPA-mediated signaling events that were required
for regression. This ROS/ERK pathway mechanism appeared to be the
same route by which Au19diabetes-induced LPA resistance of retinal neovessels.
It is concluded that diabetes/hyperglycemia reprograms signaling pathways
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in retinal endothelial cells to induce a state of LPA resistance (Aranda et al.,
2012). This and similar molecular pathways can be successfully studied to
understand endothelial cell reactions in DR.
s0200 3.3.5 Retinal explants
p0935 Retinal explants were obtained by gently peeling the choroid away from the
RPE, leaving the RPE attached to the neurosensory retina. Control retinas
were cut into 1 mm2 pieces and placed in a collagen sandwich. Vessel for-
mation was observed after 2–3 weeks. In some experiments to model dia-
betes, the medium was altered to achieve a final concentration of 25 mM
D-glucose or L-glucose during the 2–3-week period of tube formation
(Aranda et al., 2012; Lecleire-Collet et al., 2005). For other studies, rats were
killed by CO2 inhalation after 3 weeks of diabetes. Retinas were isolated
1.5 mm from the optic nerve head, excised into 36 small pieces, and placed
in a liquid collagen solution. The retinal explants were cultured to examine
the effect of diabetes on the number of regenerating neurites. The number of
neurites per retinal explant was counted under a phase-contrast microscope
on day 6 at which time point, their number was greatly increased (Oshitari
and Roy, 2005).
p0940 In an 8-week-old female, C57BL/6 mouse diabetes was induced by
STZ. Retinas were dissected from the eyeballs of both 10-week-old dia-
betic and control mice. Retinal pieces located at a distance of
1.0–1.5 mm from the optic disc were excised and cut into 16 pieces
(approximately 500 mm2) with a sharp razor blade. These retinal pieces were
embedded in collagen gel and were cultured in a medium that contained
7 mM of glucose; for high-glucose medium, 50 mM of glucose was added
(the final glucose concentration was 57 mM). The number of outgrowing
neurites from the explants was counted under a phase-contrast light micro-
scope after 3, 6, and 10 days in culture. TUNEL- and cleaved caspase
3-positive cells increased significantly in retinal explants incubated in gly-
cated bovine serum albumin (BSA) (by 2.2- and 2.5-fold, respectively).
The GCL was the most sensitive retinal layer to the glycated BSA. Neuronal
damage was confirmed by the increased GFAP labeling in Mu¨ller glial cells
from retinal explants (Lecleire-Collet et al., 2005). The number of reg-
enerating neurites in the retinal explants of diabetic rats was significantly
reduced (Oshitari and Roy, 2005). Treatment of retinal explants with high
glucose concentration (57 mM) significantly diminished the number of reg-
enerating neurites in the control mice, but not in the diabetic mice. These
results suggest that retina in diabetic mice has impaired capability of neurite
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regeneration in a normal glucose environment but is adaptable to a high-
glucose environment in vitro.
s0205 3.3.6 Choroidal explants
p0945 Choroidal explants can be prepared after removing the cornea, lens, corpus
vitreum, and retina from the inside of the globe. The posterior segment con-
taining the sclera and the choroid is sectioned into either quadrants or thirds.
After breaking any adhesions between the choroid and the sclera, the iso-
lated segment of choroid was then sectioned into 1–2 mm2 explants and
placed in the collagen gel (Lameynardie et al., 2005). Angiogenesis was trig-
gered by the injury of the dissection procedure and did not require stimu-
lation by exogenous growth factors. Angiogenesis is enhanced in diabetic
rats when compared with Wistar rats, in the presence of fetal bovine serum.
Thereafter, explants prepared as described in the preceding text were cul-
tured with different glucose concentration (Lameynardie et al., 2005).
The assay model of choroidal angiogenesis was thus established by determin-
ing the number and length of microvessels in cultured choroidal explants.
The Au20STZ-induced diabetic states of Wistar and GK rats enhanced
hyperglycemia-induced choroidal angiogenesis. This assay model is useful
for determining angiogenic activity of growth factors and effective drugs
in diabetic choroidopathy and retinopathy.
s0210 4. EXPERIMENTAL APPROACHES TO THE TREATMENT
OF DIABETIC RETINOPATHY
p0950 Several experimental therapies have been found to inhibit the devel-
opment of DR in animal models. These included treatments with endoge-
nous protective compounds, natural substances, and fully synthetic drugs
(Table 1.1). If one tries to understand this enormous body of data, a more
systematic approach is needed. Recently, Lu et al. (2013) had shown that
suppression of GLUT1 is a new strategy to prevent diabetic complications.
If one considers just the protection of RGCs, a plethora of approaches can be
collected from the literature. For example, anti-inflammatory drugs such as
nonsteroidal cyclooxygenase inhibitor nepafenac (Kern et al., 2007; Krady
et al., 2005; Vincent and Mohr, 2007); several salicylates (Zhang et al.,
2007); the glutamate NMDA receptor antagonist, memantine (Kusari
et al., 2007); cannabidiol (CBD) (El-Remessy et al., 2006); NGF
(Hammes et al., 1995b); IGF-1 (Seigel et al., 2006); aldose reductase inhib-
itors (Asnaghi et al., 2003); erythropoietin (EPO) (Zhang et al., 2008); and
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peroxynitrite decomposition catalyst (El-Remessy et al., 2005) all have been
found to inhibit RGC degeneration in diabetes. Aminoguanidine and aldose
reductase inhibitors have been found to inhibit atrophy of optic nerve axons
in diabetes (Ino-ue et al., 1998). Both the clinical trials and the laboratory
investigations agree that besides the effectivity of the drug, the manner of
administration may be the clue to treat the retinal complications, since many
of the drugs do not cross the BRB, but intraocular injection may be effec-
tive. In the next paragraphs, we will therefore review both effectivity and
administration of the different substances.
s0215 4.1. Insulin and IGFs
p0955 The retina is an insulin-sensitive tissue, especially regarding the anabolic
effects of insulin (Reiter et al., 2003). All types of retinal cells express insulin
receptors, with particularly high expression onMu¨ller cells end feet and neu-
ronal dendrites (Gosbell et al., 2002). However, insulin production within
the retina has not been described to date. Exogenous insulin stimulation of
whole retina activates the insulin receptor substrate/Akt branch of the insu-
lin receptor signaling networks (Diaz et al., 2000; Reiter et al., 2003). Insulin
provides trophic support for retinal neurons via phosphatidylinositide
3-kinase (PI3K)/Akt and P70S6 kinase pathways (Barber et al., 2001; Wu
et al., 2004b), and this trophic function of insulin on retinal neurons is
impaired by exposure to elevated glucose and glucosamine (Nakamura
et al., 2001). Constitutive insulin receptor/Akt/p70S6K prosurvival signal-
ing in retina is impaired by diabetes and may contribute to neuronal degen-
eration in DR. Vascular and neuronal survival could be compromised by
reducing insulin receptor activity directly on these cells and/or indirectly
by altering glial or microglial cell function, on which they depend. Systemic
insulin therapy from the onset of diabetes prevents loss of retinal insulin
receptor kinase activity, and importantly, for therapeutic implications, intra-
ocular insulin injection restored that activity. Retinal insulin receptor signal-
ing pathway provides neurotrophic support therefore DR may be
considered as a neurotrophin-deficient and/or neurotrophin-resistant state
(Reiter et al., 2006). Retinal apoptosis is increased 10-fold in rat retinas after
at least 1 month of diabetes. Insulin implants significantly reduced the num-
ber of apoptotic cells (Barber et al., 1998). Indeed, insulin can rescue retinal
neuronal cells from apoptosis through a PI3K/Akt-mediated mechanism,
and systematically administered insulin activates the retinal insulin receptor,
PI3K, and Akt in normal rats (Barber et al., 2001; Reiter et al., 2003). Many
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growth factors, including insulin, activate p70S6K in a PI3K-dependent
manner resulting in retinal neuronal cell survival. This pathway works
in vivo via the PI3K/Akt/mTOR signal transduction (Wu et al., 2004b).
p0960 Several authors argue that the best therapy for DR is the strict control of
blood glucose, because insulin can decrease VEGF expression in the retina
and protect retinal vessels from impairment in early STZ-induced diabetic
rats (Wang et al., 2007); a similar conclusion has been reached recently
regarding human DR (Hammes, 2013).
p0965 IGFs are neurotrophic factors that have been implicated in the pathogen-
esis of diabetic neurological disorders. The signaling pathway involves the
type 1 IGF receptor, which binds both IGF-1 and IGF-2. Early systemic
treatment with IGF or its structural analogs may prevent predegenerative
changes that lead to the death of retinal cells in diabetes. IGF can prevent
cell death in the nervous system in the context of diabetes despite the fact
that IGF-1 treatment had no effect on severity of hyperglycemia or reduced
body weight in diabetic rats (Seigel et al., 2006). IGF-1 mRNA content is
reduced in the eye in the early stages of clinical and experimental diabetes
(Gerhardinger et al., 2001), and IGF-1 levels are elevated in the vitreous
due to variable disruption of the BRB in chronic disease. IGF replacement
therapy can prevent or reverse diabetic neurological complications, such as
early treatment with IGF-1 analogs could counteract certain proapoptotic
abnormalities that precede retinal cell degeneration (Kummer et al.,
2003). Further, systemic IGF-1 administration also prevents both the
increase in p-Akt and TUNEL staining in retinal cells in diabetic rats.
IGF-1 or IGF analog treatment in diabetic rats may rescue retinal cells from
death by the inhibition of caspase 3 activation through the PI3K/Akt path-
way (Barber et al., 2001). This treatment simultaneously reduced the eleva-
tion of Bad immunoreactivity in diabetes as well (Seigel et al., 2006). IGF-1
binding to its receptor blocks apoptosis by inducing the phosphorylation and
inhibition of proapoptotic proteins such as Bad in all significantly affected
retinal layers (INL, ONL, and GCL; Barber et al., 2001; Galvan et al., 2003).
p0970 Drugs acting along the insulin/IGF pathway may have similar mode of
action. Rosiglitazone (with the trademark name Avandia) is an antidiabetic
drug in the thiazolidinedione class of drugs. It works as an insulin sensitizer,
by binding to peroxisome proliferator-activated receptors (PPARs) in fat
cells and making the cells more responsive to insulin. After treatment with
rosiglitazone in experimental STZ-induced diabetes, the thickness of
the retina and the number of cells in the GCL were significantly greater.
It also attenuated the diabetes-induced apoptosis of retinal neurons and
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mitochondrial metamorphosis in RGCs. Consistent with these effects,
decreased cleaved caspase 3 and p-STAT3 levels and increased SOCS3
expression were observed (Li et al., 2011). Consequently, rosiglitazone
might be used to prevent retinal neuronal damage in diabetes.
s0220 4.2. Neuropeptides
p0975 Apart from their well-known neuromodulatory actions in the retina, recent
investigations revealed their role in retinal development (Bagnoli et al.,
2003), and we have just started to appreciate their possible role in aging
(Reglodi et al., 2012). When examining their role in DR, some substances
of extraretinal origin must also be taken into account.
s0225 4.2.1 Somatostatin
p0980 Somatostatin (SST) is a neuropeptide widely distributed in the central
and peripheral nervous system, where it plays a variety of biological roles
(Blake et al., 2004; Olias et al., 2004). Two forms of SST have been
identified—SST-14 and SST-28—the former is the one preferentially
expressed in the mammalian retinal amacrine cells. It interacts with five main
membrane receptors (sst1–sst5) that are coupled to different transduction
pathways (Olias et al., 2004). Mostly, sst2 and sst4 receptors can be found
in the retina. Expression of sst2 is the most abundant; it can be detected
in virtually all layers (Casini et al., 2005; Thermos, 2003). sst1 and 5
receptors are also found (amacrine cells and RGCs). However, sst3 receptors
are not expressed in the mammalian retina (Ke and Zhong, 2007;
Thermos, 2003).
p0985 Potential therapeutic use of SST is based on the ability of SST to inhibit
growth hormone secretion, which was implicated in the pathogenesis of DR
(Kirkegaard et al., 1990). In some points of view, the neuronal death in dia-
betic retinas is caused by increased extracellular glutamate level. In the retina,
SST inhibits glutamate accumulation and GLAST downregulation induced
by diabetes (Hernandez et al., 2013). Indeed, potential neuroprotective roles
of SST or its analogs may be mediated by inhibition of glutamate release
through activation of K+ channels. Further, SST has a dual action in DR,
playing against both neoangiogenesis and excitotoxic neuronal death
(Casini et al., 2005). SST is downregulated in the diabetic eye; its concen-
tration is low in the vitreous body. SST-containing eye-drop treatment
prevented ERG abnormalities, glial activation, apoptosis, and misbalance
between proapoptotic and survival signaling in STZ-induced diabetic rats.
Topical administration of SST or its analogs has a potent effect in preventing
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retinal neurodegeneration induced by diabetes (Hernandez et al., 2013).
SST or SST analogs may counteract retinal damages in DR through a pro-
tective paracrine effect directly on retinal cells, which are known to express
SST re Au21ceptors. Several lines of clinical and experimental evidence suggest
that SST analogs may be efficacious in inhibiting neovascularization associ-
ated with proliferative DR (Davis et al., 2001; Grant and Caballero, 2002).
p0990 Octreotide, a peptide analog of SST, can counteract vascular endothelial
dysfunction. This drug proved to be effective in delaying or to some extent
reverting symptoms of DR (Grant et al., 2000). Acting on sst2 receptors, it
may possibly control inflammatory processes (Pinter et al., 2006), endothe-
lial symptoms (Cervia et al., 2012), and also to some extent neural symptoms
(Cervia et al., 2008; Vasilaki and Thermos, 2009; Vasilaki et al., 2002).
Additional peptide and nonpeptide analogs should be involved in future
experiments.
p0995 One of those may be cortistatin, which is produced mostly by a non-
neural cell of the retina, the RPE. Its role may lie in the activation of glial
cells under stress conditions (Carrasco et al., 2008). Its receptors are identical
with those activated by SST. The influence of cortistatin on neural informa-
tion processing is unknown at present. However, it is presumed that cor-
tistatin is a part of a signaling system residing in the RPE of the retina,
which shows some parallel properties with the hypothalamo–pituitary–
adrenal axis (Zmijewski et al., 2007).
s0230 4.2.2 Pituitary adenylate cyclase-activating polypeptide
p1000 Pituitary adenylate cyclase-activating polypeptide (PACAP), a member of
the vasoactive intestinal peptide (VIP)/secretin/glucagon peptide superfam-
ily, is a neuropeptide with highly potent neuroprotective and general cyto-
protective effects. PACAP and its receptors (PAC1, VPAC1, and VPAC2)
occur in the retina (Atlasz et al., 2010), specifically in all retinal layers except
the photoreceptors (Seki et al., 2000).
p1005 PACAP treatment has been proven to be protective in several retinal
pathologies (Nakamachi et al., 2012). It attenuates retinal damage in
excitotoxic, ischemic, traumatic, andUV light-induced retinal degeneration
(Atlasz et al., 2010; Varga et al., 2011). Several lines of evidence suggest that
PACAP might have therapeutic potential in the treatment of diabetes
(Yamamoto et al., 2003) because of its effects on insulin secretion protection
during b cell damage induced by various insults. Systemic PACAP treatment
decreases the STZ-induced nephropathy (Li et al., 2008a) and experimental
neuropathy (Dickinson et al., 1999), and PACAP inhibited the
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hyperglycemia-induced microvascular endothelial cell growth in vitro
(Castorina et al., 2010).
p1010 This peptide effectively reduced the diabetes-induced symptoms by
upregulating its own receptor, PAC1-R, and protecting several cell types
(including the dopaminergic amacrine cells and RGCs; Szabadfi et al.,
2012). An evidence was provided that RGCs, photoreceptors, and bipolar,
horizontal, Mu¨ller glial, and amacrine cells underwent apoptosis and that
PACAP treatment could attenuate this degeneration. Among amacrine cells,
dopaminergic cells are certainly affected. PACAP has an ameliorating effect
on dopaminergic cell degeneration. It has recently been suggested in an
avian model of retinal development that PACAP may support the appear-
ance of cells with newly acquired dopaminergic phenotype (Fleming et al.,
2013). Although this possibility cannot be discounted in adult rat retinas
with DR, it is less likely than protection mediated by PACAP in the case
of the original dopaminergic cells.
p1015 Ultrastructural analysis revealed that retinal ribbon synapses and other
synaptic profiles suffered alterations in diabetes and contained nontypical
elements: empty profiles and blood vessels extending into the retina were
also revealed. In PACAP-treated retinas, there were still some degenerative
profiles in the OPL, but more ribbon synapses were found in the IPL.
Noncharacteristic elements such as immune cells and blood vessels were pre-
sent in both synaptic layers, similar to diabetic retinas (K. Szabadfi,
unpublished results).
p1020 Breakdown of outer BRB is one of themajor complications ofDR,which
is associated with the reduction of claudin-1 and ZO-1 expressions. This pro-
cess was reversed by PACAP and VIP. Both peptides counteract
hyperglycemia-induced damage in ARPE-19 cells, suggesting that theymight
be relevant to the maintenance of outer BRB function (Scuderi et al., 2013).
p1025 PACAP exerts its protective effects by increasing antiapoptotic factors
and decreasing proapoptotic factors in different retinal and other injuries
(Martin et al., 2004; Racz et al., 2006; Szabo et al., 2012; Vaudry et al.,
2009). PACAP-induced pathways attenuate apoptosis in DR. Four path-
ways influenced by PACAP (MAPKs, PI3K/Akt, PKC, and inhibiting
ER stress) converge to minimize apoptotic damage of retinal neurons in
PACAP-treated diabetic retinas. PACAP (i) downregulated the precursor
and active forms of caspase 8, caspase 3, and caspase 12 in diabetic retinas.
PACAP treatment (ii) suppressed the expression and the phosphorylation
of p38 MAPK and activated ERK1/2 in diabetes after 3 weeks of diabetes
suggesting that the activity of MAPK pathways may account for at least part
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of the protection. It also potentiates (iii) PKC and Bcl-2 in early DR possibly
accounting for some of the observed protection. PACAP reduces apoptosis
via (iv) elevated level of p-Akt protein and its downstream target GSK3b
phosphorylation. Akt signaling seems to play an important role in the neu-
roprotective effects of PACAP in DR (Szabadfi et al., 2014) and also other
different retinal and other injuries (Lazarovici et al., 2012; Li et al., 2005;
Racz et al., 2006; Szabo et al., 2012). Most of the cytoprotective effects
of PACAP are mediated through activation of PAC1-R, which can induce
a signaling cascade to stimulate protective factors and block caspase activa-
tion (Seaborn et al., 2011). PAC1-R-containing cells were not TUNEL-
positive in any of the diabetic retinas, suggesting that PAC1-R-containing
cells are more resistant (Szabadfi et al., 2014) than those without. In addition,
mRNA and protein levels for PAC1-R are higher in diabetic retinas after
PACAP treatment (Szabadfi et al., 2012). Tsutsumi et al. (2002) described
that activation of VPAC1-R has been implicated in elevating glucose out-
put, whereas activation of VPAC2-R may be involved in insulin secretion.
PACAP exerts an inhibitory activity on hyperglycemia-induced endothelial
cell proliferation, thus suggesting that the effect might be mediated by PAC1
and VPAC2 receptors (Castorina et al., 2010). We have also found unusual
cells, like pericytes, granulocytes, and macrophages, in PACAP-treated dia-
betic retina (Szabadfi et al., 2012). According to our preliminary data, this
can be correlated with the changing mRNA and protein levels of
VPAC1-R and VPAC2-R, through which receptors Au22of PACAP and VIP
may have an action in inflammation. Thus, all three PACAP receptors
may have positive contribution to fighting diabetes and its consequences
(Giunta et al., 2012; Szabadfi et al., 2012, 2014).
p1030 The potency of PACAP in diabetes and related conditions in addition to
its retinoprotective actions suggests that PACAP might have a therapeutic
potential in the treatment of DR.
s0235 4.3. Therapies with vascular targets
p1035 Despite evidence that hyperactivity of the vasodeleterious axis (ACE/angio-
tensin II (Ang II)/angiotensin II type 1 receptor (AT1R)) of the renin–
angiotensin system (RAS) is associated with the pathogenesis of DR, use
of the inhibitors of this axis has had limited success in the control of this path-
ophysiology. Inhibition of the RAS has been shown to provide beneficial
effects against DR, and AT1R activation may be a clue to retinal vascular
dysfunction.
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s0240 4.3.1 Angiotensin
p1040 DR is associated with impaired balance of RAS. Increased expression of
ACE2/angiotensin(1–7) overcomes this imbalance and confers protection
against DR. Intraocular administration of ACE2/angiotensin(1–7) by a viral
vector resulted in significant reduction in diabetes-induced retinal vascular
leakage, acellular capillaries, infiltrating inflammatory cells, and oxidative
damage in both diabetic mice and rats. Thus, strategies enhancing the pro-
tective ACE2/angiotensin(1–7) axis of RAS in the eye could serve as a novel
therapeutic target for DR (Verma et al., 2012).
s0245 4.3.2 Angiotensin receptor blockers
p1045 Valsartan or telmisartan is an AT1R blocker. AT1R blockade significantly
reversed the diabetes-induced electroretinographic changes and reduction
of synaptic protein but not mRNA levels in the diabetic mouse and rat ret-
ina. Synaptophysin degradation and neuronal dysfunction ran parallel after
AT1R activation in the diabetic retina, suggesting the possibility of the
AT1R blockade as a novel neuroprotective treatment for DR (Kurihara
et al., 2008; Phipps et al., 2007). Retinal leukocytes were significantly
suppressed by AT1R blockade by valsartan. Administration of valsartan
inhibited diabetes-induced retinal expression of ICAM-1 and VEGF
(Nagai et al., 2007). Valsartan also decreased AQP1 expression in STZ-
induced diabetic rats (Qin et al., 2012). Gao et al. (2009a) described a com-
prehensive proteomic analysis in diabetic mice in which the AT1R antag-
onist candesartan ameliorated the diabetes-induced changes of metabolism,
oxidative phosphorylation, and apoptotic pathway-associated proteins. Fur-
ther, candesartan treatment decreased diabetes-stimulated retinal vascular
permeability suggesting that activation of AT1R contributes to BRB dys-
function (Phipps et al., 2009) and at the same time significantly reduced
the levels of VEGF and NADPH oxidase subunits in type 2 DR
(Fukumoto et al., 2008). Candesartan also inhibited the development of
DR by reducing the accumulation of pentosidine (an AGE) and expression
of VEGF (Sugiyama et al., 2007).
s0250 4.3.3 Angiotensin-converting enzyme inhibitors
p1050 Perindopril is an angiotensin-converting enzyme (ACE) inhibitor (ACEI).
It exerts a protective effect in DR by decreasing VEGF-to-PEDF ratio
(downregulating VEGF and upregulating PEDF). The lowering of
VEGF-to-PEDF ratio is significantly correlated with the relief of the vascu-
lar damage and was a result of reduced mitochondrial ROS production by
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increasing uncoupling protein 2 (UCP-2). ACEI can attenuate oxidative
stress through both the NADPH oxidase pathway and the UCP-2/
mitochondrial pathway. The upregulation of UCP-2 expression is mediated
by PPARg (Zheng et al., 2009). Connective tissue growth factor (CTGF)
has been postulated to have prosclerotic and angiogenic properties. DR is
associated with a greater than twofold increase in CTGF mRNA levels
and immunoreactivity, which was attenuated by perindopril treatment.
The protective effects of ACEIs on retinal pathology may be mediated
via effects on retinal CTGF expression (Tikellis et al., 2004).
p1055 The ACE inhibitor captopril completely inhibited the diabetes-induced
retinal capillary degeneration. Captopril inhibited hyperglycemia-induced
leukostasis in the retinal vasculature (Zhang et al., 2007).
s0255 4.3.4 (Pro)Renin receptor blockers
p1060 The association of receptor-associated prorenin system was defined with
diabetes-induced retinal inflammation. The administration of a prorenin
receptor blocker inhibited the diabetes-induced retinal expression of VEGF
and ICAM-1 in rats. Retinal adherent leukocytes were significantly
suppressed with a (pro)renin receptor blocker. A significant contribution
of the receptor-associated prorenin system to the pathogenesis of
diabetes-induced retinal inflammation suggests the possibility of the
prorenin receptor as a novel molecular target for the treatment of DR
(Satofuka et al., 2009).
s0260 4.3.5 Antiangiogenic treatments
p1065 One of the major problems in DR is neovascularization. Any treatment
preventing the formation of new vessels could prove to be antiangiogenic.
The major factor driving the vascularization and neovascularization is
VEGF. Reducing VEGF levels is therefore a major target in preventing
DR. Anti-VEGF therapies in the treatment of proliferative DR and the
use of intravitreal anti-VEGF therapy and anti-VEGF traps in clinical prac-
tice are now encouraged as adjuncts to corrective surgery (Hayden et al.,
2011). It is safe and efficacious for macular condition in humans, although
vitreal administration may be associated with an increased risk of systemic
thromboembolism (Zhang et al., 2009a).
s0265 4.3.5.1 Angiostatin
p1070 Angiostatin is a naturally occurring protein found in several animal species,
including humans. It is an endogenous angiogenesis inhibitor, which blocks
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the growth of new blood vessels, effecting vascular leakage in any tissue
(Sima et al., 2004). Diabetic rats showed significant increases in vascular per-
meability in the retina and iris. Angiostatin could reverse this effect.
Angiostatin downregulates VEGF expression and thus blocks the major
cause of vascular leakage in the diabetic retina (Sima et al., 2006).
Angiostatin may have a therapeutic potential in the treatment of diabetic
macular edema and other diseases with vascular leakage.
s0270 4.3.5.2 Decursin
p1075 Decursin is a compound isolated from the root of Angelica gigas Nakai that
can be a novel compound for the antiangiogenesis approach of DR (Ahn
et al., 1996). Targeting VEGFR-2 with decursin inhibits second messenger
signaling in retinal cells (Kim et al., 2009a). The antiangiogenic effects of
decursin have been largely attributed to reduced VEGFR-2 expression in
endothelial cells. Even high doses of decursin did not induce apoptosis
suggesting that it may be a safe therapeutic agent (Yang et al., 2013b).
s0275 4.3.5.3 Anti-VEGF antibodies
p1080 Bevacizumab is a humanized anti-VEGF antibody. The efficacy of intra-
vitreal injection of bevacizumab was evaluated as a preventive intervention
of vascular endothelial cell proliferation in the rat retina after 2 months of
diabetes. A single intraocular injection of bevacizumab may be beneficial
as a therapy for preventing retinal vascular endothelial cell growth
(Ma et al., 2010). Ranibizumab is a recombinant humanized monoclonal
anti-VEGF antibody fragment developed for intravitreal use. It has the abil-
ity to bind to all biologically active isoforms of VEGF. These recent devel-
opments led to their widespread use in clinical trials and even in clinical
practice (Gabriel, 2013; Hammes, 2013).
s0280 4.4. Hormones
p1085 There are a few compounds that have been tried in DR that had not been
localized to neurons in any parts of the nervous system to date and therefore
by nomeans can be considered neuropeptides or neurohormones. Delivered
via circulation to the target organs, by classical terminology, they can be
considered hormones.
s0285 4.4.1 Erythropoietin
p1090 EPO is a glycoprotein hormone and a neurotrophic and endothelial survival
factor that has both neuroprotective and vascular protective functions
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(Ghezzi and Brines, 2004; Zhong et al., 2007). EPO is upregulated in the eye
in DR. It is considered to act in a dual way as a neuroprotective factor by
inducing angiogenesis (Marti et al., 2000) and has been found in both RPE
and neuroretina in diabetic eyes. Its overexpression is unrelated to mRNA
expression of HIFs (Garcia-Ramirez et al., 2008; Hernandez et al., 2006). It
is possible that higher concentrations of EPO can be neuroprotective under
certain circumstances (Hernandez and Simo, 2012). In early diabetic retinas,
upregulation of EPO-R mRNA and protein and increased expression of
EPO-R in neurons in different layers were seen. In the experimental
STZ-induced diabetic rat, intravitreal injection of EPO caused a dose-
dependent inhibition of the breakdown of the BRB after a characteristic
cytokine response (Zhang et al., 2008). The protective effects of EPO
against the breakdown of BRB are related to the known
anti-inflammatory effect of EPO (Villa et al., 2003). Inhibition of EPO syn-
thesis or action reduces retinal neovascularization in proliferative DR and
inhibits endothelial cell proliferation in vitro (Watanabe, 2007). EPO can
prevent or delay neuronal apoptosis. Apoptotic neurons in the ONL were
essentially undetectable in EPO-treated diabetic eyes up to 4 weeks. At
6 weeks, some cell death was detectable suggesting a therapeutic window
for EPO in DR treatment. Treatment with EPO at the dose inducing eryth-
ropoiesis is beneficial not only for retinal vessels but also for retinal neuron
survival (Zhang et al., 2008). Apoptosis in EPO-R-expressing cells could be
aborted by rapid EPO binding (Brines and Cerami, 2005). Intravitreal injec-
tion of EPO resulted in downregulation of EPO-R, VEGF, and VEGF
receptor at 4 weeks of DR (Mitsuhashi et al., 2013).
p1095 Exogenous EPO administration by intravitreal or intraperitoneal injec-
tion in early diabetes may prevent structural vascular and neuronal damage in
STZ-induced diabetic rats (Wang et al., 2011; Zhang et al., 2008). Intra-
vitreal EPO administration is able to upregulate brain-derived neurotrophic
factor (BDNF) and ciliary neurotrophic factor (CNTF) expressions
(Hu et al., 2011). The EPO molecule has been successfully altered to selec-
tively eliminate erythropoietic and prothrombotic potencies, while preserv-
ing tissue-protective activities (Brines and Cerami, 2008). Administration of
the EPO helix-B domain inhibits diabetes-related edema and significantly
protects against neuroglial and vascular degenerative pathology (Brines
et al., 2008; McVicar et al., 2011). Administration of suberythropoietic
amounts of EPO delta peptide reduces oxidative stress in target tissues
and prevents pericyte loss in the diabetic retina (Wang et al., 2010b). It ame-
liorates prosurvival signals involving Akt and reduces the loss of pericytes in
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the diabetic retina. EPO can reduce oxidative stress via different mecha-
nisms, acting as a direct and indirect antioxidant by reducing superoxide
and other radicals; inducing glutathione peroxidase, which is downregulated
in the diabetic retina, thus improving the balance between pro- and
antioxidative factors; and stimulating p-Akt predominantly in cells of the
INL in the diabetic retina. EPO treatment reduces pericyte dropout via
reduction of angiotensin-2 upregulation. It also protects RPE cells against
the increase of permeability induced by diabetic conditions, and this effect
is mainly mediated by the downstream signaling of Janus kinase 2 and
PI3K/Akt pathways (Garcia-Ramı´rez et al., 2011).
p1100 Recombinant human erythropoietin (rhEPO) has roles in preventing and
reversing dysfunction of retinal neurons and glial cells in early STZ-induced
diabetic rats. The amplitudes of b wave and OPs showed no decrease in
diabetic rats with rhEPO injection. The administration of rhEPO may be
useful in the neural treatment of DR at early stage (Zhu et al., 2008).
s0290 4.4.2 Melatonin
p1105 Indoleamine hormone melatonin, secreted by pinealocytes (Stehle et al.,
2011), is a powerful free radical scavenger and lipophilic antioxidant agent
(Galano et al., 2011; Reiter et al., 2002). Apart from its main biological func-
tion (regulating circadian cycle—e.g., Lanfumey et al., 2013), melatonin
shows activity against oxidative stress and inflammatory and apoptotic pro-
cesses in diabetic complications (Chang et al., 2008; Klepac et al., 2006;
Zwirska-Korczala et al., 2005). In addition, melatonin has strong
mitochondria-protective effects (Kim and Lee, 2008). Melatonin treatment
increases the mRNA expression and the activity of both Cu–Zn SOD and
Mn SOD; thus, their activity enables a prolonged antioxidant capability
under high-glucose conditions. It also reduces the apoptosis of the retinal
neurons and caspase 3 mRNA expression. Melatonin first reduces the oxi-
dative damage to mitochondria, therefore reducing the release of cyto-
chrome c (Li et al., 2013a). Melatonin has double solubility, a high
lipophilic and partial hydrophilic property, which means that it has a high
degree of dispersion; it can easily pass through the cell and mitochondrial
membrane to exert antioxidant activity. Melatonin’s effect on retinal cell
apoptosis is not due to the hypoglycemic effect itself. Additionally, its
antioxidative and neuroprotective effects also depend on the intervention
time (Kanter et al., 2006; Sudnikovich et al., 2007). Melatonin prevents
the decrease in the ERG a and b waves and OP amplitude and the increase
in retinal lipid peroxidation, retinal catalase activity, NOS activity, and
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TNFa, GFAP, and VEGF levels in DR associated with type 2 diabetes
(Salido et al., 2013). No toxicity has been reported after long-term use.
Its safe administration makes this molecule an attractive agent for the treat-
ment of early DR.
s0295 4.4.2 Exendin-4 and its analogs
p1110 Exendin-4 (E4), a 39-amino acid peptide, is a cognate receptor (GLP-1R)
agonist. It was found in the saliva of the Gila monster. E4 has been shown to
bind to GLP-1R in pancreatic cells and to promote the proliferation of b
cells in the pancreas (Lupi et al., 2008). It was reported that both GLP-1
and E4 have neuroprotective properties. Since GLP-1R is also expressed
in the rat retina (Zhang et al., 2009b), primarily in the Mu¨ller cells, a study
was carried out to test the effects of E4a in retinal protection when delivered
intravitreally. It has been shown that intravitreal injection of E4a could pro-
tect the rat retinas from diabetic insults, but the effect was transient (Zhang
et al., 2011). The amplitudes of both b waves and OPs were reduced in dia-
betic rats, which were greatly improved at 1 month after E4a treatment.
However, such protective effects disappeared at 3 months after the treat-
ment. Such action might have occurred through a local effect of E4a by
its receptor GLP-1R because intravitreal injection of E4a had no effect
on body weight or blood glucose level. Morphological examination also
confirmed the protective effects of E4a. Themaintenance of retinal neuronal
cells by E4a might be achieved by its antiapoptotic function, but the path-
ways involved merit further exploration. E4a might exert its protective
function by upregulating its GLP-1R and GLAST expression in the Mu¨ller
cells (Zhang et al., 2009b, 2011).
p1115 Exenatide is a synthetic version of E4. The appropriate concentration of
exenatide protects RGC-5 cells from high- or low-glucose-induced RGC
impairment and mitochondrial changes. Exenatide improved the survival rate
of the cells and suppressed changes in the mitochondrial morphology. Treat-
mentwith exenatide significantly inhibited cytochrome c release and decreased
the intracellular expression levels of Bax and caspase 3, whereas Bcl-2 was
increased. It is concluded that a mitochondrial mechanism might play a key
role in the protective effect of exenatide on the RGC-5 cells, and exenatide
might be beneficial for patients with DR (Fu et al., 2012; Hao et al., 2012).
s0300 4.5. Neurotrophic factors
p1120 Neurotrophic factors are thought to play amajor role in the development and
maintenance of the neural connections. The possibility of their induction in
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the tissues and extrinsic application in degenerative disorders was coined long
time ago (Semkova and Krieglstein, 1999). Here, we describe some of the
research regarding the use of neurotrophic factors in DR.
s0305 4.5.1 Brain-derived neurotrophic factor
p1125 In low quantities, BDNF is expressed in RGCs and Mu¨ller glia (Seki et al.,
2003), and it is important for the survival of RGCs and amacrine cells
(Cusato et al., 2002). Under normal conditions, it acts as a synaptic modu-
lator in the retinal dopaminergic system (Cellerino et al., 1998). Seki et al.
(2004) reported that the degeneration of dopaminergic amacrine and RGCs
is accompanied by a reduction in BDNF levels in the retina of rats with
STZ-induced diabetes and demonstrated the therapeutic potential of BDNF
for treating neurodegeneration of dopaminergic amacrine cells in the dia-
betic retina by intraocular administration. BDNF protects the neurons
through (i) TrkB receptors, (ii) insulin-responsive pathways, and
(iii) reduction of systemic glucose level locally in the retina.
s0310 4.5.2 Nerve growth factor
p1130 NGF is the first discovered and best-characterized member of a neuro-
trophin family and is produced by a number of different cells, including
the cells of the visual system (Levi-Montalcini, 1987). However, there is
no report on retinal production. Intraocularly injected NGF can reach
the posterior portion of the eye and also the brain through the optic nerve.
The level of NGF in the retina of rats with diabetes decreased significantly
compared with the level of NGF of normal animals. The expression of NGF
receptor, TrkA, is markedly reduced in RGCs. NGF treatment prevents
both diabetes-induced programmed cell death in the neuroretina and
diabetes-specific pathology in the vascular retina in experimental diabetic
models (Colafrancesco et al., 2011; Hammes et al., 1995b).
p1135 Topical NGF administration (delivered as eye drops) can prevent the del-
eterious events that can lead the progressiveRGCdeath in diabetes. The pro-
tective action of NGF on RGCs suggests a potential benefit of NGF-based
therapy for ocular disorders such as DR (Colafrancesco et al., 2011). This
observation also suggests that NGF in cooperation with other factors can
be part of a permanently active endogenous retinoprotective mechanism.
s0315 4.5.3 Pigment epithelium-derived factor
p1140 PEDF was first purified from the conditioned media of human RPE cells
with neuronal differentiating activity (Barnstable and Tombran-Tink,
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2004). PEDF is a potent angiogenesis inhibitor in the mammalian eye. Its
amount decreases in the retina and vitreous in DR, suggesting that loss of
PEDF activity in the eye may contribute to development of proliferative
DR (Boehm et al., 2003). Intravitreal injection of PEDF can suppress
BRB breakdown and vascular permeability induced by VEGF (Liu et al.,
2004), which implies that PEDF takes part in regulating vascular permeabil-
ity. Single intravitreal injection of PEDFmRNAdelivered with the help of a
viral vector relieved BRB breakdown in STZ-induced diabetic rats for
6 months. The effect was associated with the downregulation of retinal
VEGF mRNA and ICAM-1 expression and concomitant upregulation of
occludin expression (Yu et al., 2010). PEDF inhibits retinal leukostasis in
diabetic rats by reducing ICAM-1 expression via suppressing oxidative stress
generation (Yamagishi et al., 2006b).
p1145 Diabetes decreases PEDF and GS levels in the retina. PEDF increases
expression of GS against the effect of IL-1b in early DR acting as an
anti-inflammatory factor in retinal Mu¨ller cells (Shen et al., 2011). PEDF
not only inhibits AGE-induced endothelial cell damage but also prevents
AGE-elicited retinal vascular hyperpermeability in rats by suppressing
NADPH oxidase activity (Inagaki et al., 2003; Yamagishi et al., 2006a).
The inhibition of NADPH oxidase is a molecular target for the antioxidative
and protective properties of PEDF in early DR (Yoshida et al., 2009). PEDF
application may offer a promising strategy for halting the development of
DR through its antioxidative properties and by blocking the harmful action
of AGE on diabetic retinas (Yoshida et al., 2009). Besides vascular responses,
PEDF administration restored the decrease in amplitudes of a and b waves of
ERG, which was associated with suppression of GFAP expression (Li et al.,
2002). Thus, PEDF application may be useful for long-term preventive or
adjunctive therapy for DR (Yu et al., 2010).
s0320 4.6. Others
p1150 A plethora of studies offer miscellaneous approaches to treating DR. These
range from chemical inhibition of certain metabolic processes through using
natural compounds to photomodulation. Here, we provide a short summary
of these less systematic approaches.
s0325 4.6.1 Inhibition of metabolic changes
p1155 RAGE is a signal-transducing receptor for AGEs. The engagement of
RAGE or AGEs elicits the diabetic complications; thus, the inhibition of
RAGE expression might represent a potential target for DR treatment.
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Various inhibitors of AGE–RAGE system have therapeutic utility for DR
(Chen et al., 2013).
p1160 One pharmacological strategy for the treatment of DR is to utilize the
small nucleophilic hydrazine compound, aminoguanidine (AG). This drug
is a selective inhibitor of AGEs and has been shown to prevent a range of
diabetic vascular complications, including DR (Hammes et al., 1995a;
Kern and Engerman, 2001; Kern et al., 2000). AG effectively prevents
capillary closure, microaneurysm formation, and the depletion of NOS-
containing neurons in the diabetic retina (Gardiner et al., 2003). The
beneficial effect of AG has been underlined by the fact that AG is a
non-AGE-specific inhibitor with antioxidant or inducible NOS properties
(Sakata et al., 1999). AG inhibited the development of retinal lesions in dia-
betic rats (Kern and Engerman, 2001). AG delays the development of exper-
imental DR in early stages by reducing AGE deposition in retinal blood
vessels and ameliorating the ultrastructural pathological changes in retinal
capillaries in diabetic rats. AG treatment prevented pericyte loss, endothelial
cell proliferation, capillary occlusion, and acellular capillary formation. AG
exerts protective effects through specific inhibition of AGEs (Luo et al.,
2012). AG inhibits VEGF through inhibition of AGEs and VEGF-induced
endothelial cell proliferation and migration (Luo et al., 2012). However, as
we mentioned earlier, although AG is a useful inhibitor of protein glycation,
it may be toxic from the viewpoints of vitamin B6 metabolism and also by
inhibiting pyridoxal phosphate-dependent enzymes (Okada and Ayabe,
1995). AG is known to inhibit diamine oxidase that catalyzes determination
of diamines such as histamine. This effect on histamine could be a problem if
high-histamine-generating food is consumed, but again only if one is taking
insufficient vitamin B6 (Taylor, 1986). For the aforementioned reason, AG
is not used in human therapy because of it has serious toxicity issues, which
are undetectable except by specific tests that are not part of standard clinical
blood tests.
p1165 Similar to AG, pyridoxamine and purearin Au23are also AGE inhibitors.
These compounds have been evaluated for treatment of diabetic complica-
tions (Chen et al., 2012a; Luo et al., 2012). Both substances downregulate
the expression levels of RAGE and VEGF in diabetic rat retina providing the
opportunity for management of DR.
s0330 4.6.2 Compounds and extracts from plants
p1170 Using nonsynthetic compounds of natural origin is a popular approach these
days in treating any diseases. In the PubMed database alone, there are more
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than 500,000 entries found for the isolation and use of such substances.
Applications include everything from antimicrobial use to cancer research.
Some have been tried in DR too; we found more than 200 entries for that
alone. Here is a selection of those entries, which met at least some success.
s0335 4.6.2.1 Flavonoids
p1175 Flavonoids acting as antioxidants may function as terminators of free radical
chains and as chelators of redox-active metal ions that are capable of catalyz-
ing lipid peroxidation. Flavonoids have the ability to act as a scavenger of
reactive radical species and prevent the Fenton reaction.
p1180 Baicalein (5,6,7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one) is a
type of flavonoid, originally isolated from the roots of Scutellaria baicalensis.
It has been used for centuries as a folk medicine in China and Japan, among
others, for the treatment of inflammatory disease. Given that inflammatory
processes play an important role in the pathogenesis of DR, baicalein with its
anti-inflammatory properties blocks high-glucose-induced microglial and
astroglial activation, thereby preventing the secretion of inflammatory
and/or cytotoxic factors. Baicalein treatment inhibited high-glucose-
induced Mu¨ller cell dysfunction and VEGF overexpression and conse-
quently protected neurons and vasculature from damage in DR (Yang
et al., 2009).
p1185 Phlorizin is a 20-glucoside of phloretin. It belongs to the group of
dihydrochalcones, a group of flavonoids. Phlorizin is effective in treating
diabetic complications. It significantly reduces fasting blood glucose concen-
trations and levels of AGE and remarkably inhibits apoptosis and the expres-
sion of GFAP in the retinas of db/dbmice. From the 1636 proteins that were
indentified from the retina tissue, in total, 348 proteins were differentially
expressed in db/db mice compared with the controls. Only 60 proteins
in the retinas of db/db mice were found to be differentially changed follow-
ing phlorizin treatment, including 33 proteins that were downregulated and
27 proteins that were upregulated (Zhang et al., 2013).
p1190 Eriodictyol is a strong antioxidative flavonoid extracted from Eriodictyon
californicum. Eriodictyol has effects on retinal TNFa, VEGF, ICAM-1, and
eNOS formation as well as the plasma lipid peroxidation and BRB integrity
in STZ-induced diabetic rats. Treatment with eriodictyol reduces TNFa,
VEGF, ICAM-1, and eNOS in the diabetic rat retina and suppresses
diabetes-related BRB breakdown. It does not have hypoglycemic effects
but is rather protective due to an unknown molecular mechanism
(Bucolo et al., 2012).
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:26 Page Number: 84
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
84 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
p1195 Hesperidin is a flavanone glycoside found abundantly in citrus fruits. It
significantly suppresses BRB breakdown and increases the retina thickness,
reduces blood glucose and aldose reductase activity, and downregulates ret-
inal TNFa, ICAM-1, VEGF, IL-1b, and AGEs levels. Furthermore, treat-
ment with hesperidin significantly reduces plasma malondialdehyde content
and increases SOD activity in diabetic rats. Hesperidin therefore attenuates
retinal abnormalities via antiangiogenic, anti-inflammatory, and
antioxidative effects and through an inhibitory effect on polyol pathway
and AGE accumulation (Shi et al., 2012).
p1200 The total flavonoids extracted from Flos Puerariae (TFF; Pueraria sp.)
have potential protective effects in DR of diabetic mice. The thickness of
the retina was significantly increased and the retinal capillary basement
membrane thickness was reduced in the TFF-treated diabetic mice. It also
attenuated the diabetes-induced apoptosis of retinal neurons with decreased
Bax and increased ratio of Bcl-2 to Bax (Li et al., 2013b).
s0340 4.6.2.2 Polyphenols
p1205 Green tea (GT), widely studied for its beneficial properties protecting against
brain ischemia, is a rich source of polyphenols. Diabetic rats received GT
orally for 12 weeks, which fully restored GFAP, oxidative markers
(ROS), glutamine synthetase, occludin, glutamate transporter, and receptor
levels in the retina. The protective effects of GT were also evaluated in vitro
inMu¨ller and ARPE-19 cell lines. GT treatment decreased the level of ROS
and restored the glutamate transporter levels in both cell lines. GT protects
the retina against diabetes-induced glutamate toxicity via an antioxidant
mechanism (Silva et al., 2013). GT also acts against retinal oxidative stress
and proinflammatory parameters in diabetic rats. Both SOD and CAT enzy-
matic activities were restored close to normal in GT-treated STZ-induced
diabetic animals. Expression of proinflammatory parameters (TNFa and
VEGF) was significantly inhibited in GT-treated diabetic retinas, and GT
prevented retinal capillary basement membrane thickening as well
(Kumar et al., 2012).
p1210 Chlorogenic acid (CGA) is a polyphenol found in various agricultural
products such as coffee, beans, potatoes, and apples and is formed by ester-
ification of caffeic and quinic acid. It has antibacterial, anti-inflammatory,
antioxidant, and anticarcinogenic activities and beneficial effects on glucose
metabolism (Dos Santos et al., 2006; Kim et al., 2010). Treatment with
CGA has a dose-dependent protective effect on the vascular system in
DR; it reduces VEGF expression, restores occludin, and decreases BRB
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breakdown. Partial restoration of claudin-5 level was also observed, but this
effect was not significant. At the same time, ZO-1 level was not affected by
CGA treatment (Shin et al., 2013).
p1215 Additionally, 4-methyl-2,6-diisobornylphenol facilitated reductions in
the diabetes-induced degradation of photoreceptors and RGCs (Logvinov
et al., 2010), which is probably associated mainly with the antioxidant prop-
erties of this agent.
s0345 4.6.2.3 Other plant extracts
p1220 Arctiin, a bioactive compound isolated from dry seeds of Arctium lappa L.
(Fructus Arctii), has been reported to have antidiabetic activity. At week
16 in STZ-induced diabetes Au24, the glycosylated hemoglobin level was signif-
icantly decreased in all of arctiin-treated groups, and the serum glucose level
was also decreased in the rats treated with a high dose. Treatment with
arctiin ameliorated retinal edema, detachment of the retina, and VEGF
expression in the retina. Arctiin decreases the severity of diabetic complica-
tions, demonstrating the importance of this compound as an inhibitor of DR
(Lu et al., 2012).
p1225 The total triterpenic acid mixture, isolated from Cornus mas (Fructus
Corni), could reverse the abnormalities of the diabetic retina, such as the
upregulation of mRNA levels of endothelin receptor and iNOS. It markedly
reduced vasodilatation mediated by acetylcholine and NO (Su et al., 2007).
p1230 Tinospora cordifolia (TC), commonly known as Guduchi from the Men-
ispermaceae family, has a long history of use in Ayurvedic medicine. TC
contains many pharmacologically active ingredients, such as alkaloids, gly-
cosides, and steroids. TC plays a role in the prevention and management of
DR due to its antihyperglycemic, antiangiogenic, anti-inflammatory, and
antioxidant properties and prevents cataract and vascular changes
(Agrawal et al., 2012; Rathi et al., 2002). The possible mechanism of its
hypoglycemic action is that TC may potentiate insulin effect (Stanely
et al., 2000). Apart from its antihyperglycemic actions, TC has also shown
some promising effects in preventing diabetic complications. TC reduced
VEGF levels in rats (Agrawal et al., 2012). This reduction might be due
to the presence of an active ingredient, octacosanol, which is reported to
downregulate VEGF gene expression by inhibiting matrix
metalloproteinases and nuclear translocation of NF-kB and reduce its
DNA binding activity (Agrawal et al., 2012). The expression of VEGF in
diabetic retina can be regulated by PKC, whose activation is related to many
vascular abnormalities. TC significantly reduced PKC activation and level.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:27 Page Number: 86
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
86 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
There was also an effect on the retinal cytokine elevation (Agrawal et al.,
2012). The inhibition of TNFa- and IL-1b-induced inflammation by TC
in DR may be attributed to the action of one or more of these compounds
blocking the binding of cytokines to their specific surface receptors. Both
glutathione and catalase levels increased in TC-treated group as compared
with diabetics (Agrawal et al., 2012).
p1235 Treatment with curcumin showed significant hypoglycemic activity
compared with the diabetic group. Curcumin positively modulated the anti-
oxidant system; the elevation of proinflammatory cytokines and oxidative
stress were prevented by curcumin. Curcumin prevented the structural
degeneration of endothelial cell organelles and the increase in capillary base-
ment membrane thickness and retinal Mu¨ller glial cells (prevents
upregulation of GFAP and downregulation of GS) in the diabetic rat retina.
Curcumin may have potential benefits in the prevention of DR (Gupta
et al., 2011; Zuo et al., 2013).
p1240 Several studies demonstrated that dietary fiber can significantly reduce
the risk of cardiovascular diseases and type 2 diabetes (Wursch and
Pi-Sunyer, 1997). Oat is a paradigm natural food supplement with a broad
spectrum of beneficial biochemical and cell biological effects, based on its
ability to reduce hyperglycemia-induced ROS overproduction. The inter-
ference in the overproduction of ROS by oat in diabetic rats normalizes
parameters of oxidative stress in the retina and prevents the activation of
major pathways involved in hyperglycemia-induced vascular damage. Oat
could have potential benefits in the prevention of the onset and progression
of DR. Oat reduced and even normalized downstream effectors of vascular
response to injury. Besides reduction of ROS overproduction, it also has an
indirect AGE-inhibiting effect; it disrupts the detrimental AGE–RAGE–
NF-kB pathways. Oat treatment also attenuated the increased VEGF and
TNFa levels (Al-Malki, 2013).
p1245 Grape seed proanthocyanidin extracts (GSPEs) have been reported to
possess a variety of potent properties including antioxidant, anti-
inflammation, radical scavenging, and antitumor activities (Houde et al.,
2006; Shao et al., 2003; Vayalil et al., 2004). GSPE-treated diabetic rats
showed significant reductions in AGE levels and an antinonenzymatic
glycation effect compared with untreated diabetic rats. GSPE had protective
effects on the retinal tissue of diabetic rats. Some affected proteins returned
to normal levels accompanying AGE recovery after GSPE therapy in DR.
These proteins are most likely to participate in the regulation of small heat-
shock proteins (Li et al., 2008b).
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p1250 Wolfberry (Lycium barbarum) is a fruit, which contains large amounts of
polysaccharides, phenolics, lutein, and zeaxanthin in ester forms, which are
neuroprotective in the progression of macular degeneration (Faitova et al.,
2006; Inbaraj et al., 2008). Dietary wolfberry and its bioactive constituents,
zeaxanthin and lutein, functioned as modulators of cell survival/death sig-
naling pathways through targeting pathways in cAMP-activated protein
kinase and forkhead O transcription factor 3a signaling, resulting in normal-
ization of cellular ROS and subsequent attenuation of endoplasmatic retic-
ulum stress. This could lead to prevention of apoptosis and restoration of
retinal structure in type 2 diabetic db/db mouse. RPE integrity and retinal
structure were altered at early stages of diabetes in the db/db mouse model,
and this abnormality could be attenuated by dietary wolfberry, which
prevented or delayed the onset of the disease of DR (Tang et al., 2011).
p1255 Ginkgo biloba leaf extract (GBE) contains many different flavone glyco-
sides and terpenoids, which have antioxidant action and anti-inflammatory
effects, suppressing the production of reactive oxygen and nitrogen species
(Ilieva et al., 2004). GBE inhibits the increase of low-density lipoprotein
(LDL) and prevents oxidative damage to mitochondria, suggesting that its
beneficial effects on neurodegenerative diseases are related to prevention
of chronic oxidative damage (Yoshikawa et al., 1999). GBE blunts some
of negative effects due to hyperglycemia, such as oxidation, inflammation,
and VEGF expression, which are the main causes of DR (Bucolo
et al., 2013).
p1260 Zeaxanthin is one of the dietary carotenoids that are specifically concen-
trated in the retina, especially in the macular region. Zeaxanthin significantly
inhibits diabetes-induced retinal oxidative damage and elevation of VEGF
and ICAM-1, abnormalities that are associated with the pathogenesis of
DR. These results suggest that zeaxanthin supplementation has the potential
to inhibit the development of retinopathy in diabetes (Kowluru et al., 2008).
Lutein also prevents diabetes-induced visual dysfunction. It inhibits oxida-
tive stress, thereby preserving the integrity of the neuroprotective pathways
in early diabetic retina (Sasaki et al., 2010).
p1265 Astaxanthin is a carotenoidwith powerful antioxidant properties that exists
naturally in various plants, algae, and seafood (salmon, trout, krill, crayfish,
shrimp, and other crustaceans), yeast, and the feathers of some birds.
Astaxanthinwas showntoreduce theapoptosisofRGCsand improve the levels
of oxidative stress markers, including superoxide anion, malondialdehyde
(a marker of lipid peroxidation), 8-hydroxy-2-deoxyguanosine (indicator of
oxidative DNA damage), and MnSOD activity in the retinal tissue of db/db
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mouse.Therefore, astaxanthinmaybe further developed as an antioxidantdrug
to treat DR (Dong et al., 2013).
p1270 Cilostazol is a quinolinone-derivative medication used in the alleviation
of the symptoms of intermittent claudication in individuals with peripheral
vascular disease. In the retinas of OLETF rats, cilostazol treatment reduced
GFAP and VEGF expression and the number of TUNEL-positive cells
( Jung et al., 2013).
p1275 Berberine and rosiglitazone significantly decreased PPARg expression in
diabetic retina, while berberine and fenofibrate obviously increased PPARa
and PPARd expressions in diabetic retina. Berberine modulates
PPARa/g/d protein levels in diabetic retina, which may help to ameliorate
retinopathy complication induced by STZ-induced diabetes and a high-
carbohydrate/high-fat diet. Berberine might be a more beneficial drug to
treat diabetic retinal complication compared with fenofibrate and
rosiglitazone (Zhou and Zhou, 2007).
p1280 Cannabinoids are known to possess therapeutic properties including anti-
oxidant, anti-inflammatory, andNMDA receptor activation-blocking activ-
ity (Hampson et al., 1998; Marsicano et al., 2002). Nonpsychotropic CBD
demonstrated its neuroprotective effects via anti-inflammatory and BRB-
preserving effects in diabetic rats alongwith a prominentMu¨ller glial cell acti-
vation (El-Remessy et al., 2010). Exposure of retinalMu¨ller glial cells to high
glucose levels stimulates oxidative stress and peroxynitrite formation (Shelton
et al., 2007). Diabetes-induced oxidative and nitrative stresses alter the func-
tion of Mu¨ller cells by impairing GS activity, leading to glutamate neurotox-
icity and sustaining retinal neuronal cell death. Treating diabetic animals with
CBDblocked the increases in oxidative and nitrative stresses and significantly
reduced the number of apoptotic cells. CBD restores GS activity by reducing
its tyrosine nitration in diabetic animals. This effect was associated with a sig-
nificant reduction in Mu¨ller glial cell activation, which confirms the preser-
vation of its morphology and function in diabetic animals (El-Remessy et al.,
2010). CBD represents a novel therapeutic agent in the treatment of diabetes
and stress-mediated retinal damage.
p1285 Resveratrol, a natural plant-derived phytoalexin, treatment effectively
blocked the diabetes-induced increase of vessel leakage, pericyte loss, and
VEGF protein levels in the mouse retinas. Resveratrol is effective in decreas-
ing vascular lesions and VEGF induction in mouse retinas of early diabetes
(Kim et al., 2012).
p1290 Astragalin, a 3-O-glucoside extracted from Astragalus membranaceus and
Astragalus propinquus, has a history of use as a herbal medicine in systems
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of traditional Chinese medicine and has many pharmacological properties. It
has been shown that astragalin decreases the overexpression of VEGF in cul-
tured Mu¨ller glial cells after 3 days of treatment and alleviates the effects of
high glucose. Astragalin has promising applications in preventing and
treating DR (Ke et al., 2012).
p1295 Ginseng plants (Araliaceae), including North American ginseng (Panax
quinquefolius) root extracts has multiple pharmacological actions because
of their diverse phytochemical constituents. Ginsenosides are its major bio-
active factors. Ginsenosides or panaxosides are the derivatives of
protopanaxatriol, a class of steroid glycosides, and triterpene saponins
(Wang et al., 2008). Bioactives of ginseng possess antioxidant properties,
quenching free radicals, protecting LDLs from oxidation, and inhibiting
lipid peroxidation (Kim and Park, 2003). Alcoholic ginseng root extract
(per os daily) was administered for models of both type 1 (C57BL/6 mice
with STZ-induced diabetes) and type 2 diabetes (db/db mice) for 2 or
4 months. In both the heart and retina of diabetic animals, ginseng treatment
significantly prevented oxidative stress and diabetes-induced upregulation of
extracellular matrix proteins and vasoactive factors. These data indicate that
North American ginseng prevents the diabetes-induced retinal and cardiac
biochemical and functional changes probably through inhibition of oxida-
tive stress (Sen et al., 2013).
p1300 The extract, named fenugreek, of Trigonella foenum-graecum L. contains
simple alkaloids (trigonelline, choline, gentianine, and carpaine) and other
pyridines and pyrroles. Treatment with fenugreek resulted in marked inhi-
bition in the expression of inflammatory (TNFa and IL-1b) and angiogenic
molecular biomarkers (VEGF and PKCb) and positive modulatory effects
on retinal oxidative stress. The fenugreek-treated retinas did not show
vascular leakage with and had relatively reduced thickening of capillary base-
ment membrane. Fenugreek has great potential in preventing diabetes-
induced retinal degeneration in humans with regular consumption in the
specified dosage (Gupta et al., 2014).
s0350 4.6.3 Miscellaneous compounds
p1305 Several compounds of miscellaneous origin have been tested to counteract
experimental DR symptoms. An incomplete list of these follows.
s0355 4.6.3.1 Retinoid acids
p1310 Retinoic acid (RA) and its derivatives are essential signaling molecules
throughout life and may play an important role in the induction of glial Au25cell
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line-derived neurotrophic factor (GDNF; Nishikiori et al., 2007a; Thang
et al., 2000), which is a differentiation factor in the retina (Thang et al.,
2000; Wu et al., 2004a). RA inhibits the apoptosis; a marked decrease in
apoptotic cell number could be observed during the development of DR
after treatment with RA (Nishikiori et al., 2008). A possible protective
mechanism might be that RA protects retinal cells by inducing GDNF
production in glial cells in the retina (Nishikiori et al., 2007a,b). RAs are
promising drugs for diabetic ophthalmic disease because they have
anticataractogenic effects for diabetic cataracts (Nishikiori et al., 2007b),
BRB-protective effects for vascular integrity (Miyajima et al., 2005;
Nishikiori et al., 2007a), and neuroprotective effects against apoptosis in
DR (Nishikiori et al., 2008).
s0360 4.6.3.2 Calpain inhibitors
p1315 Calpains are a family of 14 calcium-regulated, intracellular cysteine prote-
ases, which modulate cellular functions by limited specific proteolysis
(Huang and Wang, 2001). Calpains are activated by locally increased
Ca2+ levels through calcium channels and intracellular stores (Camins
et al., 2006). Inhibition of calpain signaling is a therapeutic target for several
pathological conditions, including DR. Calpain plays a crucial role in met-
abolically induced RGC degeneration caused by DR and oxidative stress.
The combination of antioxidants and calpain inhibition offers important
opportunities for future neuroprotective treatment against RGC death.
Levels of calpain are regulated by an endogenous specific inhibitor,
calpastatin. An exogenous calpain inhibitor, SNJ-1945, has shown strong
ability to penetrate BRB after oral administration (Shirasaki et al., 2005).
Four weeks after the induction of diabetes, degeneration of RGCs and their
axons was successfully prevented by SNJ-1945. This compound was able to
suppress mRNA overexpression of calpain-1, and it has a significant preven-
tive effect against diabetic changes to RGC synapses in DR. Proapoptotic
end products of cleaved a-fodrin were significantly reduced in DR by oral
administration of SNJ-1945 (Shanab et al., 2012).
s0365 4.6.3.3 Sitagliptin
p1320 Sitagliptin is an oral antihyperglycemic drug of the dipeptidyl peptidase-4
inhibitor class. Treatment with sitagliptin prevented the changes in the
endothelial subcellular distribution of the tight junction proteins (occludin
and claudin-5) induced by diabetes. Sitagliptin decreased the nitrosative
stress, the inflammatory state, and cell death in diabetic retinas. It allowed
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the recovery of a number of CD34+ cells present in the bloodstream with
levels similar to their number in controls and increased the adhesion ability
of endothelial progenitor cells to the retinal vessels and exerted beneficial
effects on the BRB integrity in ZDF rat retinas (Gonc¸alves et al., 2012).
s0370 4.6.3.4 Carnosine
p1325 Carnosine (beta-alanyl-L-histidine) is an antiglycating dipeptide of the
amino acids beta-alanine and histidine. It is highly concentrated in muscle
and brain tissues. Carnosine has a number of antioxidant properties and
has been proven to scavenge ROS and alpha–beta-unsaturated aldehydes
formed from peroxidation of cell membrane fatty acids during oxidative
stress. Oral carnosine treatment prevented retinal vascular damage after
6 months of experimental hyperglycemia. The protection was associated
with a significant induction of Hsp27 in activated glial cells and normaliza-
tion of increased angiotensin-2 levels in diabetic retinas. Oral carnosine
treatment protects retinal capillary cells in experimental DR, independently
of its other biochemical functions (Pfister et al., 2011).
s0375 4.6.3.5 Memantine
p1330 Vitreoretinal glutamate levels are elevated in experimental diabetes (Lieth
et al., 1998). The expression of the N-methyl-D-aspartate (NMDA)-type
glutamate receptors is upregulated in the diabetic retina suggesting a role
of glutamate excitotoxicity. Memantine is an NMDA receptor blocker
and acts as an uncompetitive antagonist (Smith, 2002). Long-term treatment
with memantine significantly improves retinal function and prevents RGC
loss in STZ-induced diabetic rats. Memantine also significantly reduces ele-
vated VEGF protein levels in the retina and vitreous fluid and BRB break-
down in the retinas of diabetic animals. Memantine significantly improved
amplitudes of ERG a and b waves. Another possible mechanism of the neu-
roprotective effect of memantine in the retinas of STZ-induced diabetic rats
could be the inhibition of retinal type 3 serotonin and nicotinic Ach recep-
tors, although elevated serotonin and acetylcholine levels have not been
demonstrated in diabetic retina (Kusari et al., 2007).
s0380 4.6.3.6 Nepafenac
p1335 Nepafenac is a prodrug of amfenac, a nonsteroidal anti-inflammatory drug
that inhibits COX-1 and COX-2 and the synthesis of proinflammatory
prostaglandins (Kapin et al., 2003). The administration of nepafenac inhibits
functional andmorphological lesions characteristic to the early stages of DR.
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It also inhibited the diabetes-induced apoptosis of endothelial cells and peri-
cytes and the degeneration of retinal capillaries. In the retina, nepafenac par-
tially inhibits the diabetes-induced activation of executioner caspases, such as
caspase 3 and caspase 6. It may also be a direct scavenger of superoxide. Top-
ically applied nepafenac decreased the OP latency despite persistent hyper-
glycemia. Nepafenac administered via eye drops reaches the retina of rats in
sufficient concentration to inhibit multiple biochemical and morphological
abnormalities in diabetes (Kern et al., 2007).
s0385 4.6.3.7 Vitamin D
p1340 Many studies provide evidence that lack of vitamin D has a role in patho-
genesis of both type 1 and type 2 diabetes (Takiishi et al., 2010), including
their accompanied syndromes such as DR (Aksoy et al., 2000; Albert et al.,
2007; Kaur et al., 2011). Vitamin D is a potent inhibitor of retinal
neovascularization in DR (Albert et al., 2007) through decreasing the level
of VEGF (Ren et al., 2012).
s0390 4.6.3.8 Hydrogen sulfide
p1345 Hydrogen sulfide (H2S) is the most recent addition to endogenous gas-
otransmitter family. It played beneficial roles in several diseases, and a lower
level of H2S was observed in the blood of diabetic patients and STZ-treated
rats ( Jain et al., 2010). Treatment with exogenous H2S prevented diabetic
neurodegeneration and enhanced expressions of synaptophysin and BDNF
in retinas. Reduction was seen in BRB permeability and the number of acel-
lular capillaries following treatment with exogenous H2S in retinas of STZ-
induced diabetic rats. This could be explained by the concomitant reduction
in vitreous VEGF content and gene expression of HIF-1a and VEGF-R2
and increased expression of occludin. Treatment with H2S not only func-
tioned as a direct scavenger of ROS but also influenced some important
enzymes associated with oxidative stress. Treatment with H2S or NaHS,
a donor of H2S, attenuated STZ-induced retinopathy, possibly through
abating oxidative stress and suppressing inflammation (Si et al., 2013).
s0395 4.6.3.9 Hydrogen saline
p1350 If hydrogen is dissolved in physiological saline under high pressure to a
supersaturated level, it becomes hydrogen saline (H(2)saline or hydrogen-
rich saline; Sun et al., 2011). It has considerable antioxidant and anti-
inflammatory properties, and it also suppresses oxidative stress-induced
injury. In the retina, it has protective effects against glutamate-induced
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toxicity (Wei et al., 2012). H(2)saline treatment could depress caspase 3
activity, reduce retinal apoptosis and vascular permeability, and prominently
attenuate the retinal parenchyma thickening that resulted from DR (Xiao
et al., 2012b). In H(2)saline-treated STZ-induced diabetic rats, the
diabetes-induced reduction of b wave amplitudes and OPs was restored,
and the BRB breakdown and histological changes in the inner retina were
reversed. Furthermore, H(2)saline reduced oxidative stress, increased anti-
oxidant enzyme activities, and preserved synaptophysin and BDNF levels
in diabetic rat retina (Feng et al., 2013).
s0400 4.6.3.10 N-acetylcysteine
p1355 Macrophage/microglia activation, pericyte loss, and endothelial/peri-
vascular cell changes occur early in the pathogenesis of DR. These changes
are associated with an increase in plasma markers of oxidative stress and
inflammation and are minimized by treatment with a well-known free rad-
ical scavenger, N-acetylcysteine (Tsai et al., 2009).
s0405 4.6.3.11 Fasudil
p1360 Fasudil protects the vascular endothelium by inhibiting neutrophil adhesion
and reducing neutrophil-induced endothelial injury. Intravitreal administra-
tion significantly increased eNOS phosphorylation, whereas it reduced
ICAM-1 expression, leukocyte adhesion, and the number of damaged
endothelial cells. Neutrophils from DR patients showed significantly higher
adhesion to cultured endothelium and caused endothelial apoptosis, which
was significantly reduced by fasudil. Fasudil may alter the Rho/Rho kinase
pathway, which plays a critical role in diabetic retinal microvasculopathy;
therefore, Rho kinase inhibition may become a new strategy in the manage-
ment of DR, especially in its early stages (Arita et al., 2009).
s0410 4.6.3.12 Photobiomodulation
p1365 Daily 670 nm photobiomodulation treatment resulted in a significant inhi-
bition in diabetes-induced RGC death and a 50% improvement of the ERG
amplitude, especially photopic b wave responses. Photobiomodulation did
not alter cytochrome oxidase activity in the retina or in the cultured retinal
cells, but inhibited diabetes-induced superoxide production and preserved
MnSOD expression in vivo. It essentially prevented the diabetes-induced
increase in leukostasis and expression of ICAM-1. It is a noninvasive, inex-
pensive, and easily administered simple adjunct therapy to attenuate the
development of DR (Tang et al., 2013).
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:30 Page Number: 94
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
94 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
s0415 5. CONCLUDING REMARKS
p1370 As it has been shown in the preceding text, there are numerous open
options to researchDRand its treatment possibilities. Perhaps, it is conspicuous
for the reader that symptoms of DR are identical regardless of which type of
diabetes causes this syndrome. Therefore, both type 1 and type 2 diabetes
models canbeused to study treatmentoptions.However, not all the aforemen-
tioned diabetes models are equally efficient in producing all the symptoms
observed in human patients. In our opinion, there can be two main causes
of this mismatch: (i) In humans, diabetes in most cases is controlled (i.e.,
patients use medications to lower their blood glucose levels to acceptable con-
centrations). Early good glycemic control and prevention of the abnormalities
of apoptosis are important for diabetic patients to prevent the development and
progression of sight-threateningDR(Gao et al., 2009b;Hammes, 2013). Also,
(ii) the relatively short life span of the most often used animal models may be a
problem. Rats and mice (especially those inflicted with diabetes) do not live
long enough to produce all the alterations in circulation and develop compen-
satory mechanisms for the diabetic damage, and experimenters very often use
young adult specimens for their studies. Therefore, efforts should be made to
develop chronic models with controlled blood sugar levels and to achieve
long-term survival (more than a year after diabetes induction) of experimental
animals to produce all the symptoms (or as many of them as possible). These
constrains may also explain whymice have been used less frequently as models
in studyingDR.Genetically modified transgenic or knockoutmice are widely
used in other areas of biomedical research. Several inbred strains are also used
for studying diabetes and DR, but they could be more extensively studied if
models were chosen carefully. Thus, considering all the requirements, long-
term STZ-induced diabetes in rats with carefully controlled blood glucose
level could be one of the best options to study diabetic complications such
as DR. Among the genetically diabetic strains, spontaneously type 2 diabetic
rats could be the best for this purpose; our bias is clearly toward theOLETF and
SDT rats, because they produce the symptoms that are closest to the human
disease. Ex vivo and in vitro models may be useful in studying certain aspects
of pathogenesis of DR and test drug candidates but may not be sufficiently
sophisticated to study all aspects, especially not those related to real functional
and electrophysiological properties.
p1375 As for the protective compounds, besides the strict blood glucose con-
trol, two major lines of research should be pursued in the future: (i) to find
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extremely selective blockers of specific antiapoptotic pathways or generate a
mixture of neurotrophic factors to keep nerve cells alive under damaging
metabolic conditions and (ii) to provide general protection against ischemia,
which facilitates the formation of ROS, AGE, and advanced lipoxidation
end product (ALE). For the first approach, compounds acting at different
levels of the signal transduction pathway have been tried. Among inhibitors
of neuron loss, octreotide, a peptide analog of SST acting at sst2A receptors,
has been found the most effective. If a nonpeptide analog could be devel-
oped for this receptor, chances for routine medicinal use would definitely
increase. The similar notion is true for PACAP. Currently, only shortened
or modified versions of the peptide are available for experimentation
(Bourgault et al., 2008); nonpeptide PACAP agonists do not exist. Exper-
iments are in progress to show if PACAP is protective in the form of artificial
tears (D. Reglodi, unpublished results). Likewise, if an optimal mixture of
trophic factors (IGF, NGF, BDNF, and PEDF) could be created, it could be
applied topically. PEDF is a particularly promising candidate, and since its
production is restricted to the retina, unwanted side effects can be minimal.
Hormones and hormone-like materials (angiotensin and EPO) present in
several tissues of the body carry less hope because of their potentially strong
side effects. A more promising way is to fight angiogenesis with anti-VEGF
compounds or antibodies. In fact, the latter form of treatment gains momen-
tum in clinical trials either alone or in combination with surgical treatments
in the clinical practice. A similarly promising approach is to fight ROS,
AGE, and ALE formation. GT, ginseng and Ginkgo extracts, curcumin,
and astragalin are particularly potent. Their administration is simple, but
it should be noted that these compounds have to be administered over a long
period of time. This can be done in the form of nutritional supplements.
Adverse action or side effects are improbable.
p1380 As the final point, a desirable experimental design will be described here,
which may lead to results that can be successfully translated to humans. Aged
OLETF and/or SDT rats or, alternatively, animals with STZ-induced con-
trolled long-term diabetes (at least 1-year duration) should be used. Meta-
bolic parameters should be monitored every day, blood sugar level should be
kept around 10–15 mmol/l. Control ERG measurements should be per-
formed before DR develops. When early symptoms of DR (e.g., vascular
leakage, retinal edema, and deteriorating ERG) appear, protective treatment
regimes should be initiated. Besides keeping an untreated diabetic group
alive as long as possible, one experimental group could receive specific neu-
roprotective/antiapoptotic treatment and the other nonselective anti-ROS
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compound(s). The possible protective agents should be administered either
topically (e.g., in case of neuropeptide analogs or growth factors) in a pre-
determined manner (e.g., monthly intravitreal injection) or per os daily
(anti-ROS compounds). This way, the efficacy of specific and generic treat-
ment strategies and their long-termmanageability could be determined. The
animals that die during the experimental period should be taken to autopsy
to assess the severity of diabetes and DR. There are obviously several diffi-
culties in executing such a wide-scope and long-term experiment with
enough animals to draw valid conclusions. However, at this stage of DR
research, one or more research groups have to take the risk to produce trans-
latable results.
ac0005 ACKNOWLEDGMENTS
p1385 This study was supported by OTKA K100144, OTKA K104984, TAMOP-4.2.2.A-11/1/
KONV-2012-0024, MTA Lendulet program, and the Akira Arimura Au26Foundation. The
authors are grateful to Genevieve Lind for her advice and linguistic corrections.
REFERENCES
Abu El-Asrar, A.M., Dralands, L., Missotten, L., Geboes, K., 2007. Expression of anti-
apoptotic and proapoptotic molecules in diabetic retinas. Eye (Lond). 21 (2), 238–245.
Agardh, C.D., Agardh, E., Zhang, H., Ostenson, C.G., 1997. Altered endothelial/pericyte
ratio in Goto-Kakizaki rat retina. J. Diabetes Complications 11 (3), 158–162.
Agrawal, S.S., Naqvi, S., Gupta, S.K., Srivastava, S., 2012. Prevention and management of
diabetic retinopathy in STZ diabetic rats by Tinospora cordifolia and its molecular mech-
anisms. Food Chem. Toxicol. 50 (9), 3126–3132.
Ahn, K.S., Sim, W.S., Kim, I.H., 1996. Decursin: a cytotoxic agent and protein kinase
C activator from the root of Angelica gigas. Planta Med. 62 (1), 7–9.
Aizu, Y., Oyanagi, K., Hu, J., Nakagawa, H., 2002. Degeneration of retinal neuronal pro-
cesses and pigment epithelium in the early stage of the streptozotocin-diabetic rats.
Neuropathology 22 (3), 161–170.
Aksoy, H., Akc¸ay, F., Kurtul, N., Baykal, O., Avci, B., 2000. Serum 1,25 dihydroxy vitamin
D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in dia-
betic retinopathy. Clin. Biochem. 33 (1), 47–51.
Albert, D.M., Scheef, E.A., Wang, S., Mehraein, F., Darjatmoko, S.R., Sorenson, C.M.,
Sheibani, N., 2007. Calcitriol is a potent inhibitor of retinal neovascularization. Invest.
Ophthalmol. Vis. Sci. 48 (5), 2327–2334.
Al-Gayyar, M.M., Mysona, B.A., Matragoon, S., Abdelsaid, M.A., El-Azab, M.F.,
Shanab, A.Y., Ha, Y., Smith, S.B., Bollinger, K.E., El-Remessy, A.B., 2013. Diabetes
and overexpression of proNGF cause retinal neurodegeneration via activation of RhoA
pathway. PLoS One 8 (1), e54692.
Ali, T.K., Matragoon, S., Pillai, B.A., Liou, G.I., El-Remessy, A.B., 2008. Peroxynitrite
mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling
in experimental and human diabetes. Diabetes 57 (4), 889–898.
Al-Malki, A.L., 2013. Oat attenuation of hyperglycemia-induced retinal oxidative stress and
NF-kB activation in streptozotocin-induced diabetic rats. Evid. Based Complement.
Alternat. Med. 2013, 983923.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:37 Page Number: 97
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
97Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Amandio, M., Bucolo, C., Leggio, G.M., Drago, F., Govoni, B., Pascale, A., 2010. The
PKCB/HuR/VEGF pathway in diabetic retinopathy. Biochem. Pharmacol.
80, 1230–1237.
Ambati, J., Chalam, K.V., Chawla, D.K., D’Angio, C.T., Guillet, E.G., Rose, S.J.,
Vanderlinde, R.E., Ambati, B.K., 1997. Elevated gamma-aminobutyric acid, glutamate,
and vascular endothelial growth factor levels in the vitreous of patients with proliferative
diabetic retinopathy. Arch. Ophthalmol. 115 (9), 1161–1166.
Amthor, F.R., Keyser, K.T., Dmitrieva, N.A., 2002. Effects of the destruction of starburst-
cholinergic amacrine cells by the toxin AF64A on rabbit retinal directional selectivity.
Vis. Neurosci. 19 (4), 495–509.
Aranda, J., Motiejunaite, R., Im, E., Kazlauskas, A., 2012. Diabetes disrupts the response of
retinal endothelial cells to the angiomodulator lysophosphatidic acid. Diabetes 61 (5),
1225–1233.
Arita, R., Hata, Y., Nakao, S., Kita, T., Miura, M., Kawahara, S., Zandi, S., Almulki, L.,
Tayyari, F., Shimokawa, H., Hafezi-Moghadam, A., Ishibashi, T., 2009. Rho kinase
inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes
58 (1), 215–226.
Arjamaa, O., Nikinmaa,M., 2006. Oxygen-dependent diseases in the retina: role of hypoxia-
inducible factors. Exp. Eye Res. 83 (3), 473–483.
Asnaghi, V., Gerhardinger, C., Hoehn, T., Adeboje, A., Lorenzi, M., 2003. A role for the
polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes
in the rat. Diabetes 52, 506–511.
Atlasz, T., Szabadfi, K., Kiss, P., Babai, N., Koszegi, Z., Tamas, A., Reglodi, D., Gabriel, R.,
2008. PACAP-mediated neuroprotection of neurochemically identified cell types in
MSG-induced retinal degeneration. J. Mol. Neurosci. 36, 97–104.
Atlasz, T., Szabadfi, K., Kiss, P., Racz, B., Gallyas, F., Tamas, A., Gaal, V., Marton, Zs,
Gabriel, R., Reglodi, D., 2010. Review of pituitary adenylate cyclase activating poly-
peptide in the retina: focus on the retinoprotective effects. Ann. N.Y. Acad. Sci.
1200, 128–139.
Aveleira, C.A., Lin, C.M., Abcouwer, S.F., Ambro´sio, A.F., Antonetti, D.A., 2010. TNFa
signals through PKCz/NF-kB to alter the tight junction complex and increase retinal
endothelial cell permeability. Diabetes 59 (11), 2872–2882.
Badr, G.A., Tang, J., Ismail-Beigi, F., Kern, T.S., 2000. Diabetes downregulates GLUT1
expression in the retina and its microvessels but not in the cerebral cortex or its
microvessels. Diabetes 49 (6), 1016–1021.
Bagnoli, P., Dal Monte, M., Casini, G., 2003. Expression of neuropeptides and their recep-
tors in the developing retina of mammals. Histol. Histopathol. 18, 1219–1242.
Barba, I., Garcia-Ramı´rez, M., Hernandez, C., Alonso, M.A., Masmiquel, L., Garcı´a-
Dorado, D., Simo, R., 2010. Metabolic fingerprints of proliferative diabetic retinopathy:
an 1H-NMR-based metabonomic approach using vitreous humor. Invest. Ophthalmol.
Vis. Sci. 51 (9), 4416–4421.
Barber, A.J., Lieth, E., Khin, S.A., Antonetti, D.A., Buchanan, A.G., Gardner, T.W., 1998.
Neural apoptosis in the retina during experimental and human diabetes. Early onset and
effect of insulin. J. Clin. Invest. 102, 783–791.
Barber, A.J., Nakamura, M., Wolpert, E.B., Reiter, C.E., Seigel, G.M., Antonetti, D.A.,
Gardner, T.W., 2001. Insulin rescues retinal neurons from apoptosis by a pho-
sphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of
caspase 3. J. Biol. Chem. 276 (35), 32814–32821.
Barber, A.J., Antonetti, D.A., Kern, T.S., Reiter, C.E., Soans, R.S., Krady, J.K., Levison, S.-
W., Gardner, T.W., Bronson, S.K., 2005. The Ins2Akita mouse as a model of early ret-
inal complications in diabetes. Invest. Ophthalmol. Vis. Sci. 46, 2210–2218.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:37 Page Number: 98
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
98 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Barber, A.J., Gardner, T.W., Abcouwer, S.F., 2011. The significance of vascular and neural
apoptosis to the pathology of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 52 (2),
1156–1163.
Barnstable, C.J., Tombran-Tink, J., 2004. Neuroprotective and antiangiogenic actions of
PEDF in the eye: molecular targets and therapeutic potential. Prog. Retin. Eye Res.
23 (5), 561–577.
Behl, Y., Krothapalli, P., Desta, I., DiPiazza, A., Roy, S., Graves, D.I., 2008. Diabetes-
enhanced tumor necrosis factor alpha production promotes apoptosis and the loss of ret-
inal microvascular cells in type 1 and type 2models of diabetic retinopathy. Am. J. Pathol.
172, 1411–1418.
Bhutto, I.A., Lu, Z.Y., Takami, Y., Amemiya, T., 2002. Retinal and choroidal vasculature in
rats with spontaneous diabetes type 2 treated with the angiotensin-converting enzyme
inhibitor cilazapril: corrosion cast and electron-microscopic study. Ophthalmic Res.
34 (4), 220–231.
Biro, K., Palhalmi, J., Toth, A.J., Kukorelli, T., Juhasz, G., 1998. Bimoclomol improves early
electrophysiological signs of retinopathy in diabetic rats. Neuroreport 9 (9), 2029–2033.
Blake, A.D., Badway, A.C., Strowski, M.Z., 2004. Delineating somatostatin’s neuronal
actions. Curr. Drug Targets CNS Neurol. Disord. 3 (2), 153–160.
Boehm, B.O., Lang, G., Volpert, O., Jehle, P.M., Kurkhaus, A., Rosinger, S., Lang, G.K.,
Bouck, N., 2003. Low content of the natural ocular anti-angiogenic agent pigment
epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic ret-
inopathy. Diabetologia 46 (3), 394–400.
Bourgault, S., Vaudry, D., Guilhaudis, L., Raoult, E., Couvineau, A., Laburthe, M., Se´galas-
Milazzo, I., Vaudry, H., Fournier, A., 2008. Biological and structural analysis of trun-
cated analogs of PACAP27. J. Mol. Neurosci. 36, 260–269.
Brines, M., Cerami, A., 2005. Emerging biological roles for erythropoietin in the nervous
system. Nat. Rev. Neurosci. 6 (6), 484–494.
Brines, M., Cerami, A., 2008. Erythropoietin-mediated tissue protection: reducing collateral
damage from the primary injury response. J. Intern. Med. 264 (5), 405–432.
Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z.,
Erbayraktar, S., Sepodes, B., Thiemermann, C., Ghezzi, P., Yamin, M., Hand, C.C.,
Xie, Q.W., Coleman, T., Cerami, A., 2008. Nonerythropoietic, tissue-protective pep-
tides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U.S.A.
105 (31), 10925–10930.
Bringmann, A., Wiedemann, P., 2012. Mu¨ller glial cells in retinal disease. Ophthalmologica
227, 1–12.
Bringmann, A., Pannicke, T., Grosche, J., Francke, M., Wiedemann, P., Skatchkov, S.N.,
Osborne, N.N., Reichenbach, A., 2006. Mu¨ller cells in the healthy and diseased retina.
Prog. Retin. Eye Res. 25 (4), 397–424.
Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications.
Nature 414 (6865), 813–820.
Brownlee, M., 2005. The pathobiology of diabetic complications: a unifying mechanism.
Diabetes 54 (6), 1615–1625.
Bucolo, C., Leggio, G.M., Drago, F., Salomone, S., 2012. Eriodictyol prevents early retinal
and plasma abnormalities in streptozotocin-induced diabetic rats. Biochem. Pharmacol.
84 (1), 88–92.
Bucolo, C., Marrazzo, G., Platania, C.B., Drago, F., Leggio, G.M., Salomone, S., 2013. For-
tified extract of red berry, Ginkgo biloba, and white willow bark in experimental early
diabetic retinopathy. J. Diabetes Res. 2013, 432695.
Camins, A., Verdaguer, E., Folch, J., Palla`s, M., 2006. Involvement of calpain activation in
neurodegenerative processes. CNS Drug Rev. 12 (2), 135–148.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:38 Page Number: 99
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
99Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Carmo, A., Cunha-Vaz, J.G., Carvalho, A.P., Lopes, M.C., 2000. Nitric oxide synthase
activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation
with blood-retinal barrier permeability. Nitric Oxide 4 (6), 590–596.
Carrasco, E., Hernandez, C., de Torres, I., Farre´s, J., Simo, R., 2008. Lowered cortistatin
expression is an early event in the human diabetic retina and is associated with apoptosis
and glial activation. Mol. Vis. 14, 1496–1502.
Casini, G., Catalani, E., Dal Monte, M., Bagnoli, P., 2005. Functional aspects of the
somatostatinergic system in the retina and the potential therapeutic role of somatostatin
in retinal disease. Histol. Histopathol. 20, 615–632.
Castorina, A., Giunta, S., Mazzone, V., Cardile, V., D’Agata, V., 2010. Effects of PACAP
and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial
cells. Peptides 31, 2276–2283.
Cellerino, A., Pinzo´n-Duarte, G., Carroll, P., Kohler, K., 1998. Brain-derived neurotrophic
factor modulates the development of the dopaminergic network in the rodent retina.
J. Neurosci. 18 (9), 3351–3362.
Cervia, D., Martini, D., Ristori, C., Catalani, E., Timperio, A.M., Bagnoli, P., Casini, G.,
2008. Modulation of the neuronal response to ischemia by somatostatin analogues in
wild-type and knock-out mouse retinas. J. Neurochem. 106, 2224–2235.
Cervia, D., Catalani, E., Dal Monte, M., Casini, G., 2012. Vascular endothelial growth
factor in the ischemic retina and its regulation by somatostatin. J. Neurochem.
120, 818–829.
Chang, H.M., Huang, Y.L., Lan, C.T., Wu, U.I., Hu, M.E., Youn, S.C., 2008. Melatonin
preserves superoxide dismutase activity in hypoglossal motoneurons of adult rats follow-
ing peripheral nerve injury. J. Pineal Res. 44 (2), 172–180.
Chen, H., Jia, W., Xu, X., Fan, Y., Zhu, D., Wu, H., Xie, Z., Zheng, Z., 2008.
Upregulation of PEDF expression by PARP inhibition contributes to the decrease in
hyperglycemia-induced apoptosis in HUVECs. Biochem. Biophys. Res. Commun.
369 (2), 718–724.
Chen, F., Zhang, H.Q., Zhu, J., Liu, K.Y., Cheng, H., Li, G.L., Xu, S., Lv,W.H., Xie, Z.G.,
2012a. Puerarin enhances superoxide dismutase activity and inhibits RAGE and VEGF
expression in retinas of STZ-induced early diabetic rats. Asian Pac. J. Trop. Med. 5 (11),
891–896.
Chen, Y.H., Chen, J.Y., Chen, Y.W., Lin, S.T., Chan, H.L., 2012b. High glucose-induced
proteome alterations in retinal pigmented epithelium cells and its possible relevance to
diabetic retinopathy. Mol. Biosyst. 8 (12), 3107–3124.
Chen, M., Curtis, T.M., Stitt, A.W., 2013. Advanced glycation end products and diabetic
retinopathy. Curr. Med. Chem. 20 (26), 3234–3240.
Cheung, A.K., Fung, M.K., Lo, A.C., Lam, T.T., So, K.F., Chung, S.S., Chung, S.K., 2005.
Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown,
apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54 (11),
3119–3125.
Colafrancesco, V., Coassin, M., Rossi, S., Aloe, L., 2011. Effect of eye NGF administration
on two animal models of retinal ganglion cells degeneration. Ann. Ist. Super. Sanita
47 (3), 284–289.
Cringle, S.J., Yu, D.Y., Alder, V.A., Su, E.N., 1993. Retinal blood flow by hydrogen clear-
ance polarography in the streptozotocin-induced diabetic rat. Invest. Ophthalmol. Vis.
Sci. 34 (5), 1716–1721.
Curtis, T.M., Scholfield, C.N., 2004. The role of lipids and protein kinase Cs in the
pathogenesis of diabetic retinopathy. Diabetes Metab. Res. Rev. 20 (1), 28–43, Review.
Cusato, K., Bosco, A., Linden, R., Reese, B.E., 2002. Cell death in the inner nuclear layer of
the retina is modulated by BDNF. Brain Res. Dev. Brain Res. 139 (2), 325–330.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:38 Page Number: 100
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
100 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Dagher, Z., Park, Y.S., Asnaghi, V., Hoehn, T., Gerhardinger, C., Lorenzi, M., 2004. Stud-
ies of rat and human retinas predict a role for the polyol pathway in human diabetic ret-
inopathy. Diabetes 53 (9), 2404–2411.
Das Evcimen, N., King, G.L., 2007. The role of protein kinase C activation and the vascular
complications of diabetes. Pharmacol. Res. 55 (6), 498–510.
Davis, M.I., Wilson, S.H., Grant, M.B., 2001. The therapeutic problem of proliferative dia-
betic retinopathy: targeting somatostatin receptors. Horm. Metab. Res. 33 (5), 295–299.
D’Cruz, T.S.,Weibley, B.N., Kimball, S.R., Barber, A.J., 2012. Post-translational processing
of synaptophysin in the rat retina is disrupted by diabetes. PLoS One 7 (9), e44711.
DeBosch, B.J., Deo, B.K., Kumagai, A.K., 2002. Insulin-like growth factor-1 effects on
bovine retinal endothelial cell glucose transport: role of MAP kinase. J. Neurochem.
81 (4), 728–734.
Denis, U., Lecomte, M., Paget, C., Ruggiero, D., Wiernsperger, N., Lagarde, M., 2002.
Advanced glycation end-products induce apoptosis of bovine retinal pericytes in culture:
involvement of diacylglycerol/ceramide production and oxidative stress induction. Free
Radic. Biol. Med. 33 (2), 236–247.
Diaz, B., Serna, J., De Pablo, F., de la Rosa, E.J., 2000. In vivo regulation of cell death by
embryonic (pro)insulin and the insulin receptor during early retinal neurogenesis.
Development 127 (8), 1641–1649.
Dickinson, T., Mitchell, R., Robberecht, P., Fleetwood-Walker, S.M., 1999. The role of
VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an exper-
imental peripheral mononeuropathy. Neuropharmacology 38, 167–180.
Do Carmo, A., Ramos, P., Reis, A., Proenc¸a, R., Cunha-vaz, J.G., 1998. Breakdown of the
inner and outer blood retinal barrier in streptozotocin-induced diabetes. Exp. Eye Res.
67 (5), 569–575.
Dong, C.J., Agey, P., Hare, W.A., 2004. Origins of the electroretinogram oscillatory poten-
tials in the rabbit retina. Vis. Neurosci. 21 (4), 533–543.
Dong, L.Y., Jin, J., Lu, G., Kang, X.L., 2013. Astaxanthin attenuates the apoptosis of retinal
ganglion cells in db/db mice by inhibition of oxidative stress. Mar. Drugs 11 (3),
960–974.
Dos Santos, M.D., Almeida, M.C., Lopes, N.P., de Souza, G.E., 2006. Evaluation of the
anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlo-
rogenic acid. Biol. Pharm. Bull. 29 (11), 2236–2240.
Drel, V.R., Xu, W., Zhang, J., Kador, P.F., Ali, T.K., Shin, J., Julius, U., Slusher, B., El-
Remessy, A.B., Obrosova, I.G., 2009. Poly(ADP-ribose)polymerase inhibition counter-
acts cataract formation and early retinal changes in streptozotocin-diabetic rats. Invest.
Ophthalmol. Vis. Sci. 50 (4), 1778–1790.
Du, Y., Smith, M.A., Miller, C.M., Kern, T.S., 2002. Diabetes-induced nitrative stress in the
retina, and correction by aminoguanidine. J. Neurochem. 80 (5), 771–779.
Du, Y., Miller, C.M., Kern, T.S., 2003. Hyperglycemia increases mitochondrial superoxide
in retina and retinal cells. Free Radic. Biol. Med. 35 (11), 1491–1499.
Eichler, W., Kuhrt, H., Hoffmann, S., Wiedemann, P., Reichenbach, A., 2000. VEGF
release by retinal glia depends on both oxygen and glucose supply. Neuroreport
11, 3533–3537.
El-Remessy, A.B., Behzadian, M.A., Abou-Mohamed, G., Franklin, T., Caldwell, R.W.,
Caldwell, R.B., 2003a. Experimental diabetes causes breakdown of the blood-retina bar-
rier by a mechanism involving tyrosine nitration and increases in expression of vascular
endothelial growth factor and urokinase plasminogen activator receptor. Am. J. Pathol.
162 (6), 1995–2004.
El-Remessy, A.B., Khalil, I.E., Matragoon, S., Abou-Mohamed, G., Tsai, N.J., Roon, P.,
Caldwell, R.B., Caldwell, R.W., Green, K., Liou, G.I., 2003b. Neuroprotective effect
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:38 Page Number: 101
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
101Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced
retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 163 (5), 1997–2008.
El-Remessy, A.B., Bartoli, M., Platt, D.H., Fulton, D., Caldwell, R.B., 2005. Oxidative
stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyro-
sine nitration. J. Cell Sci. 118 (Pt. 1), 243–252.
El-Remessy, A.B., Al-Shabrawey, M., Khalifa, Y., Tsai, N.T., Caldwell, R.B., Liou, G.I.,
2006. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in
experimental diabetes. Am. J. Pathol. 168 (1), 235–244.
El-Remessy, A.B., Khalifa, Y., Ola, S., Ibrahim, A.S., Liou, G.I., 2010. Cannabidiol protects
retinal neurons by preserving glutamine synthetase activity in diabetes. Mol. Vis.
16, 1487–1495.
Elsner, M., Guldbakke, B., Tiedge, M., Munday, R., Lenzen, S., 2000. Relative importance
of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin.
Diabetologia 43 (12), 1528–1533.
Engerman, R.L., Kern, T.S., 1995. Retinopathy in animal models of diabetes. Diabetes
Metab. Rev. 11 (2), 109–120, Review.
Faitova, J., Krekac, D., Hrstka, R., Vojtesek, B., 2006. Endoplasmic reticulum stress and apo-
ptosis. Cell. Mol. Biol. Lett. 11 (4), 488–505.
Feng, Y., Wang, R., Xu, J., Sun, J., Xu, T., Gu, Q., Wu, X., 2013. Hydrogen-rich saline
prevents early neurovascular dysfunction resulting from inhibition of oxidative stress in
STZ-diabetic rats. Curr. Eye Res. 38 (3), 396–404.
Fernandes, R., Suzuki, K., Kumagai, A.K., 2003. Inner blood-retinal barrier GLUT1 in
long-term diabetic rats: an immunogold electron microscopic study. Invest.
Ophthalmol. Vis. Sci. 44 (7), 3150–3154.
Fernandes, R., Hosoya, K., Pereira, P., 2011. Reactive oxygen species downregulate glucose
transport system in retinal endothelial cells. Am. J. Physiol. Cell Physiol. 300 (4),
C927–C936.
Fleming, R.L., Silveira, M.S., Santos, L.E., Henze, I.P., Gardino, P.F., de Mello, M.C., de
Mello, F.G., 2013. Pituitary adenylyl cyclase-activating polypeptide receptor
re-sensitization induces plastic changes in the dopaminergic phenotype in the mature
avian retina. J. Neurochem. 124 (5), 621–631.
Fong, D.S., Aiello, L.P., Ferris 3rd., F.L., Klein, R., 2004. Diabetic retinopathy. Diabetes
Care 27, 2540–2553.
Fox, A., Eastwood, C., Gentry, C., Manning, D., Urban, L., 1999. Critical evaluation of the
streptozotocin model of painful diabetic neuropathy in the rat. Pain 81 (3), 307–316.
Fu, Z., Kuang, H.Y., Hao, M., Gao, X.Y., Liu, Y., Shao, N., 2012. Protection of exenatide
for retinal ganglion cells with different glucose concentrations. Peptides 37 (1), 25–31.
Fukuda, M., Nakanishi, Y., Fuse, M., Yokoi, N., Hamada, Y., Fukagawa, M., Negi, A.,
Nakamura, M., 2010. Altered expression of aquaporins 1 and 4 coincides with neuro-
degenerative events in retinas of spontaneously diabetic Torii rats. Exp. Eye Res.
90 (1), 17–25.
Fukumoto, M., Takai, S., Ishizaki, E., Sugiyama, T., Oku, H., Jin, D., Sakaguchi, M.,
Sakonjo, H., Ikeda, T., Miyazaki, M., 2008. Involvement of angiotensin
II-dependent vascular endothelial growth factor gene expression via NADPH oxidase
in the retina in a type 2 diabetic rat model. Curr. Eye Res. 33, 885–891.
Fulton, A.B., Akula, J.D., Mocko, J.A., Hansen, R.M., Benador, I.Y., Beck, S.C., Fahl, E.,
Seelinger, M.W., Moskowitz, A., Harris, M.E., 2009. Retinal degenerative and hypoxic
ischemic disease. Doc. Ophthalmol. 118, 55–61.
Gabriel, R., 2013. Neuropeptides and diabetic retinopathy. Br. J. Clin. Pharmacol. 75 (5),
1189–1201.
Galano, A., Tan, D.X., Reiter, R.J., 2011. Melatonin as a natural ally against oxidative stress:
a physicochemical examination. J. Pineal Res. 51, 1–16.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:39 Page Number: 102
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
102 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Galloway, N.R., Wells, M., Barber, C., 1971. Changes in the oscillatory potential in relation
to different types diabetic retinography. Vision Res. 11, 1218.
Galvan, V., Logvinova, A., Sperandio, S., Ichijo, H., Bredesen, D.E., 2003. Type 1 insulin-
like growth factor receptor (IGF-1R) signaling inhibits apoptosis signal-regulating kinase
1 (ASK1). J. Biol. Chem. 278 (15), 13325–13332.
Gao, G., Li, Y., Zhang, D., Gee, S., Crosson, C., Ma, J., 2001. Unbalanced expression of
VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett.
489 (2–3), 270–276.
Gao, G., Li, Y., Fant, J., Crosson, C.E., Becerra, S.P., Ma, J.X., 2002. Difference in ischemic
regulation of vascular endothelial growth factor and pigment epithelium-derived factor
in brown norway and sprague dawley rats contributing to different susceptibilities to ret-
inal neovascularization. Diabetes 51 (4), 1218–1225.
Gao, B.B., Phipps, J.A., Bursell, D., Clermont, A.C., Feener, E.P., 2009a. Angiotensin AT1
receptor antagonism ameliorates murine retinal proteome changes induced by diabetes.
J. Proteome Res. 8 (12), 5541–5549.
Gao, X.Y., Kuang, H.Y., Zou, W., Liu, X.M., Lin, H.B., Yang, Y., 2009b. The timing of
re-institution of good blood glucose control affects apoptosis and expression of Bax and
Bcl-2 in the retina of diabetic rats. Mol. Biol. Rep. 36 (7), 1977–1982.
Garcia-Ramirez, M., Hernandez, C., Simo, R., 2008. Expression of erythropoietin and its
receptor in the human retina: a comparative study of diabetic and nondiabetic subjects.
Diabetes Care 31 (6), 1189–1194.
Garcia-Ramı´rez, M., Hernandez, C., Ruiz-Meana, M., Villarroel, M., Corraliza, L., Garcia-
Dorado, D., Simo, R., 2011. Erythropoietin protects retinal pigment epithelial cells
against the increase of permeability induced by diabetic conditions: essential role of
JAK2/PI3K signaling. Cell. Signal. 23 (10), 1596–1602.
Gardiner, T.A., Anderson, H.R., Stitt, A.W., 2003. Inhibition of advanced glycation end-
products protects against retinal capillary basement membrane expansion during long-
term diabetes. J. Pathol. 201 (2), 328–333.
Gastinger, M.J., Singh, R.S., Barber, A.J., 2006. Loss of cholinergic and dopaminergic
amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas.
Invest. Ophthalmol. Vis. Sci. 47 (7), 3143–3150.
Gastinger, M.J., Kunselman, A.R., Conboy, E.E., Bronson, S.K., Barber, A.J., 2008. Den-
drite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita dia-
betic mice. Invest. Ophthalmol. Vis. Sci. 49 (6), 2635–2642.
Gaucher, D., Chiappore, J.A., Paques, M., Simonutti, M., Boitard, C., Sahel, J.A.,
Massin, P., Picaud, S., 2007. Microglial changes occur without neural cell death in dia-
betic retinopathy. Vision Res. 47, 612–623.
Geraldes, P., King, G.L., 2010. Activation of protein kinase C isoforms and its impact on
diabetic complications. Circ. Res. 106 (8), 1319–1331.
Gerhardinger, C., McClure, K.D., Romeo, G., Podesta`, F., Lorenzi, M., 2001. IGF-1
mRNA and signaling in the diabetic retina. Diabetes 50 (1), 175–183.
Gerhardinger, C., Costa, M.B., Coulombe, M.C., Toth, I., Hoehn, T., Grosu, P., 2005.
Expression of acute-phase response proteins in retinal Mu¨ller cells in diabetes. Invest.
Ophthalmol. Vis. Sci. 46 (1), 349–357.
Ghezzi, P., Brines, M., 2004. Erythropoietin as an antiapoptotic, tissue-protective cytokine.
Cell Death Differ. 11 (Suppl. 1), S37–S44.
Gibson, C.J., 1988. Diurnal alterations in retinal tyrosine level and dopamine turnover in
diabetic rats. Brain Res. 454 (1–2), 60–66.
Giunta, S., Castorina, A., Bucolo, C., Magro, G., Drago, F., D’Agata, V., 2012. Early
changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide
and related receptors expression in retina of streptozotocin-induced diabetic rats.
Peptides 37 (1), 32–39.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:39 Page Number: 103
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
103Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Goh, S.Y., Cooper, M.E., 2008. Clinical review: the role of advanced glycation end products
in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 93 (4),
1143–1152, Review.
Gonc¸alves, A., Leal, E., Paiva, A., Teixeira Lemos, E., Teixeira, F., Ribeiro, C.F., Reis, F.,
Ambro´sio, A.F., Fernandes, R., 2012. Protective effects of the dipeptidyl peptidase IV
inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Dia-
betes Obes. Metab. 14 (5), 454–463.
Gorg, B.,Wettstein, M.,Metzger, S., Schliess, F., Haussinger, D., 2005. Lipopolysaccharide-
induced tyrosine nitration and inactivation of hepatic glutamine synthetase in the rat.
Hepatology 41 (5), 1065–1073.
Gorg, B., Qvartskhava, N., Voss, P., Grune, T., Haussinger, D., Schliess, F., 2007. Revers-
ible inhibition of mammalian glutamine synthetase by tyrosine nitration. FEBS Lett.
581 (1), 84–90.
Gosbell, A.D., Favilla, I., Jablonski, P., 2002. The location of insulin receptors in bovine ret-
ina and isolated retinal cells. Clin. Experiment. Ophthalmol. 30 (2), 124–130.
Goto, Y., Kakizaki, M., 1981. The spontaneous-diabetes rat: a model of noninsulin depen-
dent diabetes mellitus. Proc. Jpn Acad. 57, 381–384.
Goto, R., Doi, M., Ma, N., Semba, R., Uji, Y., 2005. Contribution of nitric oxide-
producing cells in normal and diabetic rat retina. Jpn. J. Ophthalmol. 49 (5), 363–370.
Grant, M.B., Caballero, S., 2002. Somatostatin analogues as drug therapies for retinopathies.
Drugs Today (Barc). 38 (11), 783–791.
Grant, M.B., Mames, R.N., Fitzgerald, C., Hazariwala, K.M., Cooper-DeHohh, R.,
Caballero, S., Estes, K.S., 2000. The efficacy of octreotide in the therapy of severe
proliferative and early non-proliferative diabetic retinopathy. Diabetes Care
23, 504–509.
Grunwald, J.E., Brucker, A.J., Braunstein, S.N., Schwartz, S.S., Baker, L., Petrig, B.L.,
Riva, C.E., 1994. Strict metabolic control and retinal blood flow in diabetes mellitus.
Br. J. Ophthalmol. 78 (8), 598–604.
Gupta, S.K., Kumar, B., Nag, T.C., Agrawal, S.S., Agrawal, R., Agrawal, P., Saxena, R.,
Srivastava, S., 2011. Curcumin prevents experimental diabetic retinopathy in rats
through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J. Ocul.
Pharmacol. Ther. 27, 123–130.
Au27Gupta, S.K., Kumar, B., Nag, T.C., Srinivasan, B.P., Srivastava, S., Gaur, S., Saxena, R.,
2014. Effects of Trigonella foenum-graecum (L.) on retinal oxidative stress, and
proinflammatory and angiogenic molecular biomarkers in streptozotocin-induced dia-
betic rats. Mol. Cell. Biochem. 388, 1–9.
Hajna, Z., Szabadfi, K., Gabriel, R., Balla, Z., Biro, Z., Degrell, P., Koszegi, T., Tekus, V.,
Helyes, Z., Dobos, A., Farkas, S., Szucs, G., Pinter, E., 2013. Establishment of a chronic
animal model for comprehensive preclinical investigation of drugs against diabetes-
related complications. In preparation.
Hammes, H.P., 2013. Optimal treatment of diabetic retinopathy. Ther. Adv. Endocrinol.
Metab. 4 (2), 61–71.
Hammes, H.P., Ali, S.S., Uhlmann, M., Weiss, A., Federlin, K., Geisen, K., Brownlee, M.,
1995a. Aminoguanidine does not inhibit the initial phase of experimental diabetic ret-
inopathy in rats. Diabetologia 38, 269–273.
Hammes, H.P., Federoff, H.J., Brownlee, M., 1995b. Nerve growth factor prevents both
neuroretinal programmed cell death and capillary pathology in experimental diabetes.
Mol. Med. 1, 527–534.
Hampson, A.J., Grimaldi, M., Axelrod, J., Wink, D., 1998. Cannabidiol and (-)Delta9-
tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A.
95 (14), 8268–8273.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:39 Page Number: 104
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
104 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Hancock, H.A., Kraft, T.W., 2004. Oscillatory potential analysis and ERGs of normal and
diabetic rats. Invest. Ophthalmol. Vis. Sci. 45 (3), 1002–1008.
Hao, M., Kuang, H.Y., Fu, Z., Gao, X.Y., Liu, Y., Deng, W., 2012. Exenatide prevents
high-glucose-induced damage of retinal ganglion cells through a mitochondrial mech-
anism. Neurochem. Int. 61 (1), 1–6.
Hartnett, M.E., Lappas, A., Darland, D., McColm, J.R., Lovejoy, S., D’Amore, P.A., 2003.
Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epi-
thelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp. Eye Res.
77 (5), 593–599.
Hayden, M.R., Sowers, K.M., Pulakat, L., Joginpally, T., Krueger, B., Whaley-Connell, A.,
Sowers, J.R., 2011. Possible mechanisms of local tissue renin-angiotensin system activa-
tion in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal
Med. 1 (3), 193–210.
Hazin, R., Colyer, M., Lum, F., Barazi, M.K., 2011. Revisiting Diabetes 2000: challenges in
establishing nationwide diabetic retinopathy prevention programs. Am J. Ophthalmol.
152 (5), 723–729.
Hernandez, C., Simo, R., 2012. Neuroprotection in diabetic retinopathy. Curr. Diab. Rep.
12 (4), 329–337.
Hernandez, C., Fonollosa, A., Garcia-Ramirez, M., Higuera, M., Catalan, R., Miralles, A.,
Garcia-Arumi, J., Simo, R., 2006. Erythropoietin is expressed in the human retina and it
is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes
Care 29 (9), 2028–2033.
Au28Hernandez, C., Garcia-Ramirez, M., Corraliza, L., Fernandez-Carneado, J., Farrera-Sinfreu,
J., Ponsati, B., Gonzalez-Rodriguez, A., Martinez-Valverde, A., Simo, R., 2013. Top-
ical administration of somatostatin prevents retinal neurodegeneration in experimental
diabetes. Diabetes 62, 2569–2578.
Hollborn, M., Dukic-Stefanovic, S., Pannicke, T., Ulbricht, E., Reichenbach, A.,
Wiedemann, P., Bringmann, A., Kohen, L., 2011. Expression of aquaporins in the retina
of diabetic rats. Curr. Eye Res. 36 (9), 850–856.
Houde, V., Grenier, D., Chandad, F., 2006. Protective effects of grape seed
proanthocyanidins against oxidative stress induced by lipopolysaccharides of per-
iodontopathogens. J. Periodontol. 77 (8), 1371–1379.
Hu, L.M., Luo, Y., Zhang, J., Lei, X., Shen, J., Wu, Y., Qin, M., Unver, Y.B., Zhong, Y.,
Xu, G.T., Li, W., 2011. EPO reduces reactive gliosis and stimulates neurotrophin
expression in Mu¨ller cells. Front. Biosci. 3, 1541–1555.
Hu, J., Wu, Q., Li, T., Chen, Y., Wang, S., 2013. Inhibition of high glucose-induced VEGF
release in retinal ganglion cells by RNA interference targeting G protein-coupled recep-
tor 91. Exp. Eye Res. 109, 31–39.
Huang, Q., Sheibani, N., 2008. High glucose promotes retinal endothelial cell migration
through activation of Src, PI3K/Akt1/eNOS, and ERKs. Am. J. Physiol. Cell Physiol.
295 (6), C1647–C1657.
Huang, Y., Wang, K.K., 2001. The calpain family and human disease. Trends Mol. Med.
7 (8), 355–362.
Huang, L., Yu, W., Li, X., Xu, Y., Niu, L., He, X., Dong, J., Yan, Z., 2009a. Expression of
Robo4 in the fibrovascular membranes from patients with proliferative diabetic retinop-
athy and its role in RF/6A and RPE cells. Mol. Vis. 15, 1057–1069.
Huang, L., Xu, Y., Yu, W., Li, X., Liqun, C., He, X., Peiying, H., 2009b. Robo1: a poten-
tial role in ocular angiogenesis. Curr. Eye Res. 34 (12), 1019–1029.
Huang, L., Xu, Y., Yu,W., Li, Y., Chu, L., Dong, J., Li, X., 2010. Effect of Robo1 on retinal
pigment epithelial cells and experimental proliferative vitreoretinopathy. Invest.
Ophthalmol. Vis. Sci. 51 (6), 3193–3204.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:40 Page Number: 105
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
105Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Huebschmann, A.G., Regensteiner, J.G., Vlassara, H., Reusch, J.E., 2006. Diabetes and
advanced glycoxidation end products. Diabetes Care 29 (6), 1420–1432.
Ibrahim, A.S., El-Remessy, A.B., Matragoon, S., Zhang,W., Patel, Y., Khan, S., Al-Gayyar,
M.M., El-Shishtawy, M.M., Liou, G.I., 2011. Retinal microglial activation and inflam-
mation induced by amadori-glycated albumin in a rat model of diabetes. Diabetes 60 (4),
1122–1133.
Ilieva, I., Ohgami, K., Shiratori, K., Koyama, Y., Yoshida, K., Kase, S., Kitamei, H.,
Takemoto, Y., Yazawa, K., Ohno, S., 2004. The effects of Ginkgo biloba extract on
lipopolysaccharide-induced inflammation in vitro and in vivo. Exp. Eye Res. 79 (2),
181–187.
Inagaki, Y., Yamagishi, S., Okamoto, T., Takeuchi, M., Amano, S., 2003. Pigment
epithelium-derived factor prevents advanced glycation end products-induced monocyte
chemoattractant protein-1 production in microvascular endothelial cells by suppressing
intracellular reactive oxygen species generation. Diabetologia 46 (2), 284–287.
Inbaraj, B.S., Lu, H., Hung, C.F., Wu, W.B., Lin, C.L., Chen, B.H., 2008. Determination
of carotenoids and their esters in fruits of Lycium barbarum Linnaeus by HPLC-DAD-
APCI-MS. J. Pharm. Biomed. Anal. 47 (4–5), 812–818.
Inokuchi, N., Ikeda, T., Imamura, Y., Sotozono, C., Kinoshita, S., Uchihori, Y.,
Nakamura, K., 2001. Vitreous levels of insulin-like growth factor-I in patients with pro-
liferative diabetic retinopathy. Curr. Eye Res. 23 (5), 368–371.
Ino-ue, M., Yokogawa, H., Yamamoto, M., Naka, H., Kuriyama, H., 1998. Structural
impairments in optic nerve of diabetic rats ameliorated with the aldose reductase inhib-
itor. Exp. Eye Res. 66 (4), 397–401.
Ishikawa, A., Ishiguro, S., Tamai, M., 1996. Accumulation of gamma-aminobutyric acid in
diabetic rat retinal Mu¨ller cells evidenced by electron microscopic immunocytochemis-
try. Curr. Eye Res. 15 (9), 958–964.
Islam, M.S., 2013. Animal models of diabetic neuropathy: progress since 1960s. J. Diabetes
Res. 2013, 149452.
Izuta, H., Matsunaga, N., Shimazawa, M., Sugiyama, T., Ikeda, T., Hara, H., 2010. Prolif-
erative diabetic retinopathy and relations among antioxidant activity, oxidative stress, and
VEGF in the vitreous body. Mol. Vis. 16, 130–136.
Jain, S.K., Bull, R., Rains, J.L., Bass, P.F., Levine, S.N., Reddy, S., McVie, R., Bocchini, J.-
A., 2010. Low levels of hydrogen sulfide in the blood of diabetes patients and
streptozotocin-treated rats causes vascular inflammation? Antioxid. Redox Signal.
12, 1333–1337.
Jansson, L., Naeser, P., 1987. An increased number of mast cells in the sclerae of alloxan-
diabetic mice. Acta Ophthalmol. (Copenh) 65, 203–205.
Jo, D.H., Cho, C.S., Kim, J.H., Jun, H.O., Kim, J.H., 2013. Animal models of diabetic ret-
inopathy: doors to investigate pathogenesis and potential therapeutics. J. Biomed. Sci.
20, 38.
Johnson, L.E., Larsen, M., Perez, M.T., 2013. Retinal adaptation to changing glycemic levels
in a rat model of type 2 diabetes. PLoS One 8, e55456.
Joussen, A.M., Poulaki, V., Le, M.I., Koizumi, K., Esser, C., Janicki, H., Schraer Meyer, U.,
Kociok, N., Fauser, S., Kichhof, B., Kern, T.S., Adamis, A.P., 2004. A central role for
inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18, 1450–1452.
Joussen, A.M., Doehmen, S., Le, M.L., Koizumi, K., Radetzky, S., Krohne, T.U.,
Poulaki, V., Semkova, I., Kociok, N., 2009. TNF-alpha mediated apoptosis plays an
important role in the development of early diabetic retinopathy and long-term histopath-
ological alterations. Mol. Vis. 15, 1418–1428.
Jung, K.I., Kim, J.H., Park, H.Y., Park, C.K., 2013. Neuroprotective effects of cilostazol on
retinal ganglion cell damage in diabetic rats. J. Pharmacol. Exp. Ther. 345 (3), 457–463.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:40 Page Number: 106
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
106 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Kakehashi, A., Saito, Y., Mori, K., Sugi, N., Ono, R., Yamagami, H., Shinohara, M.,
Tamemoto, H., Ishikawa, S.E., Kawakami, M., Kanazawa, Y., 2006. Characteristics
of diabetic retinopathy in SDT rats. Diabetes Metab. Res. Rev. 22 (6), 455–461.
Kamijo, M., Cherian, P.V., Sima, A.A., 1993. The preventive effect of aldose reductase inhi-
bition on diabetic optic neuropathy in the BB/W-rat. Diabetologia 36 (10), 893–898.
Kanter, M., Uysal, H., Karaca, T., Sagmanligil, H.O., 2006. Depression of glucose levels and
partial restoration of pancreatic beta-cell damage bymelatonin in streptozotocin-induced
diabetic rats. Arch. Toxicol. 80 (6), 362–369.
Kapin, M.A., Yanni, J.M., Brady, M.T., McDonough, T.J., Flanagan, J.G., Rawji, M.H.,
Dahlin, D.C., Sanders, M.E., Gamache, D.A., 2003. Inflammation-mediated retinal
edema in the rabbit is inhibited by topical nepafenac. Inflammation 27 (5), 281–291.
Kaur, H., Donaghue, K.C., Chan, A.K., Benitez-Aguirre, P., Hing, S., Lloyd, M.,
Cusumano, J., Pryke, A., Craig, M.E., 2011. Vitamin D deficiency is associated with
retinopathy in children and adolescents with type 1 diabetes. Diabetes Care 34 (6),
1400–1402.
Ke, J.B., Zhong, Y.M., 2007. Expression of somatostatin receptor subtype 5 in rat retinal
amacrine cells. Neuroscience 144, 1025–1032.
Ke, M., Hu, X.Q., Ouyang, J., Dai, B., Xu, Y., 2012. The effect of astragalin on the VEGF
production of cultured Mu¨ller cells under high glucose conditions. Biomed. Mater. Eng.
22 (1–3), 113–119.
Kern, T.S., 2007. Contributions of inflammatory processes to the development of the early
stages of diabetic retinopathy. Exp. Diabetes Res. 2007, 95–103.
Kern, T.S., Barber, A.J., 2008. Retinal ganglion cells in diabetes. J. Physiol. 586 (Pt. 18),
4401–4408.
Kern, T.S., Engerman, R.L., 1994. Comparison of retinal lesions in alloxan-diabetic rats and
galactose-fed rats. Curr. Eye Res. 13 (12), 863–867.
Kern, T.S., Engerman, R.L., 2001. Pharmacological inhibition of diabetic retinopathy: ami-
noguanidine and aspirin. Diabetes 50 (7), 1636–1642.
Kern, T.S., Tang, J., Mizutani, M., Kowluru, R.A., Nagaraj, R.H., Romeo, G., Podesta, F.,
Lorenzi, M., 2000. Response of capillary cell death to aminoguanidine predicts the
development of retinopathy: comparison of diabetes and galactosemia. Invest.
Ophthalmol. Vis. Sci. 41 (12), 3972–3978.
Kern, T.S., Miller, C.M., Du, Y., Zheng, L., Mohr, S., Ball, S.L., Kim, M., Jamison, J.A.,
Bingaman, D.P., 2007. Topical administration of nepafenac inhibits diabetes-induced
retinal microvascular disease and underlying abnormalities of retinal metabolism and
physiology. Diabetes 56 (2), 373–379.
Kim, S.H., Lee, S.M., 2008. Cytoprotective effects of melatonin against necrosis and apo-
ptosis induced by ischemia/reperfusion injury in rat liver. J. Pineal Res. 44 (2), 165–171.
Kim, S.H., Park, S.H., 2003. Effects of Panax ginseng extract on lipid metabolism in humans.
Pharmacol. Res. 48, 511–513.
Kim, Y.H., Kim, Y.S., Noh, H.S., Kang, S.S., Cheon, E.W., Park, S.K., Lee, B.J., Choi,W.-
S., Cho, G.J., 2005. Changes in rhodopsin kinase and transducin in the rat retina in early-
stage diabetes. Exp. Eye Res. 80 (6), 753–760.
Kim, J.H., Kim, J.H., Lee, Y.M., Ahn, E.M., Kim, K.W., Yu, Y.S., 2009a. Decursin inhibits
retinal neovascularization via suppression of VEGFR-2 activation. Mol. Vis.
15, 1868–1875.
Kim, J.H., Kim, J.H., Yu, Y.S., Cho, C.S., Kim, K.W., 2009b. Blockade of angiotensin II
attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.
J. Cereb. Blood Flow Metab. 29 (3), 621–628.
Kim, C., Yu, H.G., Sohn, J., 2010. The anti-angiogenic effect of chlorogenic acid on cho-
roidal neovascularization. Korean J. Ophthalmol. 24 (3), 163–168.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:40 Page Number: 107
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
107Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Kim, Y.H., Kim, Y.S., Roh, G.S., Choi,W.S., Cho, G.J., 2012. Resveratrol blocks diabetes-
induced early vascular lesions and vascular endothelial growth factor induction in mouse
retinas. Acta Ophthalmol. 90 (1), e31–e37.
Kirkegaard, C., Nørgaard, K., Snorgaard, O., Bek, T., Larsen, M., Lund-Andersen, H.,
1990. Effect of one year continuous subcutaneous infusion of a somatostatin analogue,
octreotide, on early retinopathy, metabolic control and thyroid function in Type
I (insulin-dependent) diabetes mellitus. Acta Endocrinol. (Copenh) 122 (6), 766–772.
Kishi, S., Numaga, T., Yamazaki, S., 1982. Structure of the inner retinal surface in simple
diabetic retinopathy. Jpn. J. Ophthalmol. 26 (2), 141–149.
Klepac, N., Rudes, Z., Klepac, R., 2006. Effects of melatonin on plasma oxidative stress in
rats with streptozotocin induced diabetes. Biomed. Pharmacother. 60 (1), 32–35.
Kohzaki, K., Vingrys, A.J., Armitage, J.A., Bui, B.V., 2012. Electroretinography in
streptozotocin diabetic rats following acute intraocular pressure elevation. Graefes Arch.
Clin. Exp. Ophthalmol. 251 (2), 529–535.
Komeda, K., Noda, M., Terao, K., Kuzuya, N., Kanazawa, M., Kanazawa, Y., 1998. Estab-
lishment of two substrains, diabetes-prone and non-diabetic, from Long-Evans
Tokushima Lean (LETL) rats. Endocr. J. 45 (6), 737–744.
Kondo, T., Kahn, C.R., 2004. Altered insulin signaling in retinal tissue in diabetic states.
J. Biol. Chem. 279 (36), 37997–38006.
Kong, L.L., Wu, H., Cui, W.P., Zhou, W.H., Luo, P., Sun, J., Yuan, H., Miao, L.N., 2013.
Advances in murine models of diabetic nephropathy. J. Diabetes Res. 2013, 797548.
Kowluru, R.A., 2013. Mitochondria damage in the pathogenesis of diabetic retinopathy and
in the metabolic memory associated with its continued progression. Curr. Med. Chem.
20 (26), 3226–3233.
Kowluru, R.A., Abbas, S.N., 2003. Diabetes-induced mitochondrial dysfunction in the ret-
ina. Invest. Ophthalmol. Vis. Sci. 44 (12), 5327–5334.
Kowluru, R.A., Engerman, R.L., Case, G.L., Kern, T.S., 2001. Retinal glutamate in diabe-
tes and effect of antioxidants. Neurochem. Int. 38 (5), 385–390.
Kowluru, R.A., Menon, B., Gierhart, D.L., 2008. Beneficial effect of zeaxanthin on retinal
metabolic abnormalities in diabetic rats. Invest. Ophthalmol. Vis. Sci. 49 (4), 1645–1651.
Krady, J.K., Basu,A.,Allen,C.M.,Xu,Y., LaNoue,K.F.,Gardner,T.W.,Levison, S.W., 2005.
Minocycline reduces proinflammatory cytokine expression, microglial activation, and
caspase 3 activation in a rodent model of diabetic retinopathy. Diabetes 54 (5), 1559–1565.
Kumagai, A.K., 1999. Glucose transport in brain and retina: implications in the management
and complications of diabetes. Diabetes Metab. Res. Rev. 15 (4), 261–273.
Kumar, B., Gupta, S.K., Nag, T.C., Srivastava, S., Saxena, R., 2012. Green tea prevents
hyperglycemia-induced retinal oxidative stress and inflammation in streptozotocin-
induced diabetic rats. Ophthalmic Res. 47 (2), 103–108.
Kummer, A., Pulford, B.E., Ishii, D.N., Seigel, G.M., 2003. Des(1-3)IGF-1 treatment nor-
malizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in
predegenerative retina of diabetic rats. Int. J. Exp. Diabesity Res. 4 (1), 45–57.
Kurihara, T., Ozawa, Y., Nagai, N., Shinoda, K., Noda, K., Imamura, Y., Tsubota, K.,
Okano, H., Oike, Y., Ishida, S., 2008. Angiotensin II type 1 receptor signaling contrib-
utes to synaptophysin degradation and neuronal dysfunction in the diabetic retina.
Diabetes 57 (8), 2191–2198.
Kusari, J., Zhou, S., Padillo, E., Clarke, K.G., Gil, D.W., 2007. Effect of memantine on
neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic
rats. Invest. Ophthalmol. Vis. Sci. 48 (11), 5152–5159.
Kusner, L.L., Sarthy, V.P., Mohr, S., 2004. Nuclear translocation of glyceraldehyde-3-
phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Mu¨ller
cells. Invest. Ophthalmol. Vis. Sci. 45 (5), 1553–1561.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:41 Page Number: 108
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
108 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Laabich, A., Cooper, N.G., 2000. Neuroprotective effect of AIP on N-methyl-D-aspartate-
induced cell death in retinal neurons. Brain Res. Mol. Brain Res. 85 (1–2), 32–40.
Lameynardie, S., Chiavaroli, C., Travo, P., Garay, R.P., Pare´s-Herbute´, N., 2005. Inhibi-
tion of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK
rats. Eur. J. Pharmacol. 510 (1–2), 149–156.
Lanfumey, L., Mongeau, R., Hamon, M., 2013. Biological rhythms and melatonin in mood
disorder treatments. Pharmacol. Ther. 138, 176–184.
Lazarovici, P., Cohen, G., Arien-Zakay, H., Chen, J., Zhang, C., Chopp, M., Jiang, H.,
2012. Multimodal neuroprotection induced by PACAP38 in oxygen-glucose
deprivation and middle cerebral artery occlusion stroke models. J. Mol. Neurosci.
48, 526–540.
Lecleire-Collet, A., Tessier, L.H.,Massin, P., Forster, V., Brasseur, G., Sahel, J.A., Picaud, S.,
2005. Advanced glycation end products can induce glial reaction and neuronal degen-
eration in retinal explants. Br. J. Ophthalmol. 89 (12), 1631–1633.
Levi-Montalcini, R., 1987. The nerve growth factor 35 years later. Science 237 (4819),
1154–1162, Review.
Li, Q., Puro, D.G., 2002. Diabetes-induced dysfunction of the glutamate transporter in ret-
inal Mu¨ller cells. Invest. Ophthalmol. Vis. Sci. 43 (9), 3109–3116.
Li, Q., Zemel, E., Miller, B., Perlman, I., 2002. Early retinal damage in experimental dia-
betes: electroretinographical and morphological observations. Exp. Eye Res. 74 (5),
615–625.
Li, M., David, C., Kikuta, T., Somogyvari-Vigh, A., Arimura, A., 2005. Signaling cascades
involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating
polypeptide 38. J. Mol. Neurosci. 27, 91–105.
Li, M., Maderdrut, J.L., Lertora, J.J., Arimura, A., Batuman, V., 2008a. Renoprotection by
pituitary adenylate cyclase-activating polypeptide in multiple myeloma and other kidney
diseases. Regul. Pept. 145, 24–32.
Li, M., Ma, Y.B., Gao, H.Q., Li, B.Y., Cheng, M., Xu, L., Li, X.L., Li, X.H., 2008b.
A novel approach of proteomics to study the mechanism of action of grape seed pro-
anthocyanidin extracts on diabetic retinopathy in rats. Chin. Med. J. (Engl.) 121 (24),
2544–2552.
Li, J., Wang, J.J., Chen, D., Mott, R., Yu, Q., Ma, J.X., Zhang, S.X., 2009. Systemic admin-
istration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ame-
liorates retinal inflammation in type 2 diabetes. Exp. Eye Res. 89 (1), 71–78.
Li, J., Wang, J.J., Yu, Q., Chen, K., Mahadev, K., Zhang, S.X., 2010. Inhibition of reactive
oxygen species by Lovastatin downregulates vascular endothelial growth factor expres-
sion and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH
oxidase 4. Diabetes 59 (6), 1528–1538.
Li, P., Xu, X., Zheng, Z., Zhu, B., Shi, Y., Liu, K., 2011. Protective effects of rosiglitazone
on retinal neuronal damage in diabetic rats. Curr. Eye Res. 36 (7), 673–679.
Li, X., Zhang, M., Tang, W., 2013a. Effects of melatonin on streptozotocin-induced retina
neuronal apoptosis in high blood glucose rat. Neurochem. Res. 38 (3), 669–676.
Li, D., Yang, F., Cheng, H., Liu, C., Sun, M., Wu, K., Ai, M., 2013b. Protective effects of
total flavonoids from Flos Puerariae on retinal neuronal damage in diabetic mice. Mol.
Vis. 19, 1999–2010.
Lieth, E., Barber, A.J., Xu, B., Dice, C., Ratz, M.J., Tanase, D., Strother, J.M., 1998. Glial
reactivity and impaired glutamate metabolism in short-term experimental diabetic reti-
nopathy. Diabetes 47 (5), 815–820.
Lieth, E., LaNoue, K.F., Antonetti, D.A., Ratz, M., 2000. Diabetes reduces glutamate oxi-
dation and glutamine synthesis in the retina. The Penn State Retina Research Group.
Exp. Eye Res. 70 (6), 723–730.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:41 Page Number: 109
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
109Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Like, A.A., Butler, L., Williams, R.M., Appel, M.C., Weringer, E.J., Rossini, A.A., 1982.
Spontaneous autoimmune diabetes mellitus in the BB rat. Diabetes 31 (Suppl. 1 Pt. 2),
7–13.
Lindstrom, P., 2007. The physiology of obese-hyperglycemic mice [ob/obmice]. Sci.World
J. 7, 666–685.
Liu, H., Ren, J.G., Cooper, W.L., Hawkins, C.E., Cowan, M.R., Tong, P.Y., 2004. Iden-
tification of the antivasopermeability effect of pigment epithelium-derived factor and its
active site. Proc. Natl. Acad. Sci. U.S.A. 101 (17), 6605–6610.
Liu, X., Mameza, M.G., Lee, Y.S., Eseonu, C.I., Yu, C.R., Kang Derwent, J.J.,
Egwuagu, C.E., 2008. Suppressors of cytokine-signaling proteins induce insulin resis-
tance in the retina and promote survival of retinal cells. Diabetes 57, 1651–1658.
Logvinov, S.V., Plotnikov, M.B., Zhdankina, A.A., Smolyakova, V.I., Ivanov, I.S.,
Kuchin, A.V., Chukicheva, I.V., Varakuta, E.Y., 2010.Morphological changes in retinal
neurons in streptozotocin-induced diabetes mellitus and their correction with an
isobornylphenol derivative. Neurosci. Behav. Physiol. 40 (7), 779–782.
Lorenzi, M., Gerhardinger, C., 2001. Early cellular and molecular changes induced by dia-
betes in the retina. Diabetologia 44 (7), 791–804, Review.
Losiewicz, M.K., Fort, P.E., 2011. Diabetes impairs the neuroprotective properties of retinal
alpha-crystallins. Invest. Ophthalmol. Vis. Sci. 52 (9), 5034–5042.
Lu, Z.Y., Bhutto, I.A., Amemiya, T., 2003. Retinal changes in Otsuka long-evans
Tokushima Fatty rats (spontaneously diabetic rat)—possibility of a new experimental
model for diabetic retinopathy. Jpn. J. Ophthalmol. 47 (1), 28–35.
Lu, L.C., Zhou, W., Li, Z.H., Yu, C.P., Li, C.W., Luo, M.H., Xie, H., 2012. Effects of
arctiin on streptozotocin-induced diabetic retinopathy in Sprague-Dawley rats. Planta
Med. 78 (12), 1317–1323.
Lu, L., Seidel, C.P., Iwase, T., Stevens, R.K., Gong, Y.Y., Wang, X., Hackett, S.F.,
Campochiaro, P.A., 2013. Suppression of GLUT1; a new strategy to prevent diabetic
complications. J. Cell. Physiol. 228 (2), 251–257.
Lundkvist, A., Reichenbach, A., Betsholtz, C., Carmeliet, P., Wolburg, H., Pekny, M.,
2004. Under stress, the absence of intermediate filaments from Mu¨ller cells in the retina
has structural and functional consequences. J. Cell Sci. 117, 3481–3488.
Luo, D., Fan, Y., Xu, X., 2012. The effects of aminoguanidine on retinopathy in STZ-
induced diabetic rats. Bioorg. Med. Chem. Lett. 22 (13), 4386–4390.
Lupi, R., Mancarella, R., Del Guerra, S., Bugliani, M., Del Prato, S., Boggi, U., Mosca, F.,
Filipponi, F., Marchetti, P., 2008. Effects of exendin-4 on islets from type 2 diabetes
patients. Diabetes Obes. Metab. 10, 515–519.
Ly, A., Yee, P., Vessey, K.A., Phipps, J.A., Jobling, A.I., Fletcher, E.L., 2011. Early inner
retinal astrocyte dysfunction during diabetes and development of hypoxia, retinal stress,
and neuronal functional loss. Invest. Ophthalmol. Vis. Sci. 52 (13), 9316–9326.
Ma, J., Zhu, T., Tang, X., Ye, P., Zhang, Z., 2010. Effect of an intravitreal injection of
bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats. Clin.
Exp. Ophthalmol. 38 (9), 875–884.
Maahs, D.M.,West, N.A., Lawrence, J.M., Mayer-Davis, E.J., 2010. Epidemiology of type 1
diabetes. Endocrinol. Metab. Clin. North Am. 39 (3), 481–497.
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., 2004. The che-
mokine system in diverse forms of macrophage activation and polarization. Trends
Immunol. 25, 677–686.
Marsicano, G., Moosmann, B., Hermann, H., Lutz, B., Behl, C., 2002. Neuroprotective
properties of cannabinoids against oxidative stress: role of the cannabinoid receptor
CB1. J. Neurochem. 80 (3), 448–456.
Marti, H.H., Bernaudin, M., Petit, E., Bauer, C., 2000. Neuroprotection and angiogenesis:
dual role of erythropoietin in brain ischemia. News Physiol. Sci. 15, 225–229.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:41 Page Number: 110
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
110 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Martin, P.M., Roon, P., Van Ells, T.K., Ganapathy, V., Smith, S.B., 2004. Death of retinal
neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci. 45 (9),
3330–3336.
Masuyama, T., Fuse, M., Yokoi, N., Shinohara, M., Tsujii, H., Kanazawa, M.,
Kanazawa, Y., Komeda, K., Taniguchi, K., 2003. Genetic analysis for diabetes in a
new rat model of nonobese type 2 diabetes. Spontaneously Diabetic Torii rat. Biochem.
Biophys. Res. Commun. 304 (1), 196–206.
Masuyama, T., Komeda, K., Hara, A., Noda, M., Shinohara, M., Oikawa, T., Kanazawa, Y.,
Taniguchi, K., 2004. Chronological characterization of diabetes development in male
Spontaneously Diabetic Torii rats. Biochem. Biophys. Res. Commun. 314 (3), 870–877.
Mathews, C.E., Langley, S.H., Leiter, E.H., 2002. New mouse model to study islet
transplantation in insulin-dependent diabetes mellitus. Transplantation 73 (8),
1333–1336.
Matsubara, H., Kuze, M., Sasoh, M., Ma, N., Furuta, M., Uji, Y., 2006. Time-dependent
course of electroretinograms in the spontaneous diabetic Goto-Kakizaki rat. Jpn. J.
Ophthalmol. 50 (3), 211–216.
Matsuura, T., Yamagishi, S., Kodama, Y., Shibata, R., Ueda, S., Narama, I., 2005. Otsuka
Long-Evans Tokushima fatty (OLETF) rat is not a suitable animal model for the study of
angiopathic diabetic retinopathy. Int. J. Tissue React. 27 (2), 59–62.
McLenachan, S., Chen, X., McMenamin, P.G., Rakoczy, E.P., 2013. Absence of clinical
correlates of diabetic retinopathy in the Ins2Akita retina. Clin. Experiment. Ophthalmol.
41 (6), 582–592.
McVicar, C.M., Hamilton, R., Colhoun, L.M., Gardiner, T.A., Brines, M., Cerami, A.,
Stitt, A.W., 2011. Intervention with an erythropoietin-derived peptide protects against
neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 60 (11),
2995–3005.
Meyer-Rusenberg, B., Pavlidis, M., Stupp, T., Thanos, S., 2007. Pathological changes in
human retinal ganglion cells associated with diabetic and hypertensive retinopathy.
Graefes Arch. Clin. Exp. Ophthalmol. 245 (7), 1009–1018.
Midena, E., Segato, T., Radin, S., di Giorgio, G., Meneghini, F., Piermarocchi, S.,
Belloni, A.S., 1989. Studies on the retina of the diabetic db/db mouse. I. Endothelial
cell-pericyte ratio. Ophthalmic Res. 21 (2), 106–111.
Mima, A., Qi, W., Hiraoka-Yamomoto, J., Park, K., Matsumoto, M., Kitada, M., Li, Q.,
Mizutani, K., Yu, E., Shimada, T., Lee, J., Shoelson, S.E., Jobin, C., Rask-Madsen,
C., King, G.L., 2012. Retinal not systemic oxidative and inflammatory stress correlated
with VEGF expression in rodent models of insulin resistance and diabetes. Invest.
Ophthalmol. Vis. Sci. 53 (13), 8424–8432.
Mitsuhashi, J., Morikawa, S., Shimizu, K., Ezaki, T., Yasuda, Y., Hori, S., 2013. Intravitreal
injection of erythropoietin protects against retinal vascular regression at the early stage of
diabetic retinopathy in streptozotocin-induced diabetic rats. Exp. Eye Res. 106, 64–73.
Miyajima, H., Osanai, M., Chiba, H., Nishikiori, N., Kojima, T., Ohtsuka, K., Sawada, N.,
2005. Glyceraldehyde-derived advanced glycation end-products preferentially induce
VEGF expression and reduce GDNF expression in human astrocytes. Biochem.
Biophys. Res. Commun. 330 (2), 361–366.
Miyamoto, K., Ogura, Y., Nishiwaki, H., Matsuda, N., Honda, Y., Kato, S., Ishida, H.,
Seino, Y., 1996. Evaluation of retinal microcirculatory alterations in the Goto-Kakizaki
rat. A spontaneous model of non-insulin-dependent diabetes. Invest. Ophthalmol. Vis.
Sci. 37 (5), 898–905.
Mizuno, A., Noma, Y., Kuwajima, M., Murakami, T., Zhu, M., Shima, K., 1999. Changes
in islet capillary angioarchitecture coincide with impaired B-cell function but not with
insulin resistance in male Otsuka-Long-Evans-Tokushima fatty rats: dimorphism of the
diabetic phenotype at an advanced age. Metabolism 48 (4), 477–483.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:42 Page Number: 111
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
111Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Mizutani, M., Kern, T.S., Lorenzi, M., 1996. Accelerated death of retinal microvascular cells
in human and experimental diabetic retinopathy. J. Clin. Invest. 97 (12), 2883–2890.
Moreo, G., Mariani, E., Pizzamiglio, G., Colucci, G.B., 1995. Visual evoked potentials in
NIDDM: a longitudinal study. Diabetologia 38 (5), 573–576.
Muir, E.R., Renterı´a, R.C., Duong, T.Q., 2012. Reduced ocular blood flow as an early
indicator of diabetic retinopathy in a mouse model of diabetes. Invest. Ophthalmol.
Vis. Sci. 53 (10), 6488–6494.
Mysona, B., Dun, Y., Duplantier, J., Ganapathy, V., Smith, S.B., 2009. Effects of hypergly-
cemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse
retinal Mu¨ller glial cells. Cell Tissue Res. 335 (3), 477–488.
Nagai, N., Izumi-Nagai, K., Oike, Y., Koto, T., Satofuka, S., Ozawa, Y., Yamashiro, K.,
Inoue, M., Tsubota, K., Umezawa, K., Ishida, S., 2007. Suppression of diabetes-induced
retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream
nuclear factor-kappaB pathway. Invest. Ophthalmol. Vis. Sci. 48 (9), 4342–4350.
Nakamachi, T., Matkovits, A., Seki, T., Shioda, S., 2012. Distribution and protective func-
tion of pituitary adenylate cyclase-activating polypeptide in the retina. Front.
Endocrinol. (Lausanne) 3, 145.
Nakamura, M., Barber, A.J., Antonetti, D.A., LaNoue, K.F., Robinson, K.A., Buse, M.G.,
Gardner, T.W., 2001. Excessive hexosamines block the neuroprotective effect of insulin
and induce apoptosis in retinal neurons. J. Biol. Chem. 276 (47), 43748–43755.
Nishikiori, N., Osanai, M., Chiba, H., Kojima, T., Mitamura, Y., Ohguro, H., Sawada, N.,
2007a. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in dia-
betic retinopathy. Diabetes 56 (5), 1333–1340.
Nishikiori, N., Osanai, M., Chiba, H., Kojima, T., Ohguro, H., Sawada, N., 2007b. Inhib-
itory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through
suppression of deregulated calpains. Invest. Ophthalmol. Vis. Sci. 48 (5), 2224–2229.
Nishikiori, N., Osanai, M., Chiba, H., Kojima, T., Inatomi, S., Ohguro, H., Sawada, N.,
2008. Experimental effect of retinoic acids on apoptosis during the development of dia-
betic retinopathy. Clin. Ophthalmol. 2 (1), 233–235.
Obrosova, I.G., Kador, P.F., 2011. Aldose reductase/polyol inhibitors for diabetic retinop-
athy. Curr. Pharm. Biotechnol. 12 (3), 373–385, Review.
Okada, M., Ayabe, Y., 1995. Effects of aminoguanidine and pyridoxal phosphate on
glycation reaction of aspartate aminotransferase and serum albumin. J. Nutr. Sci.
Vitaminol. (Tokyo) 41 (1), 43–50.
Okuno, T., Oku, H., Sugiyama, T., Ikeda, T., 2008. Electroretinographic study of sponta-
neously diabetic Torii rats. Doc. Ophthalmol. 117 (3), 191–196.
Ola, M.S., Moore, P., Maddox, D., El-Sherbeny, A., Huang, W., Roon, P., Agarwal, N.,
Ganapathy, V., Smith, S.B., 2002. Analysis of sigma receptor (sigmaR1) expression in
retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice.
Brain Res. Mol. Brain Res. 107 (2), 97–107.
Ola, M.S., Nawaz, M.I., Siddiquei, M.M., Al-Amro, S., Abu El-Asrar, A.M., 2012. Recent
advances in understanding the biochemical and molecular mechanism of diabetic reti-
nopathy. J. Diabetes Complications 26 (1), 56–64, Review.
Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., Meyerhof, W., 2004. Regulation and
function of somatostatin receptors. J. Neurochem. 89 (5), 1057–1091.
Omri, S., Omri, B., Savoldelli, M., Jonet, L., Thillaye-Goldenberg, B., Thuret, G., Gain, P.,
Jeanny, J.C., Crisanti, P., Behar-Cohen, F., 2010. The outer limiting membrane (OLM)
revisited: clinical implications. Clin. Ophthalmol. 4, 183–195.
Omri, S., Behar-Cohen, F., de Kozak, Y., Sennlaub, F., Verissimo, L.M., Jonet, L.,
Savoldelli, M., Omri, B., Crisanti, P., 2011. Microglia/macrophages migrate through
retinal epithelium barrier by a transcellular route in diabetic retinopathy: role of PKCz
in the Goto Kakizaki rat model. Am. J. Pathol. 179 (2), 942–953.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:49 Page Number: 112
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
112 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Osborne, N.N., Casson, R.J.,Wood, J.P., Chidlow, G., Graham,M.,Melena, J., 2004. Ret-
inal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin.
Eye Res. 23, 91–147.
Oshitari, T., Roy, S., 2005. Diabetes: a potential enhancer of retinal injury in rat retinas.
Neurosci. Lett. 390 (1), 25–30.
Pannicke, T., Iandiev, I., Wurm, A., Uckermann, O., vom Hagen, F., Reichenbach, A.,
Wiedemann, P., Hammes, H.P., Bringmann, A., 2006. Diabetes alters osmotic swelling
characteristics and membrane conductance of glial cells in rat retina. Diabetes 55 (3),
633–639.
Park, B.H., Rho, H.W., Park, J.W., Cho, C.G., Kim, J.S., Chung, H.T., Kim, H.R., 1995.
Protective mechanism of glucose against alloxan-induced pancreatic beta-cell damage.
Biochem. Biophys. Res. Commun. 210 (1), 1–6.
Patel, J.I., Tombran-Tink, J., Hykin, P.G., Gregor, Z.J., Cree, I.A., 2006. Vitreous and
aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines
in diabetic retinopathy patients with macular edema: implications for structural differ-
ences in macular profiles. Exp. Eye Res. 82 (5), 798–806.
Pfister, F., Riedl, E., Wang, Q., vom Hagen, F., Deinzer, M., Harmsen, M.C., Molema, G.,
Yard, B., Feng, Y., Hammes, H.P., 2011. Oral carnosine supplementation prevents vas-
cular damage in experimental diabetic retinopathy. Cell. Physiol. Biochem. 28 (1),
125–136.
Phipps, J.A., Wilkinson-Berka, J.L., Fletcher, E.L., 2007. Retinal dysfunction in diabetic
ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest.
Ophthalmol. Vis. Sci. 48 (2), 927–934.
Phipps, J.A., Clermont, A.C., Sinha, S., Chilcote, T.J., Bursell, S.E., Feener, E.P., 2009.
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular per-
meability. Hypertension 53 (2), 175–181.
Pinter, E., Helyes, Z., Szolcsanyi, J., 2006. Inhibitory effect of somatostatin on inflammation
and nociception. Pharmacol. Ther. 112, 440–456.
Portha, B., 2005. Programmed disorders of beta-cell development and function as one
cause for type 2 diabetes? The GK rat paradigm. Diabetes Metab. Res. Rev. 21 (6),
495–504.
Portha, B., Giroix, M.H., Tourrel-Cuzin, C., Le-Stunff, H., Movassat, J., 2012. The GK rat:
a prototype for the study of non-overweight type 2 diabetes. Methods Mol. Biol.
933, 125–159.
Puro, D.G., 2002. Diabetes-induced dysfunction of retinal Mu¨ller cells. Trans. Am.
Ophthalmol. Soc. 100, 339–352.
Qazi, Y., Maddula, S., Ambati, B.K., 2009. Mediators of ocular angiogenesis. J. Genet.
88, 495–515, Review.
Qin, Y., Ren, H., Hoffman, M.R., Fan, J., Zhang, M., Xu, G., 2012. Aquaporin changes
during diabetic retinopathy in rats are accelerated by systemic hypertension and are
linked to the renin-angiotensin system. Invest. Ophthalmol. Vis. Sci. 53, 3047–3053.
Racz, B., Gallyas Jr., F., Kiss, P., Toth, G., Hegyi, O., Gasz, B., Borsiczky, B., Ferencz, A.,
Roth, E., Tamas, A., Lengvari, I., Lubics, A., Reglodi, D., 2006. The neuroprotective
effects of PACAP in monosodium glutamate-induced retinal lesion involve inhibition of
proapoptotic signaling pathways. Regul. Pept. 137, 20–26.
Rathi, S.S., Grover, J.K., Vikrant, V., Biswas, N.R., 2002. Prevention of experimental dia-
betic cataract by Indian Ayurvedic plant extracts. Phytother. Res. 16, 774–777.
Reglodi, D., Kiss, P., Szabadfi, K., Atlasz, T., Gabriel, R., Horvath, G., Szakaly, P.,
Sandor, B., Lubics, A., Laszlo, E., Farkas, J., Matkovits, A., Brubel, R.,
Hashimoto, H., Ferencz, A., Vincze, A., Helyes, Z., Welke, L., Lakatos, A.,
Tamas, A., 2012. PACAP is an endogenous neuroprotective factor—insights from
PACAP deficient mice. J. Mol. Neurosci. 48, 482–492.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:49 Page Number: 113
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
113Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Reiter, R.J., Tan, D.X., Burkhardt, S., 2002. Reactive oxygen and nitrogen species and cel-
lular and organismal decline: amelioration with melatonin. Mech. Ageing Dev. 123 (8),
1007–1019.
Reiter, C.E., Sandirasegarane, L., Wolpert, E.B., Klinger, M., Simpson, I.A., Barber, A.J.,
Antonetti, D.A., Kester, M., Gardner, T.W., 2003. Characterization of insulin signaling
in rat retina in vivo and ex vivo. Am. J. Physiol. Endocrinol. Metab. 285, E763–E774.
Reiter, C.E., Wu, X., Sandirasegarane, L., Nakamura, M., Gilbert, K.A., Singh, R.S.,
Fort, P.E., Antonetti, D.A., Gardner, T.W., 2006. Diabetes reduces basal retinal insulin
receptor signaling: reversal with systemic and local insulin. Diabetes 55 (4), 1148–1156.
Ren, Z., Li, W., Zhao, Q., Ma, L., Zhu, J., 2012. The impact of 1,25-dihydroxy vitamin D3
on the expressions of vascular endothelial growth factor and transforming growth factor-
b(1) in the retinas of rats with diabetes. Diabetes Res. Clin. Pract. 98 (3), 474–480.
Robinson, R., Barathi, V.A., Chaurasia, S.S., Wong, T.Y., Kern, T.S., 2012. Update on
animal models of diabetic retinopathy: from molecular approaches to mice and higher
mammals. Dis. Model Mech. 5 (4), 444–456.
Rossini, A.A., Appel, M.C., Williams, R.M., Like, A.A., 1977. Genetic influence of the
streptozotocin-induced insulitis and hyperglycemia. Diabetes 26, 916–920.
Sakata, N., Imanaga, Y., Meng, J., Tachikawa, Y., Takebayashi, S., Nagai, R., Horiuchi, S.,
1999. Increased advanced glycation end products in atherosclerotic lesions of patients
with end-stage renal disease. Atherosclerosis 142 (1), 67–77.
Sakurai, K., Ogiso, T., 1995. Effect of ferritin on lambda DNA strand breaks in the reaction
system of alloxan plus NADPH-cytochrome P450 reductase: ferritin’s role in diabeto-
genic action of alloxan. Biol. Pharm. Bull. 18 (2), 262–266.
Salido, E.M., Bordone, M., De Laurentiis, A., Chianelli, M., Keller Sarmiento, M.I.,
Dorfman, D., Rosenstein, R.E., 2013. Therapeutic efficacy of melatonin in reducing
retinal damage in an experimental model of early type 2 diabetes in rats. J. Pineal
Res. 54 (2), 179–189.
Samuels, I.S., Lee, C.A., Petrash, J.M., Peachey, N.S., Kern, T.S., 2012. Exclusion of aldose
reductase as a mediator of ERG deficits in a mouse model of diabetic eye disease. Vis.
Neurosci. 29 (6), 267–274.
Sandbach, J.M., Coscun, P.E., Grossniklaus, H.E., Kokoszka, J.E., Newman, N.J.,
Wallace, D.C., 2001. Ocular pathology in mitochondrial superoxide dismutase
(Sod2)-deficient mice. Invest. Ophthalmol. Vis. Sci. 42 (10), 2173–2178.
Sandler, S., Swenne, I., 1983. Streptozotocin, but not alloxan, induces DNA repair synthesis
in mouse pancreatic islets in vitro. Diabetologia 25 (5), 444–447.
Sarthy, V.P., Harris, R., 2001. The Retinal Mu¨ller Cell: Structure and Function
(Perspectives in Vision Research). Kluwer Academic/Plenum Publishers, New York.
Sasaki, M., Ozawa, Y., Kurihara, T., Kubota, S., Yuki, K., Noda, K., Kobayashi, S.,
Ishida, S., Tsubota, K., 2010. Neurodegenerative influence of oxidative stress in the ret-
ina of a murine model of diabetes. Diabetologia 53 (5), 971–979.
Sasase, T., Morinaga, H., Abe, T., Miyajima, K., Ohta, T., Shinohara, M., Matsushita, M.,
Kakehashi, A., 2009. Protein kinase C beta inhibitor prevents diabetic peripheral neu-
ropathy, but not histopathological abnormalities of retina in Spontaneously Diabetic
Torii rat. Diabetes Obes. Metab. 11 (11), 1084–1087.
Satofuka, S., Ichihara, A., Nagai, N., Noda, K., Ozawa, Y., Fukamizu, A., Tsubota, K.,
Itoh, H., Oike, Y., Ishida, S., 2009. (Pro)renin receptor-mediated signal transduction
and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation.
Diabetes 58 (7), 1625–1633.
Scuderi, S., D’Amico, A.G., Castorina, A., Imbesi, R., Carnazza, M.L., D’Agata, V., 2013.
Ameliorative effect of PACAP andVIP against increased permeability in a model of outer
blood retinal barrier dysfunction. Peptides 39, 119–124.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:50 Page Number: 114
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
114 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Seaborn, T., Masmoudi-Kouli, O., Fournier, A., Vaudry, H., Vaudry, D., 2011. Protective
effects of pituitary adenylate cyclase-activating polypeptide (PACAP) against apoptosis.
Curr. Pharm. Des. 17, 204–214.
Segawa, Y., Shirao, Y., Yamagishi, S., Higashide, T., Kobayashi, M., Katsuno, K., Iyobe, A.,
Harada, H., Sato, F., Miyata, H., Asai, H., Nishimura, A., Takahira, M., Souno, T.,
Segawa, Y., Maeda, K., Shima, K., Mizuno, A., Yamamoto, H., Kawasaki, K., 1998.
Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously dia-
betic rats without ophthalmoscopic retinopathy. A possible participation of advanced
glycation end products in the development of the early phase of diabetic retinopathy.
Ophthalmic Res. 30 (6), 333–339.
Seigel, G.M., Lupien, S.B., Campbell, L.M., Ishii, D.N., 2006. Systemic IGF-1 treatment
inhibits cell death in diabetic rat retina. J. Diabetes Complications 20 (3), 196–204.
Seki, T., Izumi, S., Shioda, S., Zhou, C.J., Arimura, A., Koide, R., 2000. Gene expression
for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ
RT-PCR. Ann. N.Y. Acad. Sci. 921, 366–369.
Seki, M., Nawa, H., Fukuchi, T., Abe, H., Takei, N., 2003. BDNF is upregulated by post-
natal development and visual experience: quantitative and immunohistochemical ana-
lyses of BDNF in the rat retina. Invest. Ophthalmol. Vis. Sci. 44 (7), 3211–3218.
Seki, M., Tanaka, T., Nawa, H., Usui, T., Fukuchi, T., Ikeda, K., Abe, H., Takei, N., 2004.
Involvement of brain-derived neurotrophic factor in early retinal neuropathy of
streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neuro-
trophic factor for dopaminergic amacrine cells. Diabetes 53 (9), 2412–2419.
Semkova, I., Krieglstein, J., 1999. Neuroprotection mediated via neurotrophic factors and
induction of neurotrophic factors. Brain Res. Rev. 30, 176–188.
Sen, S., Chen, S., Wu, Y., Feng, B., Lui, E.K., Chakrabarti, S., 2013. Preventive effects of
North American ginseng (Panax quinquefolius) on diabetic retinopathy and cardiomyop-
athy. Phytother. Res. 27 (2), 290–298.
Shanab, A.Y., Nakazawa, T., Ryu, M., Tanaka, Y., Himori, N., Taguchi, K., Yasuda, M.,
Watanabe, R., Takano, J., Saido, T., Minegishi, N., Miyata, T., Abe, T.,
Yamamoto, M., 2012. Metabolic stress response implicated in diabetic retinopathy:
the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiol. Dis.
48 (3), 556–567.
Shanmugam, N., Figarola, J.L., Li, Y., Swiderski, P.M., Rahbar, S., Natarajan, R., 2008.
Proinflammatory effects of advanced lipoxidation end products in monocytes.
Diabetes 57 (4), 879–888.
Shao, Z.H., Becker, L.B., Vanden Hoek, T.L., Schumacker, P.T., Li, C.Q., Zhao, D.,
Wojcik, K., Anderson, T., Qin, Y., Dey, L., Yuan, C.S., 2003. Grape seed pro-
anthocyanidin extract attenuates oxidant injury in cardiomyocytes. Pharmacol. Res.
47 (6), 463–469.
Shelton, M.D., Kern, T.S., Mieyal, J.J., 2007. Glutaredoxin regulates nuclear factor kappa-B
and intercellular adhesionmolecule inMu¨ller cells: model of diabetic retinopathy. J. Biol.
Chem. 282 (17), 12467–12474.
Shelton, M.D., Distler, A.M., Kern, T.S., Mieyal, J.J., 2009. Glutaredoxin regulates auto-
crine and paracrine proinflammatory responses in retinal glial (Mu¨ller) cells. J. Biol.
Chem. 284 (8), 4760–4766.
Shen, X., Xie, B., Cheng, Y., Jiao, Q., Zhong, Y., 2011. Effect of pigment epithelium
derived factor on the expression of glutamine synthetase in early phase of experimental
diabetic retinopathy. Ocul. Immunol. Inflamm. 19 (4), 246–254.
Shi, X., Liao, S., Mi, H., Guo, C., Qi, D., Li, F., Zhang, C., Yang, Z., 2012. Hesperidin
prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
Molecules 17 (11), 12868–12881.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:50 Page Number: 115
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
115Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Shin, J.Y., Sohn, J., Park, K.H., 2013. Chlorogenic acid decreases retinal vascular hyper-
permeability in diabetic rat model. J. Korean Med. Sci. 28 (4), 608–613.
Shinohara, M., Masuyama, T., Shoda, T., Takahashi, T., Katsuda, Y., Komeda, K.,
Kuroki, M., Kakehashi, A., Kanazawa, Y., 2000. A new spontaneously diabetic
non-obese Torii rat strain with severe ocular complications. Int. J. Exp. Diabetes Res.
1 (2), 89–100.
Shirao, Y., Kawasaki, K., 1998. Electrical responses from diabetic retina. Prog. Retin. Eye
Res. 17 (1), 59–76, Review.
Shirasaki, Y., Miyashita, H., Yamaguchi, M., Inoue, J., Nakamura, M., 2005. Exploration of
orally available calpain inhibitors: peptidyl alpha-ketoamides containing an amphiphile at
P3 site. Bioorg. Med. Chem. 13 (14), 4473–4484.
Si, Y.F., Wang, J., Guan, J., Zhou, L., Sheng, Y., Zhao, J., 2013. Treatment with hydrogen
sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. Br. J. Pharmacol.
169 (3), 619–631.
Silva, K.C., Rosales, M.A., Hamassaki, D.E., Saito, K.C., Faria, A.M., Ribeiro, P.A.,
Faria, J.B., Faria, J.M., 2013. Green tea is neuroprotective in diabetic retinopathy. Invest.
Ophthalmol. Vis. Sci. 54 (2), 1325–1336.
Sima, J., Zhang, S.X., Shao, C., Fant, J., Ma, J.X., 2004. The effect of angiostatin on vascular
leakage and VEGF expression in rat retina. FEBS Lett. 564 (1–2), 19–23.
Sima, J., Ma, J., Zhang, S.X., Guo, J., 2006. Study of the influence of angiostatin intravitreal
injection on vascular leakage in retina and iris of the experimental diabetic rats. Yan Ke
Xue Bao 22 (4), 252–258.
Simo, R., Villarroel, M., Corraliza, L., Hernandez, C., Garcia-Ramirez, M., 2010. The ret-
inal pigment epithelium: something more than a constituent of the blood-retinal barrier-
implications for the pathogenesis of diabetic retinopathy. J. Biomed. Biotechnol.
2010, 190724.
Smith, S.B., 2002. Diabetic retinopathy and the NMDA receptor. Drug News Perspect.
15 (4), 226–232.
Sone, H., Kawakami, Y., Okuda, Y., Sekine, Y., Honmura, S., Matsuo, K., Segawa, T.,
Suzuki, H., Yamashita, K., 1997. Ocular vascular endothelial growth factor levels in dia-
betic rats are elevated before observable retinal proliferative changes. Diabetologia 40 (6),
726–730.
Stanely, P., Prince, M., Menon, V.P., 2000. Hypoglycaemic and other related actions of
Tinospora cordifolia roots in alloxan-induced diabetic rats. J. Ethnopharmacol. 70 (1),
9–15.
Stehle, J.H., Saade, A., Rawashdeh, O., Ackermann, K., Jilg, A., Sebesteny, T., Maronde, E.,
2011. A survey of molecular details in the human pineal gland in the light of phylogeny,
structure, function and chronobiological diseases. J. Pineal Res. 51 (1), 17–43.
Stitt, A.W., Bhaduri, T., McMullen, C.B., Gardiner, T.A., Archer, D.B., 2000. Advanced
glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats.
Mol. Cell Biol. Res. Commun. 3 (6), 380–388.
Stitt, A.W., Frizzell, N., Thorpe, S.R., 2004. Advanced glycation and advanced lipoxidation:
possible role in initiation and progression of diabetic retinopathy. Curr. Pharm. Des.
10 (27), 3349–3360, Review.
Su, W., Dai, D.Z., Liu, H.R., Na, T., Dai, Y., 2007. Upregulated endothelin system in dia-
betic vascular dysfunction and early retinopathy is reversed by CPU0213 and total
triterpene acids from Fructus Corni. Clin. Exp. Pharmacol. Physiol. 34 (12), 1228–1233.
Sudnikovich, E.J., Maksimchik, Y.Z., Zabrodskaya, S.V., Kubyshin, V.L., Lapshina, E.A.,
Bryszewska, M., Reiter, R.J., Zavodnik, I.B., 2007. Melatonin attenuates metabolic dis-
orders due to streptozotocin-induced diabetes in rats. Eur. J. Pharmacol. 569 (3),
180–187.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:50 Page Number: 116
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
116 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Sugiyama, T., Okuno, T., Fukuhara, M., Oku, H., Ikeda, T., Obayashi, H., Ohta, M.,
Fukui, M., Hasegawa, G., Nakamura, N., 2007. Angiotensin II receptor blocker inhibits
abnormal accumulation of advanced glycation end products and retinal damage in a rat
model of type 2 diabetes. Exp. Eye Res. 85 (3), 406–412.
Sun, Q., Cai, J., Zhou, J., Tao, H., Zhang, J.H., Zhang,W., Sun, X.J., 2011. Hydrogen-rich
saline reduces delayed neurologic sequelae in experimental carbon monoxide toxicity.
Crit. Care Med. 39 (4), 765–769.
Szabadfi, K., Atlasz, T., Kiss, P., Reglodi, D., Szabo, A., Kovacs, K., Szalontai, B.,
Setalo Jr., G., Banki, E., Csanaky, K., Tamas, A., Gabriel, R., 2012. Protective effects
of the neuropeptide PACAP in diabetic retinopathy. Cell Tissue Res. 348 (1), 37–46.
Au27Szabadfi, K., Szabo, A., Kiss, P., Reglodi, D., Setalo Jr., G., Kovacs, K., Tamas, A., Toth, G.,
Gabriel, R., 2014. PACAP promotes neuron survival in early experimental diabetic ret-
inopathy. Neurochem. Int. 64, 84–91.
Szabo, A., Danyadi, B., Bognar, E., Szabadfi, K., Fabian, E., Kiss, P., Mester, L.,
Sridharan, M., Atlasz, T., Gabriel, R., Toth, G., Tamas, A., Reglodi, D., Kovacs, K.,
2012. Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal
hypoperfusion. Neurosci. Lett. 523, 93–98.
Szkudelski, T., 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat
pancreas. Physiol. Res. 50 (6), 537–546.
Takeo-Goto, S., Doi, M., Ma, N., Goto, R., Semba, R., Uji, Y., 2002. Immunohistochem-
ical localization of amino acids in the diabetic retina of Goto-Kakizaki rats. Ophthalmic
Res. 34 (3), 139–145.
Takiishi, T., Gysemans, C., Bouillon, R., Mathieu, C., 2010. Vitamin D and diabetes.
Endocrinol. Metab. Clin. North Am. 39 (2), 419–446.
Tang, J., Kern, T.S., 2011. Inflammation in diabetic neuropathy. Prog. Retinal Eye Res.
30, 343–358.
Tang, L., Zhang, Y., Jiang, Y., Willard, L., Ortiz, E., Wark, L., Medeiros, D., Lin, D., 2011.
Dietary wolfberry ameliorates retinal structure abnormalities in db/db mice at the early
stage of diabetes. Exp. Biol. Med. (Maywood) 236 (9), 1051–1063.
Tang, J., Du, Y., Lee, C.A., Talahalli, R., Eells, J.T., Kern, T.S., 2013. Low-intensity far-red
light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro.
Invest. Ophthalmol. Vis. Sci. 54 (5), 3681–3690.
Taylor, S.L., 1986. Histamine food poisoning: toxicology and clinical aspects. Crit. Rev.
Toxicol. 17 (2), 91–128.
Thang, S.H., Kobayashi, M., Matsuoka, I., 2000. Regulation of glial cell line-derived neu-
rotrophic factor responsiveness in developing rat sympathetic neurons by retinoic acid
and bone morphogenetic protein-2. J. Neurosci. 20 (8), 2917–2925.
Thermos, K., 2003. Functional mapping of somatostatin receptors in the retina: a review.
Vision Res. 43 (17), 1805–1815, Review.
Thoreson, W.B., Witkovsky, P., 1999. Glutamate receptors and circuits in the vertebrate
retina. Prog. Retin. Eye Res. 18 (6), 765–810.
Tikellis, C., Cooper, M.E., Twigg, S.M., Burns, W.C., Tolcos, M., 2004. Connective tissue
growth factor is upregulated in the diabetic retina: amelioration by angiotensin-
converting enzyme inhibition. Endocrinology 145 (2), 860–866.
Tsai, G.Y., Cui, J.Z., Syed, H., Xia, Z., Ozerdem, U., McNeill, J.H., Matsubara, J.A., 2009.
Effect of N-acetylcysteine on the early expression of inflammatory markers in the retina
and plasma of diabetic rats. Clin. Exp. Ophthalmol. 37 (2), 223–231.
Tsutsumi, M., Claus, T.H., Liang, Y., Li, Y., Yang, L., Zhu, J., Dela Cruz, F., Peng, X.,
Chen, H., Yung, S.L., Hamren, S., Livingston, J.N., Pan, C.Q., 2002. A potent and
highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose
disposal: a potential therapy for type 2 diabetes. Diabetes 51 (5), 1453–1460.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:51 Page Number: 117
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
117Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
van Gurp, M., Festjens, N., van Loo, G., Saelens, X., Vandenabeele, P., 2003. Mitochondrial
intermembrane proteins in cell death. Biochem. Biophys. Res. Commun. 304 (3),
487–497.
VanGuilder, H.D., Brucklacher, R.M., Patel, K., Ellis, R.W., Freeman, W.M., Barber, A.J.,
2008. Diabetes downregulates presynaptic proteins and reduces basal synapsyn
I phosphorylation in rat retina. Eur. J. Neurosci. 28, 1–11.
Varga, B., Szabadfi, K., Kiss, P., Fabian, E., Tamas, A., Griecs, M., Gabriel, R., Reglodi, D.,
Kemeny-Beke, A., Pamer, Z., Biro, Z., Tosaki, A., Atlasz, T., Juhasz, B., 2011. PACAP
improves functional outcome in excitotoxic retinal lesion: an electroretinographic study.
J. Mol. Neurosci. 43, 44–50.
Vasilaki, A., Thermos, K., 2009. Somatostatin analogues as therapeutics in retinal disease.
Pharmacol. Ther. 122, 324–333.
Vasilaki, A., Mouratidou, M., Schulz, S., Thermos, K., 2002. Somatostatin mediates nitric
oxide production by activating sst2 receptors in the rat retina. Neuropharmacology
43, 899–909.
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D.,Wurtz, O., Fournier, A.,
Chow, B.K., Hashimoto, H., Galas, L., Vaudry, H., 2009. Pituitary adenylate cyclase
activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev.
61, 283–357.
Vayalil, P.K., Mittal, A., Katiyar, S.K., 2004. Proanthocyanidins from grape seeds inhibit
expression of matrix metalloproteinases in human prostate carcinoma cells, which is asso-
ciated with the inhibition of activation ofMAPK andNF kappa B. Carcinogenesis 25 (6),
987–995.
Verma, A., Shan, Z., Lei, B., Yuan, L., Liu, X., Nakagawa, T., Grant, M.B., Lewin, A.S.,
Hauswirth,W.W., Raizada, M.K., Li, Q., 2012. ACE2 and Ang-(1-7) confer protection
against development of diabetic retinopathy. Mol. Ther. 20 (1), 28–36.
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., Viviani, B.,
Marinovich, M., Cerami, A., Coleman, T.R., Brines, M., Ghezzi, P., 2003. Erythropoi-
etin selectively attenuates cytokine production and inflammation in cerebral ischemia by
targeting neuronal apoptosis. J. Exp. Med. 198 (6), 971–975.
Villaroel, M., Ciudin, A., Hernandez, C., Simo, R., 2010. Neurodegeneration: an early
event of diabetic retinopathy. World J. Diabetes 1, 57–64.
Vincent, J.A., Mohr, S., 2007. Inhibition of caspase-1/interleukin-1beta signaling prevents
degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56 (1), 224–230.
Wang, Y., Ma, P., Li, B., Lin, S., Wu, Y., Feng, J., Tang, S., 2007. The role of glucose con-
trol with intensive insulin therapy on retinal vessels of early diabetic rats. Yan Ke Xue
Bao 23 (4), 205–211.
Wang, C., Aungi, H.H., Zhang, B., Sun, S., Li, X.L., He, H., Xie, J.T., He, T.C., Du, W.,
Yuan, C.S., 2008. Chemopreventive effects of heat-processed Panax quinquefolius root
on human breast cancer cells. Anticancer Res. 28, 2545–2552.
Wang, J., Xu, X., Elliott, M.H., Zhu, M., Le, Y.Z., 2010a. Mu¨ller cell-derived VEGF is
essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes
59 (9), 2297–2305.
Wang, Q., Pfister, F., Dorn-Beineke, A., vom Hagen, F., Lin, J., Feng, Y., Hammes, H.P.,
2010b. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in
the experimental diabetic retina. Diabetologia 53 (6), 1227–1238.
Wang, Q., Gorbey, S., Pfister, F., H€oger, S., Dorn-Beineke, A., Kru¨gel, K., Berrone, E.,
Wu, L., Korff, T., Lin, J., Busch, S., Reichenbach, A., Feng, Y., Hammes, H.P.,
2011. Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective
in experimental diabetic retinopathy. Cell. Physiol. Biochem. 27 (6), 769–782.
Ward, M.M., Jobling, A.I., Kalloniatis, M., Fletcher, E.L., 2005. Glutamate uptake in retinal
glial cells during diabetes. Diabetologia 48 (2), 351–360.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:51 Page Number: 118
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
118 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Wassle, H., 2004. The parallel processing in the mammalian retina. Nat. Rev. 5, 1–11.
Watanabe, D., 2007. Erythropoietin as a retinal angiogenic factor in proliferative diabetic
retinopathy. Nippon Ganka Gakkai Zasshi 111, 892–898.
Weaver, D.C., McDaniel, M.L., Lacy, P.E., 1978. Alloxan uptake by isolated rat islets of
Langerhans. Endocrinology 102 (6), 1847–1855.
Wei, L., Ge, L., Qin, S., Shi, Y., Du, C., Du, H., Liu, L., Yu, Y., Sun, X., 2012. Hydrogen-
rich saline protects retina against glutamate-induced excitotoxic injury in guinea pig.
Exp. Eye Res. 94 (1), 117–127.
Wolff, B.E., Bearse, M.A., Schneck, M.E., Barez, S., Adams, A.J., 2010. Multifocal VEP
(mfVEP) reveals abnormal neuronal delays in diabetes. Doc. Ophthalmol. 121, 189–196.
Wu, W.C., Lai, C.C., Chen, S.L., Sun, M.H., Xiao, X., Chen, T.L., Tsai, R.J., Kuo, S.W.,
Tsao, Y.P., 2004a. GDNF gene therapy attenuates retinal ischemic injuries in rats. Mol.
Vis. 10, 93–102.
Wu, X., Reiter, C.E., Antonetti, D.A., Kimball, S.R., Jefferson, L.S., Gardner, T.W.,
2004b. Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent man-
ner. J. Biol. Chem. 279 (10), 9167–9175.
Wua, J., Wang, H.M., Li, J., Men, X.L., 2013. The research applications of db/db mouse.
Sheng Li Ke Xue Jin Zhan 44 (1), 12–18.
Wursch, P., Pi-Sunyer, F.X., 1997. The role of viscous soluble fiber in the metabolic control
of diabetes. A review with special emphasis on cereals rich in beta-glucan. Diabetes Care
20 (11), 1774–1780.
Xiao, C., He, M., Nan, Y., Zhang, D., Chen, B., Guan, Y., Pu, M., 2012a. Physiological
effects of superoxide dismutase on altered visual function of retinal ganglion cells in
db/db mice. PLoS One 7 (1), e30343.
Xiao, X., Cai, J., Xu, J., Wang, R., Cai, J., Liu, Y., Xu, W., Sun, X., Li, R., 2012b. Pro-
tective effects of hydrogen saline on diabetic retinopathy in a streptozotocin-induced dia-
betic rat model. J. Ocul. Pharmacol. Ther. 28 (1), 76–82.
Xie, P., Fujii, I., Zhao, J., Shinohara, M.,Matsukura, M., 2012. A novel polysaccharide com-
pound derived from algae extracts protects retinal pigment epithelial cells from high
glucose-induced oxidative damage in vitro. Biol. Pharm. Bull. 35 (9), 1447–1453.
Xu, H., Chen, M., Forrester, J.V., 2009. Para-inflammation in the aging retina. Prog. Retin.
Eye Res. 28, 348–368.
Yale, J.F., Marliss, E.B., 1984. Altered immunity and diabetes in the BB rat. Clin. Exp.
Immunol. 57 (1), 1–11.
Yamagishi, S., Nakamura, K., Matsui, T., Inagaki, Y., Takenaka, K., Jinnouchi, Y.,
Yoshida, Y., Matsuura, T., Narama, I., Motomiya, Y., Takeuchi, M., Inoue, H.,
Yoshimura, A., Bucala, R., Imaizumi, T., 2006a. Pigment epithelium-derived factor
inhibits advanced glycation end product-induced retinal vascular hyperpermeability
by blocking reactive oxygen species-mediated vascular endothelial growth factor expres-
sion. J. Biol. Chem. 281 (29), 20213–20220.
Yamagishi, S., Matsui, T., Nakamura, K., Takeuchi, M., Imaizumi, T., 2006b. Pigment
epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products
(AGE)-elicited retinal leukostasis. Microvasc. Res. 72 (1–2), 86–90.
Yamagishi, S., Ueda, S., Matsui, T., Nakamura, K., Okuda, S., 2008a. Role of advanced
glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr. Pharm.
Des. 14 (10), 962–968, Review.
Yamagishi, S., Nakamura, K., Matsui, T., Ueda, S., Fukami, K., Okuda, S., 2008b. Agents
that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative
stress system: a novel therapeutic strategy for diabetic vascular complications. Expert.
Opin. Investig. Drugs 17 (7), 983–996.
Yamamoto, K., Hashimoto, H., Tomimoto, S., Shintani, N., Miyazaki, J., Tashiro, F.,
Aihara, H., Nammo, T., Li, M., Yamagata, K., Miyagawa, J., Matsuzawa, Y.,
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:51 Page Number: 119
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
119Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Kawabata, Y., Fukuyama, Y., Koga, K., Mori, W., Tanaka, K., Matsuda, T., Baba, A.,
2003. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances
insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes
52, 1155–1162.
Yang, Y.S., Danis, R.P., Peterson, R.G., Dolan, P.L., Wu, Y.Q., 2000. Acarbose partially
inhibits microvascular retinopathy in the Zucker Diabetic Fatty rat (ZDF/Gmi-fa).
J. Ocul. Pharmacol. Ther. 16 (5), 471–479.
Yang, L.P., Sun, H.L., Wu, L.M., Guo, X.J., Dou, H.L., Tso, M.O., Zhao, L., Li, S.M.,
2009. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Invest. Ophthalmol. Vis. Sci. 50 (5), 2319–2327.
Yang, Y., Mao, D., Chen, X., Zhao, L., Tian, Q., Liu, C., Zhou, B.L.S., 2012. Decrease in
retinal neuronal cells in streptozotocin-induced diabetic mice. Mol. Vis. 18, 1411–1420.
Yang, J.H., Kwak, H.W., Kim, T.G., Han, J., Moon, S.W., Yu, S.Y., 2013a. Retinal neu-
rodegeneration in type II diabetic Otsuka Long-Evans Tokushima fatty rats. Invest.
Ophthalmol. Vis. Sci. 54 (6), 3844–3851.
Yang, Y., Yang, K., Li, Y., Li, X., Sun, Q., Meng, H., Zeng, Y., Hu, Y., Zhang, Y., 2013b.
Decursin inhibited proliferation and angiogenesis of endothelial cells to suppress diabetic
retinopathy via VEGFR2. Mol. Cell. Endocrinol. 378 (1–2), 46–52.
Yokoi, N., Hoshino, M., Hidaka, S., Yoshida, E., Beppu, M., Hoshikawa, R., Sudo, K.,
Kawada, A., Takagi, S., Seino, S., 2013. A novel rat model of type 2 diabetes: the Zucker
fatty diabetes mellitus ZFDM rat. J. Diabetes Res. 2013, 103731.
Yokouchi, H., Eto, K., Nishimura, W., Takeda, N., Kaburagi, Y., Yamamoto, S.,
Yasuda, K., 2013. Angiopoietin-like protein 4 (ANGPTL4) is induced by high glucose
in retinal pigment epithelial cells and exhibits potent angiogenic activity on retinal endo-
thelial cells. Acta Ophthalmol. 91 (4), e289–e297.
Yong, P.H., Zong, H., Medina, R.J., Limb, G.A., Uchida, K., Stitt, A.W., Curtis, T.M.,
2010. Evidence supporting a role for N-(3-formyl-3,4-dehydropiperidino)lysine accu-
mulation in Mu¨ller glia dysfunction and death in diabetic retinopathy. Mol. Vis.
16, 2524–2538.
Yoshida, Y., Yamagishi, S., Matsui, T., Jinnouchi, Y., Fukami, K., Imaizumi, T.,
Yamakawa, R., 2009. Protective role of pigment epithelium-derived factor (PEDF)
in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev.
25 (7), 678–686.
Yoshikawa, T., Naito, Y., Kondo, M., 1999. Ginkgo biloba leaf extract: review of biological
actions and clinical applications. Antioxid. Redox Signal. 1 (4), 469–480.
Yu, H., Chen, L., Jiang, J., 2010. Administration of pigment epithelium-derived factor deliv-
ered by adeno-associated virus inhibits blood-retinal barrier breakdown in diabetic rats.
Mol. Vis. 16, 2384–2394.
Zeng, X.X., Ng, Y.K., Ling, E.A., 2000. Neuronal and microglial response in the retina of
streptozotocin-induced diabetic rats. Vis. Neurosci. 17 (3), 463–471.
Zeng, H.Y., Green, W.R., Tso, M.O., 2008. Microglial activation in human diabetic ret-
inopathy. Arch. Ophthalmol. 126, 227–232.
Zeng, K., Xu, H., Mi, M., Zhang, Q., Zhang, Y., Chen, K., Chen, F., Zhu, J., Yu, X., 2009.
Dietary taurine supplementation prevents glial alterations in retina of diabetic rats.
Neurochem. Res. 34 (2), 244–254.
Zhang, J.Z., Xi, X., Gao, L., Kern, T.S., 2007. Captopril inhibits capillary degeneration in
the early stages of diabetic retinopathy. Curr. Eye Res. 32 (10), 883–889.
Zhang, J., Wu, Y., Jin, Y., Ji, F., Sinclair, S.H., Luo, Y., Xu, G., Lu, L., Dai,W., Yanoff, M.,
Li, W., Xu, G.T., 2008. Intravitreal injection of erythropoietin protects both retinal vas-
cular and neuronal cells in early diabetes. Invest. Ophthalmol. Vis. Sci. 49 (2), 732–742.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:52 Page Number: 120
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
120 Krisztina Szabadfi et al.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Zhang, X., Bao, S., Hambly, B.D., Gillies, M.C., 2009a. Vascular endothelial growth factor-
A: a multifunctional molecular player in diabetic retinopathy. Int. J. Biochem. Cell Biol.
41 (12), 2368–2371.
Zhang, Y., Wang, Q., Zhang, J., Lei, X., Xu, G.T., Ye, W., 2009b. Protection of exendin-4
analogue in early experimental diabetic retinopathy. Graefes Arch. Clin. Exp.
Ophthalmol. 247 (5), 699–706.
Zhang, Y., Zhang, J., Wang, Q., Lei, X., Chu, Q., Xu, G.T., Ye, W., 2011. Intravitreal
injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest.
Ophthalmol. Vis. Sci. 52 (1), 278–285.
Zhang, S.Y., Li, B.Y., Li, X.L., Cheng, M., Cai, Q., Yu, F.,Wang,W.D., Tan, M., Yan, G.,
Hu, S.L., Gao, H.Q., 2013. Effects of phlorizin on diabetic retinopathy according to iso-
baric tags for relative and absolute quantification-based proteomics in db/db mice. Mol.
Vis. 19, 812–821.
Zheng, Z., Chen, H., Ke, G., Fan, Y., Zou, H., Sun, X., Gu, Q., Xu, X., Ho, P.C., 2009.
Protective effect of perindopril on diabetic retinopathy is associated with decreased vas-
cular endothelial growth factor-to-pigment epithelium-derived factor ratio: involve-
ment of a mitochondria-reactive oxygen species pathway. Diabetes 58 (4), 954–964.
Zhong, L., Bradley, J., Schubert, W., Ahmed, E., Adamis, A.P., Shima, D.T., Robinson, G.-
S., Ng, Y.S., 2007. Erythropoietin promotes survival of retinal ganglion cells in DBA/2 J
glaucoma mice. Invest. Ophthalmol. Vis. Sci. 48 (3), 1212–1218.
Zhou, J.Y., Zhou, S.W., 2007. Effect of berberine on PPARalpha/delta/gamma expression
in type 2 diabetic rat retinae. Yao Xue Xue Bao 42 (12), 1243–1249.
Zhou, W., Yu, W., Xie, W., Huang, L., Xu, Y., Li, X., 2011. The role of SLIT-ROBO
signaling in proliferative diabetic retinopathy and retinal pigment epithelial cells. Mol.
Vis. 17, 1526–1536.
Zhu, B., Wang, W., Gu, Q., Xu, X., 2008. Erythropoietin protects retinal neurons and glial
cells in early-stage streptozotocin-induced diabetic rats. Exp. Eye Res. 86 (2), 375–382.
Zmijewski, M.A., Sharma, R.K., Slominski, A.T., 2007. Expression of molecular equivalent
of hypothalamic-pituitary-adrenal axis in adult retinal pigment epithelium.
J. Endocrinol. 193, 157–169.
Zong, H.,Ward,M., Stitt, A.W., 2011. AGEs, RAGE, and diabetic retinopathy. Curr. Diab.
Rep. 11 (4), 244–252, Review.
Zuo, Z.F., Zhang, Q., Liu, X.Z., 2013. Protective effects of curcumin on retinal Mu¨ller cell
in early diabetic rats. Int. J. Ophthalmol. 6 (4), 422–424.
Zwirska-Korczala, K., Jochem, J., Adamczyk-Sowa, M., Sowa, P., Polaniak, R., Birkner, E.,
Latocha, M., Pilc, K., Suchanek, R., 2005. Influence of melatonin on cell proliferation,
antioxidative enzyme activities and lipid peroxidation in 3T3-L1 preadipocytes—an
in vitro study. J. Physiol. Pharmacol. 56 (Suppl. 6), 91–99.
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:52 Page Number: 121
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
121Protective Compounds in Diabetic Retinopathy
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
Non-Print Items
Keywords: Retinal neurons, Retinal vasculature, Mu¨ller glia, Retinal pigment
epithelium, Antiapoptotic pathways, Retinoprotection, Visual functions
Comp. by: DElayaraja Stage: Proof Chapter No.: 1 Title Name: IRCMB
Date:21/4/14 Time:22:50:52 Page Number: 123
B978-0-12-800179-0.00001-5, 00001
IRCMB, 978-0-12-800179-0
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
